Protein with Tau-like repeats (PTL-1) modulates the oxidative stress response, neuronal ageing and lifespan by Chew, Yee Lian
Copyright and use of this thesis
This thesis must be used in accordance with the 
provisions of the Copyright Act 1968.
Reproduction of material protected by copyright 
may be an infringement of copyright and 
copyright owners may be entitled to take 
legal action against persons who infringe their 
copyright.
Section 51 (2) of the Copyright Act permits 
an authorized officer of a university library or 
archives to provide a copy (by communication 
or otherwise) of an unpublished thesis kept in 
the library or archives, to a person who satisfies 
the authorized officer that he or she requires 
the reproduction for the purposes of research 
or study. 
The Copyright Act grants the creator of a work 
a number of moral rights, specifically the right of 
attribution, the right against false attribution and 
the right of integrity. 
You may infringe the author’s moral rights if you:
-  fail to acknowledge the author of this thesis if 
you quote sections from the work 
- attribute this thesis to another author 
-  subject this thesis to derogatory treatment 
which may prejudice the author’s reputation
For further information contact the University’s 
Director of Copyright Services
sydney.edu.au/copyright
  
 
Protein with Tau-like repeats (PTL-1) 
modulates the oxidative stress response, 
neuronal ageing and lifespan 
Yee Lian Chew 
 
A thesis submitted in fulfilment of the requirements for the degree of Doctor of Philosophy 
 
School of Molecular Bioscience 
Faculty of Science 
University of Sydney 
December, 2014 
i 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I declare that the research presented here is my own original work unless otherwise specified. 
None of this material has been previously used for the purpose of obtaining any other degree. 
 
Yee Lian Chew  
  
ii 
 
Abstract 
Protein with Tau-like repeats (PTL-1) is the sole Tau /MAP2/MAP4 homolog in Caenorhabditis 
elegans. Dysregulation of Tau is a pathological hallmark of neurodegenerative diseases such as 
Alzheimer’s disease. Therefore, reducing Tau levels has been suggested as a therapeutic strategy.  
 
We used PTL-1 to model the biological functions of a Tau-like protein without the complication 
of functional redundancy. Firstly, our data indicate that PTL-1 in the nervous system mediates 
the oxidative stress response in a pathway that may involve the C. elegans homolog of the Nrf2 
transcription factor, SKN-1. In addition, we found that ptl-1 mutant animals are short-lived, and 
that lifespan modulation by PTL-1 may occur via similar processes to those mediated by SKN-1. 
We also observed that the short-lived phenotype of ptl-1 mutants can be rescued by transgenic 
re-expression of PTL-1 but not human Tau. Secondly, we show that PTL-1 maintains the 
structural integrity of neurons with increasing age. This phenotype observed in ptl-1 mutant 
animals could again be rescued by PTL-1 re-expression but not by human Tau. Thirdly, our data 
also indicate that the regulation of neuronal ageing by PTL-1 is cell-autonomous. We expressed 
PTL-1 in touch neurons and showed rescue of the neuronal ageing phenotype of ptl-1 mutant 
animals in these neurons but not in another neuronal subset. Knockdown of PTL-1 specifically in 
touch neurons also resulted in premature neuronal ageing in these neurons but not in a distinct 
subset of neurons, further supporting the conclusion that PTL-1 functions in a cell-autonomous 
manner. Interestingly, we showed that expression of PTL-1 in touch neurons alone was unable to 
rescue the shortened lifespan observed in null mutants, indicating that premature neuronal ageing 
in touch neurons and organismal ageing can be decoupled.  
 
Our data show that PTL-1 in C. elegans is a useful model to investigate the physiological 
functions of a Tau-like protein. Overall, our findings that PTL-1 is involved in the stress 
response, neuronal ageing and lifespan modulation suggest that some of the effects of Tau 
pathology may result from the loss of physiological Tau functions and not solely from a toxic 
gain-of-function due to an accumulation of Tau. 
  
iii 
 
Publications arising from this work 
Research articles 
Chew YL, Fan X, Gotz J, Nicholas HR. 2014. Regulation of age-related structural integrity in 
neurons by protein with Tau-like repeats (PTL-1) is cell autonomous. Sci. Rep. 4. 
Chew YL, Fan X, Gotz J, Nicholas HR. 2013. PTL-1 regulates neuronal integrity and lifespan in 
C. elegans. J Cell Sci. 126:2079-2091. 
Chew YL, Gotz J, Nicholas HR. 2014. Neuronal protein with tau-like repeats (PTL-1) regulates 
intestinal SKN-1 nuclear accumulation in response to oxidative stress. Aging cell (online) 
 Sections of the above articles were adapted for use in Chapters 3—6 of this thesis. 
 
Review articles 
Chew YL, Fan X, Gotz J, Nicholas HR. 2013. Aging in the nervous system of Caenorhabditis 
elegans. Commun. Integr. Biol. 6:e25288. 
Gotz J, Xia D, Leinenga G, Chew YL, Nicholas H. 2013. What Renders TAU Toxic. Front. 
Neurol. 4:72. 
 Sections of the above review articles were adapted for use in Chapter 1 of this thesis.. 
 
Conference presentations 
Protein with Tau-like repeats (PTL-1) regulates neuronal integrity and lifespan in 
Caenorhabditis elegans. Chew YL, Fan X, Gotz J, Nicholas HR. 
 2012/2014 Genetics Society of Australasia conference, Melbourne/Sydney, Australia  
 2013 19th International C. elegans meeting, Los Angeles, CA, USA  
 2012/2013 Alzheimer’s and Parkinson’s Disease symposium, Sydney/Brisbane, Australia  
 2012 Society for Neuroscience meeting, New Orleans, LA, USA 
 
  
iv 
 
Acknowledgements 
Thank you to everyone who walked with me on this PhD journey. It was honestly the most 
challenging and yet amazing experience of my life and I have learnt so much. 
 
Thank you to my supervisor, Dr Hannah Nicholas, for truly being an inspiration. You will 
always be the person with whom I compare all other scientists.  
 
Thank you to my second supervisor, Prof. Jürgen Götz, for your support and encouragement. 
Your dedication to your work and to your team is incredible.  
 
                                                                b  , f   b   g     b s  
PhD buddies in the world. It would have been infinitely harder without your support. Thank you 
also to Hong, Matt, Mal, Callum, Irene and Priya for strictly enforcing the morning and 
afternoon tea schedules. Thank you especially to Irene for all your hard work on the PTL-1 
project. It would not have come this far without you. 
 
Lastly, thank you to my squishy and thank you to my family. Without you it is all meaningless.  
 
 
  
v 
 
Table of Contents 
Chapter 1: Introduction ................................................................................................................1 
1.1 Alzheimer’s disease is the most common cause of dementia in the elderly  ..........................2 
1.1.1 Tau in Alzheimer’s disease  .............................................................................................4 
1.1.2 Tau and PTL-1 .................................................................................................................6 
1.1.3 C. elegans as a model organism to study ageing.............................................................9 
1.1.4 PTL-1 in C. elegans  ......................................................................................................11 
1.2 Oxidative stress in Alzheimer’s disease ...............................................................................12 
1.2.1 Oxidative stress and Tau ...............................................................................................12 
1.2.2 SKN-1 is the C. elegans homolog of the mammalian Nrf-2 family of transcription 
factors  ....................................................................................................................................13 
1.3 Neuronal ageing in C. elegans .............................................................................................18 
1.3.1 Cellular features of neuronal ageing in C. elegans .......................................................18 
1.3.2 Genetic aspects of neuronal ageing in C. elegans .........................................................23 
1.3.3 Do regulators of neuronal ageing act cell autonomously? ...........................................28 
1.4 Thesis overview  ...................................................................................................................30 
Chapter 2: Materials and methods .............................................................................................31 
2.1  Materials  ............................................................................................................................32 
2.1.1 Chemicals and reagents ................................................................................................32 
2.1.2 Antibodies ......................................................................................................................33 
2.1.3 Enzymes  ........................................................................................................................33 
2.1.4 Kits and commercial reagents  ......................................................................................34 
2.1.5 Equipment  .....................................................................................................................34 
2.1.6 External procedures  .....................................................................................................34 
2.1.7 Bacterial strains ............................................................................................................34 
2.1.8 Nematode strains  ..........................................................................................................35 
2.1.9 Integrated and extrachromosomal arrays  ....................................................................37 
2.1.10 Plasmid list  .................................................................................................................38 
2.1.11 Primers used for cloning  ............................................................................................39 
2.2  Methods  ..............................................................................................................................41 
2.2.1 Nematode maintenance .................................................................................................41 
vi 
 
2.2.2 Synchronisation of animals ...........................................................................................41 
2.2.3 Genotyping by PCR  ......................................................................................................42 
2.2.4 Generation of strains by crossing .................................................................................43 
2.2.5 Generation of plasmid constructs  .................................................................................46 
2.2.6 Generation of transgenic lines  .....................................................................................46 
2.2.7 Imaging of fluorescing transgenic lines ........................................................................48 
2.2.8 Touch sensitivity assay  .................................................................................................48 
2.2.9 SKN-1::GFP, Pgcs-1::gfp and DAF-16::GFP localisation experiments .....................49 
2.2.10 Quantification of fluorescence intensity  .....................................................................50 
2.2.11 Lifespan assay .............................................................................................................50 
2.2.12 Neuron imaging assay .................................................................................................51 
2.2.13 RNA interference experiments  ....................................................................................52 
2.2.14 Stress assays and pharmacological assays  ................................................................54 
2.2.15 Immunofluorescence  ...................................................................................................55 
2.2.16 Immunoblot  .................................................................................................................55 
2.2.17 Statistical analysis  ......................................................................................................56 
Chapter 3: Brief description of two ptl-1 deletion mutants......................................................58 
3.1 Introduction  .........................................................................................................................59 
3.2 ptl-1(tm543) and ptl-1(ok621) mutant strains  ....................................................................59 
3.3 ptl-1 mutant alleles display allelic differences in touch sensitivity ......................................63 
3.4 Discussion ............................................................................................................................64 
Chapter 4: PTL-1 is involved in the oxidative stress response and longevity regulation  ....65 
4.1 Section 1: Role of PTL-1 in the oxidative stress response   .................................................66 
4.1.1 Introduction ...................................................................................................................66 
4.1.2 ptl-1 mutant animals are defective in the response to oxidative stress  ........................66 
4.1.3 ptl-1 mutant animals display a defective SKN-1 re-localisation response to oxidative 
stress but show no defect for DAF-16 ....................................................................................69 
4.1.4 Defective SKN-1 re-localisation in ptl-1 mutant animals in response to oxidative stress 
can be rescued by PTL-1 but not human Tau re-expression  .................................................75 
4.1.5 ptl-1 mutant animals are defective in the induction of a SKN-1::GFP responsive gene 
 ................................................................................................................................................79 
vii 
 
4.1.6 PTL-1 re-expression in all neurons but not specifically in ASI neurons rescues SKN-1 
re-localisation defects  ...........................................................................................................85 
4.1.7 Synaptic vesicle mutants show defective SKN-1 re-localisation that is dependent on 
PTL-1 ......................................................................................................................................89 
4.1.8 Discussion .....................................................................................................................95 
4.2 Section 2: PTL-1 in longevity   .............................................................................................98 
4.2.1 Introduction ...................................................................................................................98 
4.2.2 ptl-1 mutant animals are short-lived .............................................................................98 
4.2.3 Lifespan reduction in ptl-1 mutant strains can be rescued by re-expression of PTL-1 
but not human Tau ..................................................................................................................99 
4.2.4 PTL-1 and SKN-1 use similar pathways to regulate longevity ...................................101 
4.2.5 Discussion ...................................................................................................................103 
Chapter 5: PTL-1 regulates ageing of the nervous system ....................................................105 
5.1 Introduction  .......................................................................................................................106 
5.2The ptl-1(ok621) and ptl-1(tm543) mutant strains show a high frequency of abnormal 
neuronal structures in touch receptor neurons in early adulthood  ........................................106 
5.3 The ptl-1(ok621) and ptl-1(tm543) mutant strains show a high frequency of abnormal 
neuronal structures in GABAergic neurons in early adulthood ..............................................112 
5.4 Functional consequences of mutations in ptl-1 ..................................................................114 
5.5 Re-expression of PTL-1 but not human Tau rescues defects observed in ptl-1 null mutant 
animals  ....................................................................................................................................116 
5.6 Discussion ..........................................................................................................................123 
5.6.1. PTL-1 is important for the maintenance of neuronal integrity in C. elegans  ...........123 
5.6.2 Tau and PTL-1 display some functional conservation in the regulation of neuronal 
ageing and longevity ............................................................................................................126 
Chapter 6: Regulation of neuronal ageing by PTL-1 is cell autonomous .............................128 
6.1 Introduction  .......................................................................................................................129 
6.2 PTL-1 is expressed in neuronal and non-neuronal tissues ................................................129 
6.3 Premature ageing of touch neurons in ptl-1 null mutant animals can be rescued by pan-
neuronal re-expression of PTL-1 .............................................................................................130 
viii 
 
6.4 Premature ageing of GABAergic neurons in ptl-1 null mutant animals can be rescued by 
pan-neuronal re-expression of PTL-1 ......................................................................................133 
6.5 The shortened lifespan observed in ptl-1 null mutant animals can be rescued by pan-
neuronal expression of PTL-1 ..................................................................................................134 
6.6 Premature ageing of touch neurons in ptl-1 null mutant animals can be rescued by touch 
neuron-specific re-expression of PTL-1 ...................................................................................135 
6.7 Premature ageing of GABAergic neurons in ptl-1 null mutant animals is not rescued by 
touch neuron-specific re-expression of PTL-1 .........................................................................139 
6.8 The shortened lifespan observed in ptl-1 null mutant animals is not rescued by touch 
neuron-specific re-expression of PTL-1 ...................................................................................140 
6.9 Knockdown of PTL-1 in touch neurons only has a cell autonomous effect on neuronal 
ageing  ......................................................................................................................................142 
6.10 Discussion  .......................................................................................................................150 
6.10.1 The regulation of neuronal ageing by PTL-1 is cell autonomous  ............................150 
6.10.2 PTL-1 does not regulate longevity via the touch neurons  ........................................151 
6.10.3 Regulation of neuronal ageing and lifespan by PTL-1 can be separable  ................152 
Chapter 7: General discussion ..................................................................................................154 
7.1 Summary .............................................................................................................................155 
7.2 PTL-1 in the nervous system regulates the oxidative stress response in a pathway that may 
involve SKN-1 ...........................................................................................................................156 
7.3 PTL-1 modulates longevity from the nervous system  ........................................................158 
7.4 PTL-1 maintains age-related structural integrity in neurons potentially by stabilising 
microtubules  ............................................................................................................................161 
7.5 Conclusions  .......................................................................................................................163 
References ...................................................................................................................................165 
Appendices ..................................................................................................................................179 
  
ix 
 
List of figures 
Figure 1.1: Alignment of human Tau, murine Tau and C. elegans PTL-1 ..................................... 8 
Figure 1.2: The C. elegans life cycle ............................................................................................ 11 
Figure 1.3: The skn-1(T19E7.2) locus on C. elegans chromosome IV. ....................................... 15 
Figure 1.4: Schematic of the IIS pathway in C. elegans, showing the involvement of DAF-2, 
DAF-16, and SKN-1 ..................................................................................................................... 17 
Figure 1.5: Fluorescence reporter lines enable the visualisation of neurons in C. elegans. ......... 19 
Figure 1.6: Neuronal ageing phenotypes observed in C. elegans touch receptor neurons and 
GABAergic neurons...................................................................................................................... 20 
Figure 1.7: Touch receptor neurons develop abnormal structures in the cell body and axon in a 
progressive, age-dependent manner. ............................................................................................. 21 
Figure 1.8: Summary of genetic regulators of neuronal ageing in C. elegans .............................. 28 
Figure 2.1: Schematic for the generation of skn-1(zu67); ptl-1(ok621) double mutant animals. . 46 
Figure 2.2: Generation of transgenic C. elegans. .......................................................................... 48 
Figure 2.3: Schematic for two imaging experiments to investigate neuronal ageing. .................. 52 
Figure 3.1: Schematic of ptl-1 (F42G9.9) genomic locus, showing alleles ok621 and tm543, and 
predicted protein sequence. ........................................................................................................... 61 
Figure 3.2: Genotyping of ptl-1(tm543) using PCR. .................................................................... 62 
Figure 3.3: ptl-1(ok621) and ptl-1(tm543) mutant animals display allelic differences in touch 
sensitivity. ..................................................................................................................................... 64 
Figure 4.1: PTL-1 regulates the response to oxidative stress. ...................................................... 68 
Figure 4.2: PTL-1 regulates the stress-mediated SKN-1 re-localisation to intestinal nuclei. ....... 71 
Figure 4.3: PTL-1 does not regulate DAF-16::GFP nuclear localisation, and SKN-1 nuclear re-
localisation  is not affected by mutations in daf-2. ....................................................................... 74 
Figure 4.4: Defective SKN-1::GFP re-localisation in response to stress can be rescued by re-
expression of PTL-1 but not human Tau. ..................................................................................... 78 
Figure 4.5: ptl-1 mutants show defective induction of the SKN-1-regulated gcs-1 promoter. .... 81 
Figure 4.6: PTL-1 is enriched in neurons but is also expressed in non-neuronal tissues ............. 83 
Figure 4.7: Pan-neuronal knockdown of ptl-1 by RNAi feeding at post-developmental stage. ... 84 
Figure 4.8: PTL-1 in neurons regulates SKN-1 nuclear re-localisation in the intestine. .............. 86 
Figure 4.9: ASI-specific PTL-1 re-expression does not rescue SKN-1::GFP re-localisation and 
Pgcs-1::gfp induction in ptl-1(ok621) mutant animals when exposed to azide stress. ................. 88 
Figure 4.10: SKN-1::GFP re-localisation and Pgcs-1::gfp induction are defective in unc-13 
mutant animals. ............................................................................................................................. 90 
Figure 4.11: SKN-1::GFP re-localisation and Pgcs-1::gfp induction are not defective in unc-31 
mutants. ......................................................................................................................................... 92 
Figure 4.12: ptl-1(ok621) mutant animals have fewer synaptic vesicles in ALM neurons 
compared with wild-type. ............................................................................................................. 94 
Figure 4.13: ptl-1 mutant animals are short-lived compared with wild-type. .............................. 99 
x 
 
Figure 4.14: The reduction in lifespan observed in ptl-1 null mutant animals can be rescued by 
re-expression of PTL-1 but not human Tau. ............................................................................... 100 
Figure 4.15: ptl-1(ok621);skn-1(zu67) double mutant animals are not significantly shorter or 
longer lived compared to ptl-1(ok621) or skn-1(zu67) single mutant animals. .......................... 102 
Figure 5.1: Imaging worms every day until death reveals that ptl-1(ok621) mutant animals 
display a higher frequency of abnormal neuronal structures in touch neurons compared with 
wild-type. .................................................................................................................................... 107 
Figure 5.2: The ptl-1(ok621) mutant strain displays an accelerated onset of appearance of 
abnormal neuronal structures in ALM touch neurons. ............................................................... 109 
Figure 5.3: The ptl-1(ok621) and ptl-1(tm543) mutant strains display accelerated onset of 
appearance of abnormal neuronal structures in touch receptor neurons. .................................... 110 
Figure 5.4: The ptl-1(ok621) and ptl-1(tm543) mutant strains show defects in maintaining 
neuronal integrity with age in GABAergic neurons. .................................................................. 114 
Figure 5.5: The ptl-1(ok621) and ptl-1(tm543) mutant strains display allelic differences in 
levamisole sensitivity. ................................................................................................................. 115 
Figure 5.6: Re-expression of PTL-1 rescues age-related abnormal neuron morphology and touch 
sensitivity in the ptl-1(ok621) mutant. ........................................................................................ 118 
Figure 5.7: Expression of human Tau does not robustly rescue age-related abnormal neuron 
morphology in the ptl-1(ok621) mutant. ..................................................................................... 120 
Figure 5.8: Re-expression of PTL-1 but not human Tau rescues touch insensitivity in the ptl-
1(ok621) mutant. ......................................................................................................................... 122 
Figure 6.1: Pan-neuronal re-expression of PTL-1 rescues the neuronal ageing phenotype in touch 
neurons that is observed in the ptl-1(ok621) null mutant. .......................................................... 132 
Figure 6.2: Pan-neuronal re-expression of PTL-1 rescues the neuronal ageing phenotype in 
GABAergic neurons that is observed in the ptl-1(ok621) null mutant. ...................................... 134 
Figure 6.3: The short-lived phenotype of ptl-1 null mutant animals can be rescued by pan-
neuronal re-expression of PTL-1. ............................................................................................... 135 
Figure 6.4: Touch neuron-specific expression of PTL-1 can be achieved using a Pmec-7::ptl-1-v5 
transgene. .................................................................................................................................... 136 
Figure 6.5: Touch neuron-specific re-expression of PTL-1 rescues the neuronal ageing phenotype 
in touch neurons that is observed in the ptl-1(ok621) null mutant. ............................................ 138 
Figure 6.6: Touch neuron-specific re-expression of PTL-1 does not rescue the neuronal ageing 
phenotype in GABAergic neurons that is observed in the ptl-1(ok621) null mutant. ................ 140 
Figure 6.7: The short-lived phenotype of ptl-1 null mutant animals cannot be rescued by touch 
neuron-specific re-expression of PTL-1. .................................................................................... 141 
Figure 6.8: Schematic of the protocol for RNAi knockdown experiments. ............................... 143 
Figure 6.9: Knockdown of PTL-1 in touch neuron RNAi sensitised strains expressing PTL-
1::GFP results in loss of fluorescence in touch neurons. ............................................................ 145 
Figure 6.9 (continued from previous page) ................................................................................. 146 
Figure 6.10: Non-neuronal knockdown of PTL-1 has no effect on neuronal ageing. ................ 146 
xi 
 
Figure 6.11: Knockdown of PTL-1 in touch neurons results in a loss of structural integrity. ... 148 
Figure 6.12: Knockdown of PTL-1 in touch neurons does not affect GABAergic neuron integrity 
during ageing. ............................................................................................................................. 149 
Figure 7.1: Summary of the functions of PTL-1 determined in this investigation ..................... 165 
  
xii 
 
Abbreviations 
AD  Alzheimer’s disease 
bp   Base pairs 
cDNA   Complementary DNA 
DAPI   4',6-diamidino-2-phenylindole 
DIC   Differential Interference Contrast 
DNA   Deoxyribonucleic acid 
Ex  Extrachromosomal array 
GABA  Gamma-aminobutyric acid 
GFP   Green Fluorescent Protein 
IIS  Insulin-like/IGF-1 signalling 
IPTG   Isopropyl β-D-1-thiogalactopyranoside 
Is   Integrated array 
MAP  Microtubule-associated protein 
MAPK  Mitogen-activated protein kinase 
MBR  Microtubule-binding repeat 
mRNA  Messenger RNA 
mRFP   Monomeric red fluorescent protein 
PHP   Pseudo hyperphosphorylated  
RNA   Ribonucleic acid 
S.E.M.  Standard Error of Mean 
SV  Synaptic vesicle 
Tg  Transgenic 
TRN  Touch receptor neuron 
UV/TMP Ultraviolet trimethylpsoralen 
 
C. elegans gene names are italicised and in lowercase letters e.g., ptl-1, while protein names are 
abbreviated with all capital letters e.g., PTL-1. 
Chapter 1: Introduction 
 
1 
 
 
 
 
 
Chapter 1:  
Introduction 
  
Chapter 1: Introduction 
 
2 
 
1.1 Alzheimer’s disease is the most common cause of dementia in the elderly 
Dementia is characterised by a progressive loss of cognitive function and is a common feature of 
neurodegenerative disorders. Alzheimer’s disease (AD) is the most common neurodegenerative 
disease leading to dementia in Western communities, with an estimated 35.6 million people 
worldwide suffering from this disease (WHO, 2012). Age is the most significant risk factor for 
developing dementia, which, given the ageing global population, means that this condition is 
rapidly rising in prevalence. Despite limited data from developing countries, it is estimated that 
the worldwide incidence of this disease will increase dramatically in the near future. Some 
estimates indicate that disease incidence will double by 2030 and triple by 2050 (Blennow et al., 
2006).  
 
There are two major histopathological hallmarks that are detectable in the brains of people 
suffering from AD: plaques formed from aggregated β-amyloid (Aβ), and neurofibrillary tangles 
(NFTs) composed primarily of hyperphosphorylated and aggregated Tau (Riddle et al., 1981). A 
simplified model for Aβ processing is as follows. Briefly, Aβ cleavage products, including the 
pathology-associated Aβ1-42 peptide, are generated from processing of the amyloid precursor 
protein (APP) via an amyloidogenic pathway involving sequential cleavage by β-secretase 1 
(BACE-1) and γ-secretase complexes. An alternative non-amyloidogenic pathway requires 
processing by α-secretase and γ-secretase. Both pathways generate soluble ectodomains and an 
identical intracellular C-terminal fragment (APP intracellular domain, AICD), but only the 
amyloidogenic pathway generates Aβ products (reviewed in (O'Brien and Wong, 2011, 
Thinakaran and Koo, 2008)). Mutations in presenilin-1 and -2, which are components of the γ-
secretase complex, are associated with an increased risk of early-onset, familial AD, possibly by 
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favouring the generation of more toxic forms of Aβ (Shen and Kelleher, 2007). In addition, 
genetic variants of APOE4 (apolipoprotein E4) have been associated with late-onset, sporadic 
AD (Avramopoulos, 2009, Singh et al., 2006). APOE has many roles in brain physiology, 
including binding Aβ, and some theories on the role of the APOE4 variant in AD imply that it 
may be involved in the clearance of toxic Aβ (Kim et al., 2009, Tokuda et al., 2000, Tiraboschi 
et al., 2004).  
 
Phosphorylated Tau is the major component of NFTs found not only in AD, but in other 
conditions collectively known as Tauopathies, which includes another dementia, Frontotemporal 
dementia with Parkinsonism associated with chromosome 17 (FTDP-17) (Lee and Leugers, 
2012, Iqbal et al., 2010, Ittner and Gotz, 2011, Gotz et al., 2013, Ittner et al., 2011). No 
mutations in MAPT, the gene that encodes Tau, have thus far been associated with AD. 
However, mutations in this gene cause several Tauopathies including FTDP-17 (Wade-Martins, 
2012). The presence of both Aβ plaques and Tau tangles in AD suggests that both proteins play a 
pathological role in the disease, although the exact interplay between these factors is still unclear 
(Lee et al., 2001b, Iqbal et al., 2010, Ittner and Gotz, 2011). Despite this lack of clarity, the 
importance of Tau in Aβ-dependent neurodegenerative disease is demonstrated by observations 
that knocking out Tau dramatically reduces Aβ pathology both in in vitro and in vivo models 
(Rapoport et al., 2002, Roberson et al., 2007, Ittner et al., 2010). Furthermore, methylene blue, 
which has been presented as a therapeutic agent for AD, is a chemical that inhibits the 
aggregation of proteins that adopt a β-sheet conformation, such as Tau (Guzman-Martinez et al., 
2013). Improved cognition in AD rodent models treated with methylene blue has been linked to 
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decreased levels of soluble Tau (O'Leary et al., 2010), suggesting that reducing Tau levels would 
be favourable for AD patients.  
 
The remainder of this thesis will focus on the role of Tau and Tau-related proteins in 
neurodegenerative disease and ageing.  
 
1.1.1 Tau in Alzheimer’s disease 
Tau is a neuronal microtubule-associated protein (MAP) that is predominantly localised to axons 
(Kosik and Finch, 1987, Weingarten et al., 1975). In mammals, Tau has a role in regulating 
microtubule assembly, stability, and organisation (Harada et al., 1994, Chen et al., 1992, 
Cleveland et al., 1977). MAP2, which is expressed in neurons, and MAP4, which is non-
neuronal, are other mammalian MAPs that contain similar microtubule-binding domains to Tau. 
These proteins together comprise the Tau/MAP2/MAP4 family, and in vivo studies imply that 
they display considerable functional redundancy (Dehmelt and Halpain, 2005). In AD and other 
Tauopathies, it is only partly understood how Tau exerts its toxic effects, whether in fibrillar 
form (Ittner et al., 2008), or before the formation of tangles due to the loss of some important 
physiological functions (Gomez-Isla et al., 1997, Lee and Leugers, 2012). Despite the significant 
advances in understanding Tau functions made using Tau transgenic and knockout models 
(reviewed in (Ittner et al., 2011, Ke et al., 2012, Gotz and Ittner, 2008, Gotz et al., 2010, Avila et 
al., 2004, Lee et al., 2001b)), these studies are complicated by the presence of other neuronal 
MAPs such as MAP2, which may share several physiological roles with Tau. In fact, Tau 
knockout mice do not display overt defects in neuronal development or function until late stages 
of adulthood (Harada et al., 1994, Dawson et al., 2001, Tucker et al., 2001). 
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While most studies on Tau are conducted using the mouse as a model organism, several wild-
type and mutant human Tau transgenic models have been established in the nematode 
Caenorhabditis elegans (Kraemer et al., 2003, Miyasaka et al., 2005, Brandt et al., 2009, 
Fatouros et al., 2012). Kraemer et al. expressed wild-type and FTDP-17 mutant human Tau 
(mutations P301L and V337M) in C. elegans to model Tauopathy disorders and found that these 
Tau transgenic worms were all short-lived and displayed impaired motility, decreased 
cholinergic transmission and increased GABAergic neuron degeneration compared with non-
transgenic worms. Although the expression of both wild-type and mutant human Tau was 
detrimental to C. elegans, transgenic animals expressing mutant Tau were considerably more 
impaired in the latter three phenotypes compared with transgenic animals expressing wild-type 
Tau (Kraemer et al., 2003). A forward genetic screen for mutants that ameliorate Tau pathology 
in these transgenic lines revealed two suppressors of Tau (sut) genes, sut-1 and sut-2, which 
encode a cytoskeletal regulatory protein (Kraemer and Schellenberg, 2007) and a zinc-finger 
protein (Guthrie et al., 2009), respectively. In a separate study, transgenic C. elegans carrying 
pathology-associated P301L and R406W variants of human Tau displayed a progressive loss of 
touch sensitivity, which appeared to correlate with the presence of structural abnormalities and 
aggregated Tau in mechanosensory touch receptor neurons (Miyasaka et al., 2005). Another 
transgenic line generated by Brandt and colleagues expressed a pseudo-hyperphosphorylated 
(PHP) Tau in which several serine/threonine residues were mutated to glutamic acid. PHP Tau 
formed aggregates in transgenic C. elegans and led to defects in neuronal development (Brandt 
et al., 2009). Furthermore, allele ΔK280, a pro-aggregant mutant form of human Tau, was 
expressed in worms and resulted in defective motility, synaptic transmission and axonal transport 
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(Fatouros et al., 2012). These investigations demonstrate the usefulness of C. elegans as a model 
for Tauopathies. Given the ease of genetic manipulation of the nematode model, transgenic lines 
generated could be used to screen for interacting partners of mutated Tau forms, such as the sut 
genes described above, which further illuminate the processes mediating Tau pathology. In fact, 
some of these models have been used in pharmacological screens to isolate chemical substances 
that can counteract Tau pathology (McCormick et al., 2013).  
 
1.1.2 Tau and PTL-1 
C. elegans has one putative homolog in the Tau/MAP2/MAP4 family of MAPs, called protein 
with Tau-like repeats-1 (PTL-1) (Goedert et al., 1996, McDermott et al., 1996). PTL-1 contains a 
high level of sequence homology to Tau/MAP2/MAP4 within the microtubule-binding repeat 
(MBR) domain in the carboxyl (C)-terminus, and has been shown to regulate microtubule 
assembly in vitro (McDermott et al., 1996, Goedert et al., 1996). Immunohistochemistry and 
analysis of a ptl-1 transcriptional reporter line demonstrated that PTL-1 has a neuronal 
expression pattern in adult worms (Goedert et al., 1996, Gordon et al., 2008). Henceforth PTL-1 
will be referred to as the Tau/MAP2 homolog since these are the neuronal MAPs in mammals 
(Dehmelt and Halpain, 2005). PTL-1 has also been shown to have neuronal functions in worms, 
as it has been implicated in the regulation of microtubule-based motility in several neurons (Tien 
et al., 2011) and for the optimal functioning of touch receptor neurons in the response to gentle 
touch (Gordon et al., 2008). Therefore, C. elegans is a convenient in vivo model in which to 
study the physiological roles of a Tau/MAP2-like protein without having to consider 
compensatory effects produced by other closely-related MAPs.   
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Amino acid sequence alignment of the longest isoforms of human Tau and mouse Tau together 
with PTL-1a, the longest isoform in C. elegans, indicates a high level of sequence conservation 
in the C-terminal region of these proteins (Figure 1.1). As noted above, the C-terminus contains 
the MBRs, of which there are four in human and mouse Tau and putatively five in C. elegans 
PTL-1 (Goedert et al., 1996). Although human and mouse Tau show some similarity in the N-
terminus, known as the projection domain, there is limited sequence identity. In the N-terminus, 
C. elegans PTL-1 contains a large proline-rich region containing 29 glutamic acid-proline 
dipeptide repeats, which is not present in the projection domain of human or mouse Tau, 
although a proline-rich region exists in both mammalian forms immediately upstream of the 
MBR domain (Buee et al., 2000). The N-terminus in mammalian Tau has been shown to be 
important for interactions with proteins other than microtubules, such as the kinase Fyn (Ittner et 
al., 2010, Kanaan et al., 2012). Targeting of Fyn by Tau to the dendritic compartment facilitates 
Fyn-dependent phosphorylation of the NMDA receptor, which results in excitotoxicity, an 
important component of Aβ pathology (Ittner et al., 2010).  
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Figure 1.1: Alignment of human Tau, murine Tau and C. elegans PTL-1. Alignment was generated using the T-
Coffee program (Di Tommaso et al., 2011) using the longest isoform for all organisms, which is P10636.5 for 
human Tau, P10637.3 for mouse Tau and F42G9.9a for PTL-1. The gradient of blue highlighting indicates the level 
of similarity between all three sequences – the darker blue highlighting indicates higher sequence similarity whereas 
lighter blue indicates lower sequence similarity. Dashed lines indicate the absence of identity/similarity. The red 
boxes indicate the conserved MBRs. The dashed red box indicates a unique MBR for PTL-1.  
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1.1.3 C. elegans as a model organism to study ageing 
Ageing is one of the most significant risk factors for the development of neurodegenerative 
disease. However, the cellular and molecular changes that occur with ageing are not fully 
understood. C. elegans is a useful model in which to study ageing owing, in particular, to its 
relatively short lifespan and life cycle (Figure 1.2). Like in humans, ageing in worms is 
accompanied by physiological changes including progressive loss of mobility (Herndon et al., 
2002, Huang et al., 2004), sarcopenia and deterioration of other tissues (Garigan et al., 2002, 
Herndon et al., 2002), and a decline in immune function (Youngman et al., 2011). Human 
physiological ageing (as differentiated from pathological ageing) is additionally associated with 
subtle physical changes in the brain, such as neuronal restructuring, synaptic loss, and altered 
calcium homeostasis (Yankner et al., 2008, Hedden and Gabrieli, 2004, Khachaturian, 1994), 
and these changes have been linked to a progressive impairment of cognitive function (Yankner 
et al., 2008, Bishop et al., 2010). In light of these observations, it was somewhat surprising that 
initial studies did not detect any structural decline in the C. elegans nervous system with age 
(Herndon et al., 2002). Recently, however, close examination of neuronal morphology in the 
nematode has revealed pronounced ageing phenotypes such as aberrant outgrowths and beading 
along neuron processes, and age-associated synaptic deterioration has also been detected (Tank 
et al., 2011, Toth et al., 2012, Pan et al., 2011). The nematode model system therefore presents 
an opportunity to explore the mechanisms by which neuronal ageing is regulated. In this model, 
it is also possible to dissect the relationship between neuronal ageing and ageing of the whole 
organism, by examining for example whether accelerated neuronal ageing has repercussions for 
the entire organism. 
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Such explorations are greatly facilitated by the simplicity of the C. elegans nervous system, 
which consists of only 302 neurons. These neurons have been anatomically mapped and develop 
in a stereotypical manner (Hall and Russell, 1991, White et al., 1986), facilitating the study of 
age-related structural changes. Furthermore, C. elegans is small (1mm length in adults), feeds on 
Escherichia coli bacteria seeded onto agar plates, and maintains its population by self-
fertilisation (Brenner, 1974), making the maintenance of large numbers of nematode strains 
simple and relatively affordable. The worm is also transparent (Brenner, 1974), facilitating the 
study of detailed anatomical structures by both differential interference contrast and fluorescence 
microscopy in live animals.  
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Figure 1.2: The C. elegans life cycle (from WormAtlas (Altun and Hall, 2005)). The developmental processes in 
C. elegans are highly stereotyped. The life cycle from egg to egg-laying adult takes 3-7 days depending on the 
temperature of incubation.  
 
1.1.4 PTL-1 in C. elegans 
PTL-1 is expressed predominantly in the nervous system, although expression has also been 
demonstrated in the embryonic hypodermis and in some adult muscle (Gordon et al., 2008, 
Goedert et al., 1996). As mentioned above, PTL-1 functions within neurons to regulate touch 
sensitivity (Gordon et al., 2008) and microtubule-based motility (Tien et al., 2011). ptl-1 null 
mutant animals also have fewer viable offspring despite no defects in egg-laying, suggesting that 
PTL-1 is also involved in essential stages of embryonic development (Gordon et al., 2008). 
Recently, PTL-1 has been shown to bind to SUP-36 (SUPpressor 36), an S-phase kinase-
associated protein (Skp) family member that is involved in pharyngeal development. This 
association may be required to tether SUP-36 to microtubules (Polley et al., 2014).  
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1.2 Oxidative stress in Alzheimer’s disease 
Aside from Aβ plaques and Tau NFTs (Riddle et al., 1981, Ittner and Gotz, 2011), increased 
oxidative stress has also been observed in the brains of AD patients and in animal AD models 
(Butterfield et al., 2007, Filipcik et al., 2006, Guglielmotto et al., 2009, Zhao and Zhao, 2013). 
This indicates that oxidative stress could be either an unrelated by-product of disease, a major or 
minor driver of pathology, or involved in a feedback loop to amplify AD pathology. Despite this 
finding, the use of antioxidants in clinical trials for cognitive impairment has produced only 
marginal or no improvement in patients (Petersen et al., 2005, Yaffe et al., 2004, Kang et al., 
2006). Therefore, an improved understanding of the role of oxidative stress in the pathogenesis 
of AD may be useful for developing alternative avenues of treatment.  
 
1.2.1 Oxidative stress and Tau 
Investigations into a pathological link between oxidative stress and Tau have been increasingly 
developed in several disease models. Mitochondrial dysfunction can result in an imbalance in the 
release of reactive oxygen species (ROS). Tau transgenic mice display substantial deficits in 
mitochondria complex I (David et al., 2005), and this is worsened in combination with increased 
Aβ oligomers (Eckert et al., 2008). Oxidative stress has also been implicated as a causal factor 
for Tau-induced neurodegeneration in Drosophila melanogaster (Dias-Santagata et al., 2007), 
and for increased Tau phosphorylation and aggregation in vitro (Su et al., 2010, Gamblin et al., 
2000). These processes have been shown to involve the p38 mitogen-activated protein kinases 
(MAPKs) that are activated in response to oxidative stress (Zhu et al., 2000, Buee-Scherrer and 
Goedert, 2002, Goedert et al., 1997). Activated p38 MAPKs have been shown to phosphorylate 
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Tau (Reynolds et al., 1997), which may contribute to pathological Tau hyperphosphorylation, 
and also appear to physically associate with filamentous Tau in vivo (Zhu et al., 2000). 
 
In addition, activation of an important mediator of the oxidative stress response in mammals, the 
transcription factor Nrf2/NFE2 (Nuclear factor, erythroid-derived 2), has been recently linked to 
reduction in the levels of phosphorylated Tau in primary neuron culture via an autophagy adaptor 
protein NDP52 (Jo et al., 2014). Behavioural improvements in response to methylene blue 
treatment in an AD mouse model have also been associated with increased expression of Nrf2-
regulated genes (Stack et al., 2014). Nrf2 has a cytoprotective effect in several model systems, 
including mice and C. elegans, and this has been linked to increased lifespan in these organisms 
(Leiser and Miller, 2010, Bishop and Guarente, 2007, Lewis et al., 2010). 
 
1.2.2 SKN-1 is the C. elegans homolog of the mammalian Nrf-2 family of transcription factors 
SKN-1 is the C. elegans homolog of the bZIP (basic region-leucine zipper) Nrf family of 
transcription factors, which include Jun, c-Fos, and Nrf2 (Bowerman et al., 1992, Amoutzias et 
al., 2007). In addition to a myriad of roles in cell fate specification in the developing embryo 
(Bowerman et al., 1992), pathogen resistance (Papp et al., 2012), the unfolded protein response 
(Glover-Cutter et al., 2013), the starvation response (Paek et al., 2012), longevity (Bishop and 
Guarente, 2007, Robida-Stubbs et al., 2012, Okuyama et al., 2010, Park et al., 2009, Tullet et al., 
2008) and dietary restriction-mediated lifespan extension (Bishop and Guarente, 2007), SKN-1 
has also been shown to regulate a conserved response to oxidative stress (An and Blackwell, 
2003, An et al., 2005, Inoue et al., 2005, Kahn et al., 2008, Park et al., 2009, Wang et al., 2010). 
Interestingly, some of these responses appear to be age-dependent, as old worms fail to induce 
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the SKN-1-dependent gene gst-4 (glutathione S-transferase 4) in response to stress (Przybysz et 
al., 2009), and skn-1 mutant animals display accelerated immunosenescence, or deterioration of 
the immune system with age (Papp et al., 2012). There are three isoforms of SKN-1, isoforms a, 
b, and c, and these appear to be regulated from different promoters at the same genetic locus 
(Bishop and Guarente, 2007) (Figure 1.3). Most investigations have focused on isoforms b and 
c, largely due to the generation of a SKN-1b/c GFP reporter transgenic line. This has facilitated 
expression studies of these isoforms, which are found in the intestine (SKN-1c) and the ASI 
neurons (SKN-1b) (An and Blackwell, 2003). Recently another transgenic line encoding all three 
SKN-1 isoforms within a large transgene has been generated, and the expression patterns in both 
transgenic lines appear largely similar (Tullet et al., 2008). Yet another transgenic line 
specifically examining SKN-1a showed widespread expression in the nervous system and also in 
non-neuronal tissues, albeit these observations are confounded by the fact that the 7.3 kb 
promoter region in this transgene includes an upstream gene bec-1, which is known to be 
expressed in many tissues (Staab et al., 2014). Importantly, SKN-1b/c re-expression fully 
compensates for the loss of all three isoforms in dietary-restriction mediated longevity (Bishop 
and Guarente, 2007), as well as in mutant strains lacking isoforms a and c with regards to the 
oxidative stress response (An and Blackwell, 2003). Interestingly, the zu135 allele of skn-1 that 
lacks all three isoforms has a wild-type lifespan, but the zu67 allele lacking SKN-1a/c is short-
lived (Bishop and Guarente, 2007). The position of these alleles within the genomic locus is 
shown in Figure 1.3. 
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Figure 1.3: The skn-1(T19E7.2) locus on C. elegans chromosome IV. There are three SKN-1 isoforms confirmed 
by cDNA: isoforms a, b and c. Two missense alleles discussed in this thesis are zu135, which affects all three 
isoforms, and zu67, which affects skn-1a/c (http://www.wormbase.org/), indicated by arrows.  
 
The best characterised function of SKN-1 is as a transcription factor that localises to the nucleus 
to induce the transcription of stress-responsive genes (An and Blackwell, 2003). The SKN-1c 
isoform in the intestine is normally diffuse in the cytoplasm, but is rapidly localised to the 
nucleus during stress conditions. The nuclear re-localisation of intestinal SKN-1 in response to 
stress directly requires phosphorylation by p38 MAPK (Inoue et al., 2005), and is negatively 
regulated by glycogen synthase kinase-3β (An et al., 2005). In contrast, the SKN-1b isoform in 
the ASI neurons in the head is constitutively present in the nucleus, and this does not alter when 
the animal is stressed (An and Blackwell, 2003, Bishop and Guarente, 2007). Expression 
changes in SKN-1a in response to stress have not yet been examined.  
 
The insulin/IGF-1 signalling (IIS) pathway has also been implicated in the regulation of SKN-1 
activity (Tullet et al., 2008). In the context of ageing, the IIS pathway is one of the most well 
understood regulators of longevity and stress tolerance. When activated by ligand binding, the 
DAF-2 insulin receptor signals to downstream kinases to phosphorylate the FOXO transcription 
factor DAF-16, resulting in its exclusion from the nucleus and preventing the subsequent 
induction of genes involved in longevity and the stress response (Larsen et al., 1995, Kenyon et 
al., 1993, Ogg et al., 1997). Reduction-of-function mutations in DAF-2 result in a dramatic 
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extension of lifespan (Kenyon et al., 1993). Mutations in DAF-16 result in premature ageing, and 
the lifespan extension observed in daf-2 mutants is dependent on DAF-16 (Kenyon et al., 1993, 
Ogg et al., 1997, Larsen et al., 1995). It was previously demonstrated that DAF-2 influences 
SKN-1 re-localisation to intestinal nuclei in response to stress (Tullet et al., 2008), and that SKN-
1-mediated modulation of lifespan involves DAF-2 and the downstream effector DAF-16, 
although the evidence thus far is not entirely consistent (Bishop and Guarente, 2007, Tullet et al., 
2008, Wang et al., 2010, Robida-Stubbs et al., 2012). A simplified schematic for lifespan 
regulation via DAF-2, DAF-16, and SKN-1 is shown in Figure 1.4. For example, the skn-
1(zu67) mutation affecting isoforms a and c does not affect the long-lived phenotype of daf-
2(e1370) mutant strains, suggesting that SKN-1 is upstream of DAF-2 (Inoue et al., 2005, Tullet 
et al., 2008). In contrast, knockdown of skn-1 a/c suppressed longevity in a daf-2(e1368) mutant 
(Tullet et al., 2008). It is important to note that phenotypic differences exist between these daf-2 
mutant strains: daf-2(e1370) animals are long-lived and stress resistant but also display a number 
of abnormalities such as the formation of dauer larvae at 20—25 °C under normal conditions 
(wild-type animals usually form dauers in stress conditions); whilst daf-2(e1368) animals are 
long-lived, albeit less so than e1370 animals, but otherwise appear essentially normal (Gems et 
al., 1998). Therefore, although the regulation of longevity by SKN-1 involves the IIS pathway, 
the exact mechanism of this regulation has not yet been clarified. 
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Figure 1.4: Schematic of the IIS pathway in C. elegans, showing the involvement of DAF-2, DAF-16, and 
SKN-1. Briefly, ligand binding to the DAF-2 insulin-like receptor results in the activation of negative regulators of 
both DAF-16/FOXO and SKN-1/Nrf2 transcription factors, thus preventing the translocation of these factors to the 
nucleus to induce expression of genes involved in stress tolerance and lifespan extension. In the absence of ligand 
binding or in daf-2 reduction-of-function mutants, the negative regulation of DAF-16 and/or SKN-1 is removed and 
these transcription factors are able to move into the nucleus to regulate transcription.  
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1.3 Neuronal ageing in C. elegans 
1.3.1 Cellular features of neuronal ageing in C. elegans 
Although ageing has been described as the most significant risk factor for neurodegenerative 
disease, the factors that influence the development of dementia are unclear. Furthermore, the 
complexity of the mammalian nervous system provides a significant challenge to the study of 
neuronal ageing in mammals. Given the short lifespan of C. elegans and the ease of observation 
using microscopy, the nematode system is a convenient model by which to identify factors that 
contribute to neuronal ageing. To date, among the 302 neurons of C. elegans, age-associated 
changes have been identified in the mechanosensory touch receptor neurons, in the axons of 
cholinergic neurons in the ventral nerve cord (VNC), in the axons of GABAergic motor neurons 
in the ventral and dorsal nerve cord, and in the nerve ring. Figure 1.5 shows the nervous system 
visualised using gfp reporter lines, and Figure 1.6 shows age-associated structural changes in 
touch neurons and GABAergic neurons. For clarity, all neurons in C. elegans are described using 
the conventional unique three-letter identifiers. For example, the six touch neurons are the two 
ALM (Anterior Lateral Microtubule) cells, the AVM (Anterior Ventral Microtubule), the two 
PLMs (Posterior Lateral Microtubule), and the PVM (Posterior Ventral Microtubule) (Altun and 
Hall, 2005). Age-associated changes in the nervous system include branching from the cell body 
and axon, as well as blebbing and beading along the axon (Pan et al., 2011, Tank et al., 2011, 
Toth et al., 2012). Representative images of these structures are shown in (Figure 1.7). In 
neurons displaying such structures, nuclear DAPI staining appears intact even in severe cases, 
suggesting that these aged neurons are not undergoing apoptosis or necrosis (Pan et al., 2011).  
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Figure 1.5: Fluorescence reporter lines enable the visualisation of neurons in C. elegans. A) Nerve ring (green), 
positioned between the anterior and terminal bulbs of the pharynx, indicated in the phase image. The Pptl-1::gfp 
(sIs11686) reporter line is shown (McKay et al., 2003). B) Touch receptor neurons, showing the cell bodies of the 
AVM, ALMs, PVM and PLMs. The Pmec-4::gfp (zdIs5) reporter line is shown (Clark and Chiu, 2003). C) Ventral 
nerve cord GABAergic motor neurons. The Punc-47::gfp (oxIs12) reporter line is shown (McIntire et al., 1997). The 
images are taken from the current study and not from the referenced articles, which indicate the source of the 
transgenic lines used. Anterior is left. Scale, 10 µm. 
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Figure 1.6: Neuronal ageing phenotypes observed in C. elegans touch receptor neurons and GABAergic 
neurons. (Top) Touch receptor neurons are visualised using the Pmec-4::gfp (zdIs5) reporter. Young adult animals 
have a long, straight and unbranched axon with a round cell body in the ALM neuron. Older animals accumulate 
structural abnormalities such as (i) cell body branching, (ii) axon blebbing, and (iii) axon branching. (Bottom) 
Ventral nerve cord GABAergic neurons are visualised using the Punc-47::gfp (oxIs12) reporter. Young adult 
animals have unbranched commissures that extend dorsally from the ventral cord. Older animals display branching 
from these commissures. 
 
Blebs are defined as triangular-shaped protrusions from the processes (Pan et al., 2011). When 
several of these blebs form along the process, this can distort the structure of the axon, such that 
the axon adopts a wavy appearance (Pan et al., 2011) (Figure 1.7B). These wavy processes have 
been quantified in touch neurons and found to increase in frequency with age (Toth et al., 2012). 
In old animals, branches or even axon splitting can sometimes be observed at the sites of these 
blebs (Pan et al., 2011). Neither branches nor blebs co-localise with late endosome or lysosome 
markers (Pan et al., 2011), or with synaptic protein markers (Toth et al., 2012). 
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Beading, or bubble-like lesions, refers to focal enlargements that occur along the length of the 
axonal process (Pan et al., 2011, Toth et al., 2012). These beads were observed in touch neurons, 
and have dark, fluorescence-free regions in the centre of the structure (Pan et al., 2011, Toth et 
al., 2012) (Figure 1.7C). 
 
 
Figure 1.7: Touch receptor neurons develop abnormal structures in the cell body and axon in a progressive, 
age-dependent manner. Here, touch neurons are visualised using the Pmec-4::gfp reporter line. A) A ‘normal’ 
touch receptor neuron (ALM). The cell body of AVM is out of focus. (B-E) Age-associated abnormal structures in 
ALM touch neurons. B) Blebs (arrows) form along the process, creating a wavy appearance along the axon. C) 
Beading (arrowheads) along the axon. D) Branching (asterisks) along the axon. Some branches appear to develop 
from blebs. E) Branching from the cell body. Scale, 10 µm. 
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Branching refers to novel extensions emanating from the neuronal cell body or along the axonal 
process. Branches have been visualized using several distinct fluorescent neuronal reporter 
transgenes (Pan et al., 2011, Tank et al., 2011, Toth et al., 2012) (Figure 1.7D,E) and were also 
observed by immunostaining with an anti-acetylated α-tubulin antibody, revealing that the 
outgrowths contain acetylated microtubules (Pan et al., 2011). The branching process is dynamic, 
since protrusions have been observed to form and retract, and secondary branches may extend 
from existing branches (Pan et al., 2011, Toth et al., 2012). Interestingly, a small but significant 
correlation was observed between the presence of extra branches in touch neurons and decreased 
mobility and sensitivity to gentle touch (Tank et al., 2011).  
 
Complementing the work performed using transgenic strains expressing fluorescence reporter 
transgenes, examination of touch neurons in non-transgenic wild-type animals by electron 
microscopy (EM) also revealed these morphological changes. This indicates that the observed 
structures are not simply an artefact associated with fluorescence transgenes (Toth et al., 2012). 
In addition, EM studies revealed that some novel outgrowths developing from touch neuron 
processes co-localise with mitochondria at the branch points (Toth et al., 2012). These 
observations were confirmed by assays showing co-localisation of these branch points with 
mitochondria-specific GFP in touch neurons (Toth et al., 2012). It is unclear if mitochondria 
accumulate due to cytoskeletal changes at these points, or if the presence of mitochondria 
induces branching at these sites.  
 
Another age-related effect found in the worm neurons is synaptic deterioration, such as a 
reduction in synaptic vesicles and size of the presynaptic terminal (Toth et al., 2012). Synaptic 
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integrity is a well-established parameter of neuronal ageing in mammals (BertoniFreddari et al., 
1996, Matsumoto, 1998, Geinisman et al., 1986), and loss of synaptic integrity correlates well 
with memory and behavioural regression (Geinisman et al., 1995). Similarly, reduction in 
synaptic integrity is associated with impaired locomotion in aged C. elegans (Toth et al., 2012). 
Using EM studies, the number of synaptic vesicles in the nerve ring could be quantified, 
revealing that old adult worms have significantly fewer synaptic vesicles compared with young 
adult animals (Toth et al., 2012).  
 
Notably, different types of neurons showed differential susceptibility to age-related changes. For 
example, touch receptor neurons accumulate aberrant branching with age, whereas two of the 
nerve ring interneurons and some dopaminergic neurons appear to remain intact (Toth et al., 
2012). Moreover, different subsets of touch neurons also display differential severity of 
morphological defects, and even vary in the type of defects that can be observed (Toth et al., 
2012, Pan et al., 2011). It is intriguing that this kind of ageing heterogeneity exists even between 
neurons of the same type.  
 
1.3.2 Genetic aspects of neuronal ageing in C. elegans 
In addition to the cellular characteristics of neuronal ageing in C. elegans that are reminiscent of 
age-associated neuronal changes in higher organisms, several conserved regulators of ageing 
have also been identified (Apfeld and Kenyon, 1998, Kenyon et al., 1993, Gaglia et al., 2012, 
Youngman et al., 2011, Alper et al., 2010). 
 
1.3.2.1 The IIS pathway 
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In addition to its roles in whole organism lifespan as detailed above, the IIS pathway in C. 
elegans has been found to be involved in nervous system ageing. daf-2 reduction-of-function 
mutants display delayed neuronal branching in touch receptor and cholinergic neurons (Pan et 
al., 2011, Tank et al., 2011, Toth et al., 2012). Furthermore, daf-16 appears to be required for the 
daf-2-mediated delay in appearance of neuronal defects, since daf-16;daf-2 double mutants 
display wild-type levels of branching in touch neurons (Tank et al., 2011). Interestingly, Toth 
and colleagues reported that the branching phenotypes observed in daf-2 and daf-16 mutant 
strains have subtle differences compared with those observed in aged wild-type animals. For 
example, ALM branching is rare (close to 0% incidence) in aged wild-type worms, but occurs at 
a ~10% frequency in daf-2 mutant animals of the same stage (Toth et al., 2012). This suggests 
that the profile of neuronal ageing phenotypes is different between wild-type animals and IIS 
mutants, although the reasons for this have not yet been explored.  
Like DAF-16, the heat shock factor (HSF)-1 transcription factor is repressed by insulin 
signalling. HSF-1 functions with DAF-16 to regulate proteostasis and chaperone expression 
when active in response to heat stress (Garigan et al., 2002). Reduction of HSF-1 activity results 
in a shortened lifespan (Morley and Morimoto, 2004) as well as a significantly higher frequency 
of touch neuron defects compared with wild-type (Toth et al., 2012, Pan et al., 2011). 
Furthermore, hsf-1;daf-16 double mutants do not show enhancement of the accelerated onset of 
phenotypes observed in single mutants, suggesting that these transcription factors may largely 
act within the same pathway to regulate neuronal ageing (Pan et al., 2011). Similarly, 
knockdown of HSF-1 by RNAi does not affect the lifespan of daf-16 mutants (Morley and 
Morimoto, 2004). 
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1.3.2.2 Mechanosensory signal transduction 
Mechanosensory-defective (or mec) mutants are defective in their response to gentle touch. 
Interestingly, some of these mutants also show lifespan phenotypes. Mutations in 
mechanosensory channel components MEC-2, MEC-4, MEC-6, MEC-10 and extracellular 
matrix (ECM) proteins MEC-5 and MEC-9 result in a shortened lifespan, whereas mutations in 
ECM protein MEC-1 and α-tubulin MEC-12 do not (Pan et al., 2011). However, these mutants 
all display a high frequency of neuronal defects at earlier ages compared with wild-type (Pan et 
al., 2011). Pan and colleagues suggest that defects in nerve attachment in certain mec-1 mutants 
may be responsible for the accelerated onset of defects observed in touch neurons. This is 
supported by the finding that animals carrying mutations in him-4 and fbl-1, which encode ECM 
proteins hemicentin (Vogel and Hedgecock, 2001) and fibulin (Kubota et al., 2012), are 
defective in nerve attachment and also display a high frequency of touch neuron defects at a 
young age (Pan et al., 2011).  
 
Some reports suggest that the ability of touch neurons to function correctly is correlated with 
healthy neuronal ageing. Tank and colleagues found that animals that display high levels of 
branching in touch neurons are also generally less touch sensitive (Tank et al., 2011), although a 
similar experiment led by others did not find any significant correlation (Toth et al., 2012). In 
addition, a gain-of-function mutation in the neuronal SLO-1 hyperpolarising ion channel results 
in touch insensitivity. slo-1 mutant animals also display an accelerated onset of touch neuron 
defects (Pan et al., 2011). The involvement of synaptic activity in neuronal ageing is not limited 
to touch neurons, as mutations in unc-13, unc-18 and dgk-1 that impact synaptic transmission in 
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the ventral and dorsal nerve cord also result in higher levels of beading in axons at young stages 
(Pan et al., 2011).  
 
1.3.2.3 MAPK signalling pathway 
MAPK signalling pathways regulate many processes including cell proliferation, differentiation, 
survival, and apoptosis. The neuronal c-Jun N-terminal kinase (jnk-1) is a positive modulator of 
DAF-16 and is involved in regulating longevity. Over-expression of jnk-1 extends lifespan in C. 
elegans, whereas loss of jnk-1 shortens lifespan (Oh et al., 2005). Loss of jnk-1 also results in a 
higher frequency of branching in both touch receptor and GABAergic neurons (Tank et al., 
2011). JKK-1 and MEK-1 are stress-responsive kinases upstream of JNK-1 that both show 
strong similarity to the mammalian MAP kinase kinase MKK-7 (Villanueva et al., 2001). Loss of 
mek-1 did not affect branching frequency, but loss of jkk-1 resulted in the acceleration of the 
branching phenotype (Tank et al., 2011). This suggests that a pathway involving JNK-1 and 
JKK-1, but not MEK-1, regulates neuronal ageing in C. elegans.  
 
Interestingly, the loss of genes strictly required for axon regeneration following laser axotomy, 
namely dlk-1, mkk-4 and pmk-3 (Hammarlund et al., 2009), does not affect the frequency of 
branching in touch neurons (Tank et al., 2011). This indicates that pathways involved in axon 
regeneration and age-related branching are distinct. Other C. elegans MAPK genes are also 
differentially involved in neuronal ageing. MLK-1 is thought to activate the p38 homolog PMK-
1, and loss of this protein results in accelerated branching in touch neurons. However, loss of 
NSY-1, orthologous to the human apoptosis signal-regulating kinases (ASKs) (Wes and 
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Bargmann, 2001), or SEK-1, a MAP kinase kinase able to activate both PMK-1 and JNK-1 
(Tanaka-Hino et al., 2002), did not affect neuronal ageing (Tank et al., 2011). 
 
1.3.2.4 Longevity and ageing effectors 
The capacity of other factors that regulate lifespan independently of IIS signalling to influence 
neuronal ageing has also been explored. For instance, the eat-2 mutant has impaired pharyngeal 
pumping that prevents feeding, and therefore displays a  DAF-16-independent lifespan extension 
that is attributed to caloric restriction (Raizen et al., 1995). Caloric restriction has been well-
studied in many systems and is one of the strongest environmental contributors to longevity 
(Fontana et al., 2010). Unlike daf-2 mutants, eat-2 mutants did not show a delayed onset of 
neuronal defects (Pan et al., 2011, Tank et al., 2011). 
 
lmn-1 encodes a conserved nuclear lamin protein in C. elegans. Mutations in lamin genes in 
humans are associated with an ageing disorder known as Hutchinson-Gilford Progeria Syndrome 
(HGPS) (Prokocimer et al., 2013), and in C. elegans result in a shortened lifespan (Haithcock et 
al., 2005). Transcript levels of lmn-1 are also reduced in adult worms compared with embryos 
(D'Angelo et al., 2009). Interestingly, mutations in lmn-1 also result in a higher frequency of 
touch neuron defects in young adulthood (Pan et al., 2011). 
 
Respiration can also affect ageing. Modest inhibition of respiration leads to an extension of 
lifespan in both invertebrates (Copeland et al., 2009, Kayser et al., 2004) and vertebrates 
(Lapointe and Hekimi, 2008, Dell'agnello et al., 2007), whereas severe impairments shorten 
lifespan (Rea et al., 2007). clk-1 encodes a ubiquinone biosynthetic enzyme, and mutations in 
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this gene result in reduced respiration and lifespan extension (Kayser et al., 2004). clk-1 mutants 
also show delayed touch neuron branching (Tank et al., 2011). In contrast, mev-1 respiratory 
chain mutants are short-lived (Ishii et al., 1990) and display an accelerated onset of branching 
(Tank et al., 2011). These data suggest that factors that affect respiration rates also affect 
neuronal health.  
 
The genetic factors that have been shown to modulate neuronal ageing as detailed above are 
summarised in Figure 1.8. 
 
Figure 1.8: Summary of genetic regulators of neuronal ageing in C. elegans. For details and citations, see text. 
Proteins of which loss/reduction-of-function have been shown to result in accelerated neuronal ageing are indicated 
in red, whereas proteins of which loss/reduction-of-function result in delayed neuronal ageing are indicated in blue.  
 
1.3.3 Do regulators of neuronal ageing act cell autonomously? 
These reports indicate that many molecular players regulate neuronal ageing in C. elegans. 
Although many of these genes are expressed in neurons, some, including daf-2 and daf-16, are 
also expressed in other tissues (Kimura et al., 2011). Despite this potential complexity, Tank and 
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colleagues found that neuronal re-expression of DAF-16 in daf-16;daf-2 double mutants was 
sufficient to rescue the delayed onset of neuronal defects observed in daf-2 single mutants, 
identifying neurons as the cellular focus of DAF-16-mediated control of neuronal ageing (Tank 
et al., 2011). The converse experiment, using RNAi to knock down daf-16 solely in non-neuronal 
cells in a daf-2 mutant, resulted in a restoration to wild-type lifespan, but did not affect the delay 
in neuronal branching that is observed in daf-2 mutants (Tank et al., 2011). In contrast, others 
showed that re-expression of DAF-16 in all neurons or in body wall muscles in a daf-16 single 
mutant was not sufficient to rescue the onset of neuronal defects (Pan et al., 2011). It is possible 
that these contrasting observations could be due to differences in scoring parameters. In addition, 
Tank et al., observed that knock down of daf-2 in non-neuronal cells resulted in wild-type levels 
of branching in touch neurons despite these animals displaying an extended lifespan (Tank et al., 
2011). Together these observations suggest that daf-2 and daf-16 are able to regulate neuronal 
ageing in a cell-autonomous manner. In addition, these findings indicate that, at least in the case 
of the IIS pathway, regulation of neuronal ageing and whole organism lifespan can be decoupled 
from one another.  
 
As previously mentioned, the IIS-regulated transcription factor HSF-1 was also reported to 
regulate neuronal ageing (Pan et al., 2011, Toth et al., 2012). Interestingly, re-expression of 
HSF-1 solely in touch neurons was able to completely rescue this phenotype (Toth et al., 2012), 
indicating that, like DAF-16, HSF-1 can also act cell-autonomously to regulate neuronal ageing.  
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1.4 Thesis overview 
There is strong interest in the roles of Tau in neuronal ageing and pathology, and significant 
advancement has been made in this field despite the challenges involved with functional 
redundancy in rodent models. In C. elegans, the Tau homolog PTL-1 was first characterised 
almost two decades ago, but until now only a limited understanding of its functions within 
neurons and in the context of ageing has been gained. We have investigated the functions of 
PTL-1 within the stress response, neuronal ageing, and longevity in C. elegans. Results of these 
investigations are detailed in four chapters. The first chapter is a brief description of the ptl-1 
mutant strains used in this study. The second chapter explores the role of PTL-1 in the stress 
response and longevity, and its relationship with the transcription factor SKN-1 that is involved 
in the induction of detoxification enzymes. The third chapter describes the functions of PTL-1 in 
neuronal ageing in two distinct subsets of neurons and demonstrates that the levels of PTL-1 are 
critical in regulating both tissue ageing and lifespan. In the fourth chapter, investigations on the 
role of PTL-1 in ageing are extended by investigating whether the maintenance of structural 
integrity by PTL-1 is cell autonomous, and also by exploring the role of PTL-1 within the touch 
neurons in regulating longevity.  
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2.1 Materials 
2.1.1 Chemicals and reagents 
- 6x Loading Dye Solution (Fermentas, Glen Burnie, MD, Australia) 
- Acetic acid, glacial (Ajax Laboratory Chemicals, Taren Point, NSW, Australia) 
- Agar bacteriological (In Vitro, Noble Park North, VIC, Australia) 
- Agarose (DNA grade) (Progen Industries, Darra, QLD, Australia) 
- Ampicillin sodium salt (Amresco, Solon, USA) 
- Bacto peptone (Amyl Media, Dandenong, VIC, Australia) 
- Calcium chloride (Riedel-de Haën, Seelze, Germany) 
- Carbenicillin (AG Scientific, San Diego, CA, USA) 
- Cholesterol (Sigma Chemical Company, Castle Hill, NSW, Australia) 
- Copper (II) Sulfate Pentahydrate  (Ajax Laboratory Chemicals) 
- DAKO pen (Dako, North Sydney, NSW, Australia) 
- DAPI fluorescent mounting medium (Dako) 
- Deoxynucleotide triphosphates (dNTPs) (Bioline, Alexandria, NSW, Australia) 
- Di-potassium hydrogen orthophosphate (Ajax Laboratory Chemicals) 
- Disodium ethylenediamine tetraacetate (Ajax Laboratory Chemicals) 
- Di-sodium hydrogen orthophosphate (Ajax Laboratory Chemicals) 
- Ethidium bromide (Roche Molecular Biochemicals) 
- Ethylene glycol tetraacetic acid (EGTA) (Amresco) 
- Ethylenediaminetetraacetic acid (EDTA) (Ajax Laboratory Chemicals) 
- Generuler™ DNA ladder mix (Progen Industries) 
- Glucose (Ajax Laboratory Chemicals) 
- Glycerol (Sigma Chemical Company, Castle Hill, NSW, Australia) 
- Hydrogen peroxide (H2O2) 30 % (w/v) (Sigma Chemical Company, NSW, Australia) 
- Iron(II) sulfate (Sigma Chemical Company, Castle Hill, NSW, Australia) 
- Isopropanol (BDH Chemicals, Port Fairy, VIC, Australia) 
- Isopropyl β-D-1-thiogalactopyranoside (IPTG) (Biochemicals, Gymea, NSW, Australia) 
- Magnesium chloride (Biolab Scientific) 
- Magnesium sulfate heptahydrate (BDH Chemicals, Port Fairy, VIC, Australia) 
- Methanol (Sigma-Aldrich) 
- Mounting media (Dako) 
- Neomycin, G418 (Sigma-Aldrich) 
- Normal goat serum (Life Technologies-Invitrogen) 
- Nystatin (Sigma-Aldrich) 
- Paraformaldehyde (Sigma Chemical Company, Castle Hill, NSW, Australia) 
- Paraquat dichloride hydrate (Sigma Chemical Company, Castle Hill, NSW, Australia) 
- Poly-L-lysine (Sigma-Aldrich) 
- Potassium acetate (Crown Technology Inc., Indianapolis, IN, USA) 
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- Potassium chloride (BDH Chemicals) 
- Potassium dihydrogen orthophosphate (BDH Chemicals) 
- Potassium phosphate (Ajax Laboratory Chemicals) 
- Puromycin dihydrochloride (Sigma-Aldrich) 
- Sodium acetate (Ajax Laboratory Chemicals) 
- Sodium azide (Sigma Chemical Company, Castle Hill, NSW, Australia) 
- Sodium chloride (Ajax Laboratory Chemicals) 
- Sodium dodecyl sulfate (lauryl sulfate sodium salt) (SDS) (Sigma Chemical Company) 
- Sodium hydroxide (Ajax Laboratory Chemicals) 
- Sodium hypochlorite 12.5% w/v solution (Nuplex Industries, Seven Hills, Australia) 
- Levamisole hydrochloride (Sigma Chemical Company, Castle Hill, NSW, Australia) 
- Tris‐hydroxymethyl‐methylamine (Tris) (Ajax Laboratory Chemicals) 
- Triton X (Amresco) 
- Tween 20 (Amresco) 
- Yeast extract (In Vitro, Noble Park North, VIC, Australia) 
- Zinc sulfate (Sigma Chemical Company, Castle Hill, NSW, Australia) 
 
2.1.2 Antibodies 
- Anti V5-HRP, generating by crosslinking an Anti-V5 antibody (R960-25; mouse 
monoclonal IgG2) with horseradish peroxidase (HRP) using glutaraldehyde (Life 
Technologies) 
- Monoclonal Anti-Acetylated Tubulin antibody produced in mouse, clone 6-11B-1 
(Sigma-Aldrich; #T7451) 
- Alexa Fluor 555 goat anti-rabbit IgG (Invitrogen, # A-21428) 
- Alexa Fluor 488 F(ab')2 Fragment of Goat Anti-Mouse IgG (H+L) Antibody (Invitrogen 
#A-11017) 
 
2.1.3 Enzymes 
- Phusion® High-Fidelity DNA Polymerase (New England Biolabs, #M0530S) 
- Taq DNA Polymerase with Standard Taq Buffer (New England Biolabs, #M0273S) 
- T4 DNA ligase (New England Biolabs) 
- Gateway® BP Clonase® II enzyme (Life Technologies- Invitrogen) 
- Gateway® LR Clonase® II enzyme (Life Technologies- Invitrogen) 
- Gateway® LR Clonase® II Plus enzyme (Life Technologies- Invitrogen) 
- Proteinase K (Boehringer Ingelheim Pty. Ltd., North Ryde, NSW, Australia) 
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2.1.4 Kits and commercial reagents 
- S.N.A.P.™ UV-Free Gel Purification Kit (Life Technologies) 
- QIAquick PCR Purification Kit (Qiagen) 
- JETSTAR 2.0 Plasmid Midiprep kit (Astral Scientific) 
 
2.1.5 Equipment 
- Microscopes: Nikon stereo microscope, Olympus BX51 Microscope, Olympus 
- Biolistic transformation of C. elegans: PDS-1000/He™ System from BioRad 
 
2.1.6 External procedures 
- Sequencing of DNA was performed by Macrogen (Seoul, Korea)  
- Oligonucleotide primers for PCR were generated by Sigma-Aldrich and Integrated DNA 
Technologies.  
 
2.1.7 Bacterial strains 
- OP50 E. coli 
- HB101 E. coli [F- mcrB mrr hsdS20(rB- mB-) recA13 leuB6 ara-14 proA2 lacY1 galK2 
xyl-5 mtl-1 rpsL20(SmR) glnV44 λ-] 
- HT115 E. coli [F-, mcrA, mcrB, IN(rrnD-rrnE)1, rnc14::Tn10(DE3 lysogen: lavUV5 
promoter -T7 polymerase]. 
- DH5alpha E. coli [F- endA1 glnV44 thi-1 recA1 relA1 gyrA96 deoR nupG 
Φ80dlacZΔM15Δ(lacZYA-argF)U169, hsdR17(rK- mK+), λ–] 
- One Shot® TOP10 Chemically Competent E. coli (Life Technologies- Invitrogen) 
[FmcrAΔ(mrr-hsdRMS-mcrBC) φ80lacZΔM15 ΔlacX74 nupG recA1 araD139 
Δ(araleu)7697 galE15 galK16 rpsL(StrR) endA1 λ-] 
- Alpha-select silver efficiency Chemically Competent E. coli (Bioline) [F-
 deoR endA1 recA1 relA1 gyrA96 hsdR17(rk-, mk+) supE44 thi-1 phoA Δ(lacZYA-
argF)U169 Φ80lacZΔM15 λ-] 
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2.1.8 Nematode strains 
2.1.8.1 Strains received from the Caenorhabditis Genetics Centre (CGC) 
Strain name Genotype Source 
N2 Wild-type, strain Bristol CGC 
RB809 ptl-1(ok621) III; not outcrossed CGC 
FX00543 ptl-1(tm543) III; not outcrossed National Bioresource 
Project, Japan 
CZ10175 zdIs5[Pmec-4::gfp + lin-15(+)] I CGC 
EG1285 oxIs12[Punc-47::gfp + lin-15(+)] X CGC 
MT464  unc-5(e53) IV; dpy-11(e224) V; lon-2(e678) X CGC 
LD1 ldIs7 [skn-1B/C::GFP + pRF4(rol-6(su1006))] CGC 
LD1171 ldIs3 [Pgcs-1::GFP + pRF4(rol-6(su1006))] CGC 
CB450 unc-13(e450) I CGC 
CB928 unc-31(e928) IV CGC 
TU3403 ccIs4251 [Pmyo-3::GFP(NLS)::LacZ  + Pmyo-3::GFP + 
dpy-20(+)]. uIs71 [pCFJ90(Pmyo-2::mCherry) + Pmec-
18::sid-1]; sid-1(qt2) V 
CGC 
TJ356 zIs356 [Pdaf-16::daf-16a/b::GFP + rol-6] IV CGC 
EU1 skn-1(zu67) IV/ nT1 [unc-?(n754) let-?] (IV;V) CGC 
TU3401 ccIs4251 [Pmyo-3::GFP(NLS)::LacZ + Pmyo-3::GFP + 
dpy-20(+)]. uIs71 [pCFJ90(Pmyo-2::mCherry) + mec-
18p::sid-1] ; sid-1(qt2) V 
CGC 
SJ4005 zcIs4[Phsp-4::gfp] CGC 
 
2.1.8.2 Strains generated in this project 
Strain name Genotype 
APD004 ptl-1(ok621) III; outcrossed 6x to wild-type 
APD009 ptl-1(ok621) III; oxIs12[Punc-47::gfp + lin-15(+)] X 
APD010 ptl-1(ok621) III; zdIs5[Pmec-4::gfp + lin-15(+)] I 
APD011 ptl-1(ok621) III; bus-17(e2800) X. 
APD015 ptl-1(tm543) III 
APD016 zdIs5 I;  ptl-1(tm543) III 
APD017 oxIs12 X; ptl-1(tm543) III 
APD018 apdIs4[Pptl-1:hTau40:ptl-1 3′ UTR; Pmyo-2::mCherry; Prpl-28::PuroR::rpl-
16_outron::NeoR::let-858_3′ UTR] 
APD021 apdIs5[Pptl-1:ptl-1::v5:ptl-1 3′ UTR; Pmyo-2::mCherry; Prpl-28::PuroR::rpl-
16_outron::NeoR::let-858_3′ UTR] 
APD025 apdIs4; outcrossed 6x to wild-type 
APD026 apdIs5; outcrossed 6x to wild-type 
APD030 apdIs4; zdIs5 I; ptl-1(ok621) III 
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Strain name Genotype 
APD031 apdIs4; zdIs5 I 
APD032 apdIs4; oxIs12 X; ptl-1(ok621) III 
APD033 apdIs4; oxIs12 X 
APD034 apdIs4; ptl-1(ok621) III 
APD035 apdIs5; zdIs5 I; ptl-1(ok621) III) 
APD036 apdIs5; zdIs5 I 
APD037 apdIs5; oxIs12 X; ptl-1(ok621) III 
APD038 apdIs5; oxIs12 X 
APD039 apdIs5; ptl-1(ok621) III 
APD050 zdIs5 I; uIs71 
APD055 ptl-1(ok621) III;ldIs7  
APD059 ptl-1(ok621); zIs356 IV 
APD062 ptl-1(ok621) III;daf-2(e1370) III 
APD069 ptl-1(tm543) III;ldIs7  
APD066 oxIs12; Pmec-18::sid-1; Pmyo-2::mCherry; sid-1(qt2) 
APD070 apdIs9[Pmec-7:ptl-1::v5:PTL-1 3′UTR]; outcrossed 6x to wild-type 
APD074 apdIs9[Pmec-7:ptl-1::v5:PTL-1 3′UTR]; ptl-1(ok621) III; oxIs12 
APD075 apdIs9[Pmec-7:ptl-1::v5:PTL-1 3′UTR]; ptl-1(ok621) III; zdIs5 
APD076 apdIs9[Pmec-7:ptl-1::v5:PTL-1 3′UTR]; ptl-1(ok621) III 
APD077 apdIs5; ldIs7  
APD078 apdIs5; ldIs7; ptl-1(ok621) III 
APD081 apdIs9[Pmec-7:ptl-1::v5:PTL-1 3′UTR]; oxIs12 
APD082 apdIs9[Pmec-7:ptl-1::v5:PTL-1 3′UTR]; zdIs5 
APD083 daf-2(e1370) III; ldIs7 
APD084 daf-2(e1370) III; ldIs7; ptl-1(ok621) III 
APD088 apdIs10[Paex-3:ptl-1::v5:ptl-1 3′ UTR; Pmyo-2::mCherry; Prpl-28::PuroR::rpl-
16_outron::NeoR::let-858_3′ UTR] 
APD089 apdIs4; ldIs7 
APD090 apdIs4; ldIs7; ptl-1(ok621) III 
APD091 ldIs3; ptl-1(ok621) III 
APD092 ldIs3; ptl-1(tm543) III 
APD093 apdIs5; ldIs3  
APD094 apdIs5; ldIs7; ptl-1(ok621) III 
APD096 apdIs10; outcrossed 6x to wild-type 
APD097 apdIs10; zdIs5 I 
APD098 apdIs10; zdIs5 I; ptl-1(ok621) III 
APD099 apdIs10; oxIs12 X 
APD100 apdIs10; oxIs12 X; ptl-1(ok621) III 
APD101 apdIs10; ldIs7 
APD102 apdIs10; ldIs7; ptl-1(ok621) III 
APD103 apdIs10; ldIs3 
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Strain name Genotype 
APD104 apdIs10; ldIs3; ptl-1(ok621) III 
APD105 apdIs10; ptl-1(ok621) III 
APD113 jsIs682[Prab-3::GFP::RAB-3; pJM23];lin-15B(n765) X; vdEx263[Pmec-4::mCherry + 
odr-1::dsRed]. vdEx263 was a kind gift from Nick Valmas and Massimo Hilliard 
(Queensland Brain Institute, University of Queensland) 
APD114 jsIs682;lin-15B(n765) X; vdEx263; ptl-1(ok621) 
APD118 unc-13(e450) I; ldIs7  
APD120 unc-31(e928) IV; ldIs7  
APD121 unc-13(e450) I; ldIs3  
APD122 unc-31(e928) IV; ldIs3 
APD123 apdEx10[Pptl-1:ptl-1::gfp:ptl-1 3′ UTR; Prpl-28::PuroR::rpl-16_outron::NeoR::let-
858_3′ UTR] 
APD125 unc-13(e450) I; ldIs7; ptl-1(ok621) III 
APD126 unc-31(e928) X; ldIs7; ptl-1(ok621) III 
APD127 ptl-1(ok621) III; skn-1(zu67) IV/nT1[unc-?(n754) let-?](IV;V) 
APD128 apdEx10; sid-1(pk3321); uIs69  
APD130 apdEx10; sid-1(qt2); uIs71  
APD136 apdEx13; outcrossed 6x to wild-type 
APD138 apdEx13; ldIs7 
APD139 apdEx13; ldIs7; ptl-1(ok621) III 
APD140 apdEx13; ldIs3 
APD141 apdEx13; ldIs3; ptl-1(ok621) III 
 
2.1.9 Integrated and extrachromosomal arrays 
Array name Plasmid used Genotype 
apdIs4 pY007 apdIs4[Pptl-1:hTau40:ptl-1 3′ UTR; Pmyo-2::mCherry; Prpl-
28::PuroR::rpl-16_outron::NeoR::let-858_3′ UTR] 
apdIs5 pY005 apdIs5[Pptl-1:ptl-1::v5:ptl-1 3′ UTR; Pmyo-2::gfp; Prpl-28::PuroR::rpl-
16_outron::NeoR::let-858_3′ UTR] 
apdIs9 pY009 apdIs9[Pmec-7:ptl-1::v5:ptl-1 3′ UTR; Pmyo-2::mCherry; Prpl-
28::PuroR::rpl-16_outron::NeoR::let-858_3′ UTR] 
apdIs10 pY011 apdIs10[Paex-3:ptl-1::v5:ptl-1 3′ UTR; Pmyo-2::mCherry; Prpl-
28::PuroR::rpl-16_outron::NeoR::let-858_3′ UTR] 
apdEx10 pY013 apdEx10[Pptl-1:ptl-1::gfp:ptl-1 3′ UTR; Prpl-28::PuroR::rpl-
16_outron::NeoR::let-858_3′ UTR] 
apdEx13 pY015 apdEx13[Pgpa-4:ptl-1::v5:ptl-1 3′ UTR; Pmyo-2::mCherry; Prpl-
28::PuroR::rpl-16_outron::NeoR::let-858_3′ UTR] 
 
2.1.10 Plasmid list 
Plasmid Composition Vector Insert Generated by 
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name 
pY001 Pptl-1 L4L1R pDONRP4P1R Pptl-1 (from gDNA) YL Chew 
pY002 ptl-1::v5 L1L2 pDONR221 ptl-1::v5 (from cDNA) YL Chew 
pY003 ptl-1 3′UTR L2RL3 pDONRP2RP3 ptl-1 3′UTR (from gDNA) YL Chew 
pY004 v5::ptl-1 L1L2 pDONR221 v5::ptl-1 (from cDNA) YL Chew 
pY005 Pptl-1: ptl-1::v5: ptl-1 
3′UTR in pBCN41 
pBCN41 Multisite LR of pY001, 
PY002, pY003  
YL Chew 
pY006 Pmec-7 L4L1R pDONRP4P1R Pmec-7 (from gDNA) YL Chew 
pY007 Pptl-1: hTau40: ptl-1 
3′UTR in pBCN40 
pBCN40 Multisite LR of pY001, 
hTau40 (LI), pY003 
YL Chew 
pY008 Pptl-1: v5::ptl-1: ptl-1 
3′UTR in pBCN40 
pBCN40 Multisite LR of pY001, 
PY004, pY003 
YL Chew 
pY009 Pmec-7: v5::ptl-1: ptl-1 
3′UTR in pBCN40 
pBCN40 Multisite LR of pY006, 
pY002, pY003 
YL Chew 
pY010 Pmec-7: v5::ptl-1: ptl-1 
3′UTR in pBCN40 
pBCN40 Multisite LR of pY006, 
PY004, pY003 
YL Chew 
pY011 Paex-3 L4L1R pDONRP4P1R Paex-3(from gDNA) YL Chew 
pY012 ptl-1::gfp in pPD95.75 pPD95.75 ptl-1 (from cDNA) cloned 
HindIII/SmaI into pPD95.75 
X Fan 
pY013 Pptl-1:ptl-1gfp:unc-54 
3′ UTR in pBCN41 
pBCN41 ptl-1::gfp  from pY012 
cloned ClaI/ApaI into pY005 
X Fan 
pY014 Pgpa-4 L4L1R pSBlim-7 Pgpa-4 (from gDNA) cloned 
SphI/AgeI into pSBlim-7 
YL Chew 
pY015 Pgpa-4: ptl-1::v5: ptl-1 
3′UTR in pBCN40 
pBCN40 Multisite LR of pY014, 
pY002, pY003 
YL Chew 
Where cDNA is complementary DNA and gDNA is genomic DNA from C. elegans. 
 
2.1.11 Primers used for cloning (    s q     s     w       5′    3′) 
To amplify PTL-1::V5 cDNA with attB1 and attB2 sites 
Forward: 
GGGGACAAGTTTGTACAAAAAAGCAGGCTCAATGTCAACCCCTCAATCAGAG 
Reverse: 
TCACGTAGAATCGAGACCGAGGAGAGGGTTAGGGATAGGCTTACCCGCCGCGCGAT
TGAATATAAAATCAGG 
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To amplify V5::PTL-1 cDNA with attB1 and attB2 sites 
Forward: 
ATGGGTAAGCCTATCCCTAACCCTCTCCTCGGTCTCGATTCTACGGCGGCGTCAACC
CCTCAATCAGAG 
Reverse: 
GGGGACCACTTTGTACAAGAAAGCTGGGTTCAGCGATTGAATATAAAATCAGGAG 
 
To clone the PTL-1 cDNA into pPD95.75 using HindIII and SmaI restriction sites 
Forward: TTTTAAGCTTTTGGTCCGTTGTCAGTCGAG 
Reverse: TTTTCCCGGGGGAGACCGAGGAGAGGGTTAG 
 
To amplify the ptl-1 promoter with attB4 and attB1r sites 
Forward: GGGGACAACTTTGTATAGAAAAGTTGCATTCCGCATGGTTGGAAAGAG 
Reverse: 
GGGGACTGCTTTTTTGTACAAACTTGATTTTTCCTGAAAAATTGAAATTGGGAG 
 
To clone the gpa-4 promoter into pSBlim-7 (entry clone with attL4 and attL1r sites) using 
SphI and AgeI restriction sites 
Forward: AATTGCATGCGCTGATTTGCCGTTTGTCG  
Reverse: CTTATTCATTTTGTGAACACTTTTCAACAACCGGT 
 
To amplify the aex-3 promoter with attB4 and attB1r sites 
Forward: GGGGCAACTTTGTATAGAAAAGTTGGCTTCCACAAAAACTGCCGC 
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Reverse: GGGGCTGCTTTTTTGTACAAACTTGTTTTTATTAGGATAGGTACATTGG 
 
To amplify the mec-7 promoter with attB4 and attB1r sites 
Forward: GGGGCAACTTTGTATAGAAAAGTTGTAGTAATCTAGAAATGTAAACC 
Reverse: GGGGCTGCTTTTTTGTACAAACTTGGTTGCTTGAAATTTGGACCC 
 
To amplify the ptl-1 3′UTR with attB4 and attB1r sites 
Forward: 
GGGGACAGCTTTCTTGTACAAAGTGGGATAACAATCGCTGATGTATACCGCGC 
Reverse: 
GGGGACAACTTTGTATAATAAAGTTGACACTTTTAATTACCACTTTATTGAAGAG 
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2.2 Methods 
2.2.1 Nematode maintenance 
C. elegans strains were cultured on Nematode Growth Medium [NGM: 2 % (w/v) agar, 50 mM 
NaCl, 0.25 % (w/v) peptone, 1 mM CaCl2, 5 µg/ml cholesterol, 25 mM KH2PO4 and 1 mM 
MgSO4 in H2O] plates seeded with the Escherichia coli strain OP50, unless otherwise specified. 
Hermaphrodite animals were used for all experiments. The wild-type strain used for all 
experiments is N2 (Bristol), obtained from the CGC. These were cultured at 15–25 ºC depending 
on the desired growth rate.  
For maintenance in liquid culture: liquid medium consisted of S-Basal [0.1 M NaCl, 50 mM 
potassium phosphate pH 6.0, 5 µg/ml cholesterol in H2O] that was supplemented with 10 mM 
potassium citrate pH 6.0, 1% (v/v) trace metals solution [5 mM Na2EDTA (1.86 g), 2.5 mM 
FeSO4, 1 mM MnCl2, 1 mM ZnSO4, 0.1 mM CuSO4], 3 mM CaCl, and 3 mM MgSO4 to make 
S-Medium. Up to 300,000 young adult animals could be cultured in 50 mL of S-Medium 
supplemented with HB101 bacteria used to feed the worms. To prevent microbial contamination, 
streptomycin (50 µg/mL) and nystatin (300 U/mL) were added to the culture medium.  
In the case where animals were contaminated with bacterial or fungal contamination, gravid 
hermaphrodites were placed into 20 µl of bleaching solution (1.7 M NaOH, 2.1% v/v NaOCl) on 
an OP50-seeded NGM plate. Surviving eggs were maintained on plates or in liquid as described. 
 
2.2.2 Synchronisation of animals 
Large synchronous populations were obtained by washing a few thousand gravid hermaphrodites 
in bleaching solution. Bleaching solution ruptures adult hermaphrodites but the eggs that are 
released survive and are recovered in M9 buffer [22 mM KH2PO4, 50 mM Na2HPO4, 86 mM 
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NaCl, 1 mM MgSO4] in the absence of bacterial food. Eggs were left in M9 buffer for at least 8 
hours to allow them to hatch and arrest at the first larval stage (L1). Larvae were then distributed 
on to OP50-seeded NGM plates allowing them to grow synchronously. Alternatively, young 
adult animals were plated onto an OP50-seeded NGM plate and allowed to lay eggs for up to 4 
hours at the desired temperature. The parent was then removed and the eggs allowed to hatch.  
 
2.2.3 Genotyping by PCR 
For determination of the strain genotype, individual worms were picked into a lysis solution [50 
mM KCl, 10 mM Tris pH8.3, 2.5 mM MgCl2, 0.45 % NP-40, 0.45 % Tween-20, 0.01 % gelatine 
and 0.5 mg/ml Proteinase K (Promega)] in a 0.2 mL tube and frozen at -80 °C for at least 10 
minutes. These were then placed at 65 °C for 60 minutes followed by incubating at 95 °C for 15 
minutes in a thermocycler. The entire lysed sample was then used as a template for PCR using 
the standard Taq polymerase and buffer system [20 mM Tris-HCl, 10 mM (NH4)2SO4, 10 mM 
KCl, 2 mM MgSO4, 0.1% Triton
®
 X-100 pH 8.8 @ 25°C] from New England Biolabs. Primers 
were used at a final concentration of 0.2 µM for all reactions. PCR conditions for the ptl-1 
mutant alleles are detailed below: 
 
ptl-1(ok621) genotyping:  
Primers used are PTL-1 FF2 (CGAACCTGAACCGGAACCAG), PTL-1 IR2 
(GAGATGGCGCTGTTGAAGCAG) and PTL-1 FR2 (GCCACTTCGCTGGAAATTACC). 
Cycling conditions for the PCR: 94°C 2 min, then 94°C 20 sec, 65°C 20 sec, 72°C 45 sec (33 
cycles in total of steps 2 to 4), then 72° C 5 min.  
Expected size for: wild-type allele: 751 bp; ok621 allele: 461 bp. 
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ptl-1(tm543) genotyping:  
Primers used are PTL-1 FR2 (GCCACTTCGCTGGAAATTACC), PTL1tm543 FF 
(GTTCTGTCCGTCTTATTGTATCC). Cycling conditions for the PCR: 94°C 2 min, then 94°C 
20 sec, 65°C 20 sec, 72°C 45 sec (33 cycles in total of steps 2 to 4), then 72° C 5 min.  
Expected size for: wild-type allele: 1170 bp; tm543 allele: 382 bp. 
 
2.2.4 Generation of strains by crossing 
For outcrossing, all strains were mated with N2 males for six generations.  
 
For crosses with strains containing fluorescent reporters, progeny of the cross were genotyped 
for the desired mutant allele by PCR and screened by microscopy (both under the dissecting and 
upright microscope) to return both components to homozygosity. An exception is the Pgcs-1:gfp 
(ldIs3) fluorescence reporter, which has a low signal under normal (unstressed) conditions. These 
were genotyped by PCR for the Pgcs-1::gfp transgene using primers Pgcs-1for 
(GGACTACGGTAGGAGTTCTG) and gfp_rev (CGGGCATGGCACTCTTG). Animals that 
contained the transgene produced a band at 586 bp.  In addition, for the GFP::RAB-3 (jsIs821 
III) transgene that is on the same chromosome as ptl-1, recombinant animals that contained both 
the GFP::RAB-3 transgene and a ptl-1(ok621) mutation were generated by allowing 
heterozygous progeny of a cross between ptl-1(ok621) males and  GFP::RAB-3  hermaphrodites 
to generate self progeny. At a low frequency (~3-4 per 100), these self progeny undergo 
recombination on one chromosome in between these genetic components. Recombinant progeny 
were isolated after screening for both components. 
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For crosses with strains containing mutant alleles, progeny of the cross were allowed to self and 
the parent genotyped by PCR for the allele in question. For the daf-2(e1370) III allele, which is a 
single base change, animals were genotyped by dauer assay, as daf-2 mutant animals but not 
wild-type or ptl-1(ok621) animals would form dauers constitutively when moved to 25 °C 
(Riddle et al., 1981, Vowels and Thomas, 1992). As both daf-2 and ptl-1 genes are located on 
chromosome III, it was necessary to isolate recombinant animals to return both daf-2(e1370) and 
ptl-1(ok621) alleles to homozygosity. 5 recombinant lines were isolated and three were assayed 
for the same phenotype (SKN-1::GFP re-localisation to intestinal nuclei in response to stress, see 
section 2.2.9). As all three lines produced the same phenotype (Appendix 1), we proceeded to 
use one line (APD084) for subsequent experiments.  
 
Another more complicated cross involved the skn-1(zu67) IV mutation, which is also a single 
base change. As skn-1(zu67) animals are maternal lethal (Bowerman et al., 1992), i.e. they 
produce dead eggs and no live progeny, the mutation is balanced with a nT1[unc-?(n754) let-?] 
(IV;V) chromosomal translocation. In summary, animals that are homozygous for the nT1 
balancer (nT1/nT1) are dead, animals that are heterozygous (skn-1(zu67)/nT1) are alive but move 
in an uncoordinated manner (due to the presence of the unc allele in nT1), and animals that are 
homozygous for the skn-1 allele and do not contain the nT1 balancer (skn-1(zu67)/skn-1(zu67)) 
are alive and display wild-type movement but produce dead eggs. To generate skn-1(zu67);ptl-
1(ok621) double mutant animals, ptl-1(ok621) males were mated with skn-1(zu67)/nT1 
hermaphrodites and wild-type moving progeny containing the ptl-1(ok621) allele were then 
crossed with progeny displaying uncoordinated movement and also containing ptl-1(ok621). A 
detailed schematic for this cross is shown in Figure 2.1.  
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Figure 2.1: Schematic for the generation of skn-1(zu67); ptl-1(ok621) double mutant animals. Details of strain 
construction are provided in the text. For all assays using skn-1(zu67), first generation skn-1(zu67)/skn-1(zu67) 
progeny of skn-1(zu67)/nT1[unc-?(n754) let-?] parents with or without the ptl-1(ok621) allele were picked based on 
a wild-type movement phenotype. The phrase “to self” indicates that animals were allowed to self-fertilise. 
 
The presence of single base changes was verified by sequencing (Macrogen, Korea).  
 
2.2.5 Generation of plasmid constructs 
Cloning was performed using the Gateway (Invitrogen, Life Technologies) system according to 
the manufacturer’s instructions or by conventional restriction enzyme digest where appropriate. 
Dual antibiotic selection plasmids pBCN40 and pBCN41, encoding visual markers Pmyo-
2::mCherry and Pmyo-2::gfp, respectively, were generously provided by Drs J. Semple and B. 
Lehner (EMBL Centre for Genomic Regulation Systems Biology Unit, Barcelona). The hTau40 
entry clone (in pENTR-SD-D-Topo) was kindly provided by Dr L. Ittner (Brain and Mind 
Research Institute, University of Sydney). Detailed information regarding templates and primers 
used can be found in sections 2.1.10 and 2.1.11 The Multisite LR reaction (Invitrogen) was used 
to combine entry clones into destination vector pBCN40 or pBCN41. 
 
2.2.6 Generation of transgenic lines  
Transgenic worms for rescue experiments were generated by biolistic transformation using the 
PDS-1000/He™ particle delivery system (BioRad) according to the manufacturer’s instructions. 
Wild-type worms were bombarded with 7 µg of linearised plasmid DNA using previously 
established methods (Praitis et al., 2001). Selection post-bombardment was undertaken using the 
dual antibiotic selection protocol (Semple et al., 2012) (Figure 2.2). 
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Figure 2.2: Generation of transgenic C. elegans. Using the Gateway recombination cloning system (Life 
Technologies), 5ʹ entry clones containing the promoter sequence, middle entry clones containing the gene coding 
sequence, and 3ʹ entry clones containing the 3ʹ UTR were generated following a BP reaction. These were combined 
in a second (LR) recombination reaction to generate destination vectors that also contained a dual antibiotic 
selection marker and a fluorescence visual marker to facilitate selection of transformed animals. These constructs 
were introduced into wild-type animals by biolistic transformation. The progeny of these bombarded worms were 
isolated and incubated in antibiotic selection media for 3-4 days. Surviving animals were screened for the presence 
of the visual marker (Pmyo-2::gfp or Pmyo-2::mCherry) and transgenic lines were subsequently isolated.  
 
Integrated lines or extrachromosomal lines were selected using the visual marker Pmyo-
2::mCherry or Pmyo-2::gfp. Transgenic lines were all outcrossed six times to wild-type before 
assays were conducted.  
 
2.2.7 Imaging of fluorescing transgenic lines 
Animals were prepared for microscopy by anesthetising them in 0.1–0.2% levamisole (Sigma) in 
M9 buffer on small pads made of 3–4% agarose (Progen) in M9 buffer.  
 
2.2.8 Touch sensitivity assay: 
Animals were synchronised by hypochlorite treatment and cultured at 25 °C, with one day-old 
adults used for all assays. Touch assays were performed according to established methods 
(Chalfie and Sulston, 1981). A positive response was determined as acceleration of the animal 
away from touch. The number of positive responses was then expressed as a percentage of total 
touches (ten) for each animal. This positive score was combined for all animals of the same 
genotype and strains compared using a One-way ANOVA, Bonferroni post-test (GraphPad Prism 
6, GraphPad Software Inc.). Assays were conducted blind to the genotype of the worms. 
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2.2.9 SKN-1::GFP, Pgcs-1::gfp and DAF-16::GFP localisation experiments 
For SKN-1::GFP experiments: animals were cultured at 20 °C and larval stage 2 (L2) worms 
used for analysis in all experiments. To observe GFP re-localisation under stress conditions, 
animals were incubated with 50 mM sodium azide (Sigma) in M9 buffer (azide treated), or M9 
alone (untreated) for 10 minutes with gentle agitation at room temperature. SKN-1::GFP 
localisation experiments were conducted using the ldIs7 strain (integrated SKN-1 B/C::GFP), 
where expression was reported to be the highest in the L2 stage (An and Blackwell, 2003). 
Initially, SKN-1::GFP intestinal nuclear localisation was scored as positive if GFP was observed 
in any of the intestinal nuclei. We later refined our scoring scheme for all other SKN-1::GFP 
assays such that SKN-1::GFP nuclear localisation was scored as “high” if GFP was seen in all 
intestinal nuclei, “medium” if GFP was observed only in anterior or posterior nuclei, or “low” if 
GFP was not observed in any intestinal nuclei, essentially as in (Tullet et al., 2008). Untreated 
animals for all experiments showed no response. For daf-2(e1370) mutant strains, animals were 
incubated at either 15 or 20 °C and SKN-1::GFP assays conducted using the refined scoring 
scheme as above. 
DAF-16::GFP localisation assays were conducted using the zIs356 transgene (integrated DAF-
16::GFP). For DAF-16::GFP localisation experiments, day 1 adult animals incubated with 50 
mM sodium azide (azide treated) or M9 buffer (untreated) for 10 minutes with gentle agitation at 
room temperature were scored as positive if GFP was observed in any of the intestinal nuclei.  
For Pgcs-1::gfp experiments, day 1 adult animals were treated in 50 mM sodium azide (azide 
treated) or M9 buffer (untreated) for 10 minutes and scored as “high” if GFP was clearly seen in 
the intestine, “medium” if GFP was seen in both anterior and posterior ends of the animal, or 
“low” if GFP was observed only around the pharynx, as in (Wang et al., 2010). Untreated 
Chapter 2: Materials and Methods 
 
50 
 
animals for all experiments showed no response or a very low basal response in all genotypes 
tested.  
In all experiments, samples were imaged using a BX51 Microscope (Olympus) and micrographs 
captured using AnalySIS software (Olympus). Experiments were conducted blind to the 
genotype of the strains. 
 
2.2.10 Quantification of fluorescence intensity 
Fluorescence images were captured on a BX51 Microscope (Olympus) using AnalySIS software 
(Olympus). ImageJ (Schneider et al., 2012) was used to analyse images. The integrated density 
in the selected regions, which normalises the fluorescence intensity to the area of the selected 
region, was quantified and corrected by subtracting the mean fluorescence of the background. 
This corrected total fluorescence was then used for statistical analysis (one-way ANOVA, 
GraphPad Prism, GraphPad Software Inc.).  
 
2.2.11 Lifespan assay 
Age-matched animals synchronised by egg-laying were cultured on plates at 25 °C and the 
number of surviving animals recorded every day until death. 100-120 day 1 adults per strain 
were plated at the start of each assay. Animals that were lost or displayed internal hatching or 
bursting were censored. To separate adult worms from their progeny, adult worms were moved 
to new NGM plates every second day until the assay was completed. Survival curves were 
generated using GraphPad Prism 6 (GraphPad Software Inc.). For several strains, lifespan assays 
were conducted twice independently and these are highlighted in the text.  
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2.2.12 Neuron imaging assay: 
Age-matched animals synchronised by egg-laying were cultured on plates at 20 or 25 °C. 
Starting animals were day one adults in all cases. For longitudinal assays where individual 
animals were monitored every day during their lifetimes, these animals were individually 
mounted into 0.2% levamisole (Sigma) on 3% agarose pads prepared on standard microscope 
slides. These animals were rescued by picking them onto a drop of M9 buffer, and recovered 
well if incubated in levamisole for under two minutes. For transverse assays where populations 
of animals were monitored every second day for 15 days, surviving adult worms on a plate were 
mounted as described, but were not recovered post-imaging. To separate adult worms from their 
progeny, adult worms were moved to new NGM plates every second day until the assay was 
completed. Assays were conducted blind to the genotype of the worms. To score the incidence of 
aberrant neuronal structures in touch receptor neurons, worms were scored as positive if the 
neuron displayed branching or blebbing at the cell body or axon. For some experiments, cell 
body branching and axon branching/blebbing were scored separately. For scoring in GABAergic 
neurons, worms were scored as positive if at least one of the observed commissures displayed 
branching. For all transverse assays, the proportion of animals scored as positive was expressed 
then as a percentage of the sample size observed at that time point. A schematic for each of the 
neuronal imaging experiments is shown in Figure 2.3.  
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Figure 2.3: Schematic for two imaging experiments to investigate neuronal ageing. Longitudinal (individual) 
and transverse (population-based) experiments were conducted to visualise neurons with age. For longitudinal 
experiments, one plate held a single animal that was imaged, recovered after imaging, and this process repeated for 
the same worm every day until death. In this method, five worms per genotype were assayed per biological replicate. 
For transverse experiments, many worms (~40 per genotype per replicate) are moved to one plate per time point, for 
example day 1, 5, 7, and 9 of adulthood. At each time point, all the worms on that plate are imaged and the 
population subsequently discarded.  
 
2.2.13 RNA interference experiments 
For touch neuron-specific RNA interference (RNAi) experiments using strains APD050 and 
APD066 and control strains CZ10175 (zdIs5) and EG1285 (oxIs12): Experiments were 
conducted at 20 °C. sid-1(qt2) animals expressing SID-1 in touch neurons only (Pmec-18::sid-1 
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transgene) from parent strain TU3403 (Calixto et al., 2010) were synchronised by hypochlorite 
bleaching and L1 worms plated onto 25 µg/mL carbenicillin plates seeded with RNAi bacteria. 
The bacterial strain is E. coli HT115, which contains the T7 RNA polymerase gene under the 
control of lac operon regulatory elements. HT115 RNAi feeding bacteria were transformed with 
the pL4440 empty vector (EV), or pL4440 containing ptl-1 or unc-22 DNA from the C. elegans 
RNAi library generated by the Ahringer laboratory (Fraser et al., 2000). 3 mM isopropyl β-D-1-
thiogalactopyranoside (IPTG) was used to induce T7 RNA polymerase expression in HT115 
bacterial cultures. The pL4440 plasmid contains two T7 promoter regions flanking the gene-
specific cDNA such that induction of T7 RNA polymerase will result in RNA being transcribed 
in both directions, forming dsRNA. unc-22 knockdown was used as a control for the experiment; 
knockdown of unc-22 in muscle results in paralysis/twitching (Fire et al., 1991), so animals that 
have the sid-1(qt2) mutation are no longer susceptible to RNAi knockdown in muscle and will 
not be paralysed, whereas animals that are wild-type for sid-1 will be paralysed. CZ10175 and 
EG1285 strains, which are wild-type at the sid-1 locus and also contained the relevant gfp 
transgenes (zdIs5 or oxIs12), were used as negative controls. After one generation fed on RNAi 
bacteria, animals were imaged at day 1, 3, 5 and 7 of adulthood to visualise touch receptor 
neurons or GABAergic neurons. To maintain knockdown, animals were transferred to new RNAi 
plates on days 2, 4 and 6 of the experiment. Scoring was conducted in the same manner as for 
other neuronal imaging assays. Imaging was conducted blind to the identity of the RNAi clones. 
To test knockdown of ptl-1 in touch neurons by feeding RNAi, PTL-1::GFP animals with the 
touch neuron-specific SID-1 transgene (strain APD130) were treated as described above by 
feeding either EV or ptl-1 RNAi bacteria and imaged after two generations of RNAi treatment to 
determine if GFP levels were decreased in touch neurons after ptl-1 but not EV RNAi treatment. 
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RNAi knockdown confirmation was conducted via knockdown of PTL-1::GFP animals instead 
of quantitative PCR of ptl-1 transcripts as we aimed to show not only that knockdown of PTL-1 
was occurring, but also that it was taking place in particular neurons. 
 
For pan-neuronal knockdown experiments using strain APD128: Animals were treated for two 
generations with RNAi bacteria on NGM-carbenicillin-IPTG plates essentially as described 
above. In the pan-neuronal RNAi strain derived from parent strain TU3401, sid-1(pk3321) 
animals contained a Punc-119::sid-1 transgene that expressed SID-1 in all neurons (Calixto et 
al., 2010) and a PTL-1::GFP transgene. Knockdown of PTL-1::GFP in these transgenic lines by 
ptl-1 RNAi feeding was determined by scoring the brightness of the fluorescence signal in the 
nerve ring of ptl-1 RNAi-treated animals and EV RNAi-treated animals as detailed in section 
2.2.10. Fluorescence intensity was measured using ImageJ software and compared using 
GraphPad Prism 6 (GraphPad Software Inc.).  
 
2.2.14 Stress assays and pharmacological assays 
For oxidative stress assays using H2O2, animals were incubated at 1 or 10 mM hydrogen 
peroxide for 1-2 hours in M9 buffer at room temperature. Untreated animals were incubated 
period in M9 buffer. Animals were scored for survival 2-3 hours after treatment. For oxidative 
stress assays using paraquat, animals were incubated with paraquat (100 mM) or were untreated 
(M9 buffer) for 3 or 5 hours in M9 buffer at room temperature. Survival was scored 24 hours 
post-recovery. For acute heat shock assays using an incubator, animals were heat-shocked at 37.5 
°C for 2 hours or kept at 25 °C for 2 hours (control) and survival scored 48 hours later. For acute 
heat shock assays using a water bath, animals were heat-shocked using the same conditions as 
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above and survival scored 24 hours later. For all stress experiments, at least 100 day one adult 
animals synchronised by hypochlorite treatment were assayed. Scoring was conducted blind to 
the genotype of the worms. 
Pharmacological assays were performed on unseeded plates spread with levamisole (Sigma) at a 
final concentration of 1 mM. Animals to be assayed were synchronised by egg-laying at 20 °C. 
Animals were picked onto drug plates and scored at room temperature for paralysis (defined as 
no response to tapping with a platinum wire) at 15-minute intervals for 90 minutes. Scoring was 
conducted blind to the genotype of the worms. 
 
2.2.15 Immunofluorescence 
One day-old adults synchronised by egg-laying or hypochlorite treatment and cultured at room 
temperature were used for all experiments. Animals were permeabilised using the freeze-crack 
protocol as previously described (Crittenden and Kimble, 1999). Samples were immediately 
fixed in ice-cold 4% paraformaldehyde at 4 °C for >12 hours. The primary antibody used was 
mouse monoclonal anti-V5 (R960-25, Life Technologies) [1:200] or mouse monoclonal anti-
acetyl alpha-tubulin (T7451, Sigma) [1:200]. The secondary antibody used was goat anti-mouse 
Alexa Fluor-568 or Alexa Fluor -488 (Sigma) [1:500]. All antibody dilutions were made in 30% 
(v/v) normal goat serum (Life Technologies). Samples were mounted onto microscope slides 
using VectaShield mounting medium (Vector Labs) containing 4ʹ,6-diamidino-2-phenylindole 
(DAPI) where applicable. Samples were imaged using a BX51 Microscope (Olympus). 
Micrographs were captured using AnalySIS software (Olympus).  
 
2.2.16 Immunoblot 
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Samples for immunoblot were prepared by washing worms off plates in M9 buffer, followed by 
repeated washes in M9 and a final wash in distilled water. Samples resuspended in Laemmli 
buffer underwent three freeze-thaw cycles in liquid nitrogen before boiling for 5 minutes at 95 
°C, and were immediately loaded onto 10% acrylamide gels. Primary antibodies used are mouse 
monoclonal Tau-13 antibody (Abcam) [1:5000] that binds human Tau, mouse monoclonal anti-
V5 antibody conjugated to HRP (R961-25, Life Technologies) [1:2000], and mouse monoclonal 
anti-acetyl alpha-tubulin (T7451, Sigma) [1:2000]. The secondary antibody used was goat anti-
mouse conjugated to horseradish peroxidase (NA931, GE Healthcare) [1:10000]. Blots were 
developed with Immobilon Western chemiluminescent substrate (Millipore) on film. 
 
2.2.17 Statistical analysis:  
The α-level is 0.05 for all analyses. Statistical analyses for the major experiments conducted in 
this work are detailed below: 
For SKN-1::GFP and Pgcs-1::gfp localisation experiments, experiments were conducted three 
times and the data from all biological replicates averaged and converted to percentages. These 
were then compared using a one-way ANOVA for the percentage of animals displaying “low” 
fluorescence (according to the scoring scheme detailed above) in GraphPad Prism 6 (GraphPad 
Software Inc.). This analysis provides two-tailed p-values.  
Survival curves were analysed in GraphPad Prism 6 (GraphPad Software Inc.) to provide two-
tailed p-values. Tests used were the log-rank test, which gives equal weight to deaths at all time 
points, and the Wilcoxon test, which gives more weight to deaths at early time points (Machin et 
al., 2006). The log-rank test is commonly used for C. elegans lifespan data (Apfeld and Kenyon, 
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1999, Tank et al., 2011, Huang et al., 2004) but we also report p-values from the Wilcoxon test 
to accommodate the possibility that hazard ratios were not consistent through the assay.  
For neuron imaging experiments, we grouped data into categories of “displays 
branching/blebbing” or “does not display branching/blebbing” and used Pearson’s chi-squared 
test in Microsoft Excel (Microsoft) to determine if the incidence of branching/blebbing in a 
mutant population at a single time point is different from the ‘expected value’ of the wild-type 
strain at the same time point. This analysis provides one-tailed p-values that were used to 
determine if the incidence of abnormal neuronal structures in a mutant strain at a time point was 
different from the wild-type strain. 
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3.1 Introduction 
PTL-1 has been previously shown to be involved in the regulation of microtubule-based 
transport (Tien et al., 2011), embryogenesis (Gordon et al., 2008), and sensitivity to gentle touch 
(Gordon et al., 2008). These phenotypes were determined using a ptl-1(ok621) null mutant strain. 
For our investigations into the functions of PTL-1 as a Tau-like protein, we tested several 
phenotypes using ptl-1(ok621) mutant animals, and also elected to assay a previously 
uncharacterised ptl-1 allele, referred to as tm543. These experiments would then form the basis 
for further investigation into the roles of PTL-1 in the stress response and ageing. In this chapter, 
a basic characterisation of this new allele is presented. 
 
3.2 ptl-1(tm543) and ptl-1(ok621) mutant strains 
PTL-1 in C. elegans displays high sequence similarity to mammalian Tau/MAP2/MAP4 in the 
C-terminal MBR domain. It is encoded on chromosome III by the gene ptl-1 (F42G9.9), which is 
predicted to contain four distinct transcripts (a-d; http://www.wormbase.org)  (Figure 3.1A). The 
longest predicted isoform (F42G9.9a) is composed of eight coding exons, with exons 5–7 
encoding the MBRs (Figure 3.1B). Two deletion alleles have been generated for ptl-1: the ok621 
mutation generated by the Oklahoma Medical Research Foundation (OMRF) arm of the C. 
elegans Knockout Consortium (WormBase ID: WBVar00091905), and the tm543 mutation 
generated by the National Bioresource Project, Japan (WormBase ID: WBVar00249582) 
(Figure 3.1B). ptl-1(ok621) is reported to be a null mutation (Gordon et al., 2008), whereas ptl-
1(tm543) is a shorter deletion encompassing the exons encoding the MBR region, and may result 
in a truncated protein that has retained the N-terminal projection domain (Figure 3.1C). Both 
mutant strains were generated using ultraviolet trimethylpsoralen (UV/TMP) treatment.  
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As a reference for our experiments, we used the sequence of isoform a (F42G9.9a) since this is a 
confirmed transcript that generates a protein with five MBRs (Gordon et al., 2008, Goedert et al., 
1996), whereas the other confirmed isoform of PTL-1 (isoform b) has only four putative MBRs 
(Goedert et al., 1996, McDermott et al., 1996). That is, in the generation of all transgenic lines 
used in this study, we used the sequence of the longest isoform of PTL-1.  
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Figure 3.1: Schematic of ptl-1 (F42G9.9) genomic locus, showing alleles ok621 and tm543, and predicted 
protein sequence. A) Sequence of C. elegans chromosome III indicating predicted ptl-1 transcripts F42G9.9 
isoforms a-d. B) Genomic locus of the longest isoform of ptl-1 (PTL-1a) from transcript F42G9.9a indicating 
regions comprising the ok621 and tm543 deletions. Exons are shown as black boxes, introns as solid lines and 
untranslated regions at the 5ʹ and 3ʹ ends as white boxes. 5ʹ is on the left. Regions encoding putative microtubule-
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binding repeats are marked 1-5 with arrowheads. The coloured arrows below the schematic indicate where 
genotyping primers bind for ok621 (red) and tm543 (orange). The red arrow with an asterisk (*) was used as a 
reverse primer for genotyping both alleles. C) Schematic of the PTL-1 protein highlighting the microtubule-binding 
domain and predicted protein products of ptl-1(ok621) (predicted null mutant) and ptl-1(tm543) (microtubule-
binding domain-deficient allele). The conceptual translation of the PTL-1a isoform is shown below, indicating the 
MBRs and the regions deleted by ok621 and tm534 mutations. 
  
We attempted to confirm the end points of the tm543 deletion, but technical difficulties in the 
sequencing reaction due to the presence of the C-terminal repeat region prevented us from 
confirming the exact sequence of the deletion (data not shown). However, using primers flanking 
the putative deleted region, we were able to robustly genotype for ptl-1(tm543) mutant animals 
(Figure 3.2).  
 
Figure 3.2: Genotyping of ptl-1(tm543) using PCR. Primers used were “PTL-1 tm543 FF” and “PTL-1 ok621 
FR2”, sequences given in the Methods section. The first lane shows the product generated using genomic DNA from 
a wild-type animal, lane two shows the product from a ptl-1(tm543) animal, and lane three shows the absence of 
contaminating DNA in the no DNA template control. PCR products were run on a 1% agarose gel. The approximate 
sizes (in kb) of the PCR products are shown on the left.  
 
The FX00543 strain had not previously been outcrossed, and we used our newly established PCR 
protocol to genotype ptl-1(tm543) animals to facilitate outcrossing of this strain six times to 
wild-type. This outcrossed strain was renamed APD015 and was used for the remainder of the 
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experiments using the tm543 allele. At the start of this investigation, FX00543 had only been 
partially characterised, with mutant animals curated as being homozygous viable and mildly 
defective in chemotaxis towards sodium chloride (S Mitani, National Bioresource Project, 
Japan).  
 
3.3 ptl-1 mutant alleles display allelic differences in touch sensitivity 
Mammalian MAPs such as Tau and MAP2 are known to execute a range of physiological 
functions in neurons (Drubin and Kirschner, 1986, Avila et al., 2004, Ittner et al., 2010, Dehmelt 
and Halpain, 2005). As two alleles of ptl-1 are now available, we investigated the functions of 
PTL-1 in C. elegans neurons by assaying both ptl-1(ok621) and ptl-1(tm543) mutant strains. 
Although PTL-1 is expressed in several neuronal subtypes in adult worms, the highest levels are 
detected in the touch receptor neurons (Gordon et al., 2008, Goedert et al., 1996), which regulate 
the response to gentle touch (Chalfie et al., 1985, Chalfie and Sulston, 1981). We first tested 
whether we could detect touch insensitivity in a positive control strain mec-12(e1605) 
(Fukushige et al., 1999), and indeed we found that this strain was significantly less touch 
sensitive compared with wild-type (Figure 3.3A) Previously published data indicate that ptl-
1(ok621) mutants are mildly touch insensitive compared with wild-type worms (Gordon et al., 
2008). In line with this, we found that ptl-1(ok621) worms were less touch sensitive (touch 
sensitivity = 74±2 %) compared with wild-type (82±2 %) (Figure 3.3A). We also tested animals 
carrying the ptl-1(tm543) C-terminal deletion, and observed that there was no difference in touch 
sensitivity between this mutant (83±2 %) and wild-type (Figure 3.3B). These findings suggest 
that loss of full-length PTL-1, but not the MBR domain alone, results in a small but significant 
difference in touch response.   
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Figure 3.3: ptl-1(ok621) and ptl-1(tm543) mutant animals display allelic differences in touch sensitivity. Data 
for sensitivity to gentle touch, shown for A) ptl-1(ok621) (n = 30 total for two biological replicates) and B) ptl-
1(tm543) mutant animals and wild-type controls (n = 45 total for three biological replicates). Error bars indicate 
mean ± SEM. One-way ANOVA, Bonferroni post-test, p value is indicated by ns = no significance, * <0.05.  
 
3.4 Discussion 
Given the availability of two ptl-1 deletion alleles, including the previously uncharacterised 
MBR-deficient tm543 allele, we now have the opportunity to investigate functions that are 
attributable to the MBR domain alone. ptl-1(ok621) animals do not generate a protein product 
whereas ptl-1(tm543) animals are predicted to produce a truncated protein containing only the N-
terminus and lacking the MBRs. The N-terminus of PTL-1 is largely conserved amongst 
nematodes, is proline-rich, highly acidic, and also contains several serine/threonine-proline 
motifs that are potential phosphorylation sites (Goedert et al., 1996, Gordon et al., 2008, 
McDermott et al., 1996). By assaying for touch sensitivity, we have found allelic differences 
between these strains, where full length PTL-1, but not the MBR domain, is necessary to confer 
wild-type sensitivity to gentle touch. Using both deletion alleles, we aimed to expand our 
knowledge on PTL-1 function by testing both alleles in the contexts of stress responsiveness and 
ageing. The results of these investigations will be reported in the subsequent three results 
chapters.
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4.1 Section 1: Role of PTL-1 in the oxidative stress response 
4.1.1 Introduction 
Oxidative stress has been implicated as a major pathological factor in AD and other dementias. 
Furthermore, markers of Tau pathology such as increased phosphorylation and aggregation have 
been linked to increased oxidative stress (Su et al., 2010, Gamblin et al., 2000, Dias-Santagata et 
al., 2007). One proposed mechanism by which oxidative stress influences Tau pathology is via 
the transcription factor Nrf2, which regulates the detoxification response. Activation of Nrf2 and 
induction of Nrf2-responsive genes after methylene blue treatment have been correlated with 
decreased Tau phosphorylation and improved behavioural responses (Stack et al., 2014, Jo et al., 
2014). We tested if PTL-1 in neurons could interact with the Nrf2 homolog in C. elegans, SKN-
1, in the regulation of both the stress response and longevity. Section one of this chapter details 
the investigation of the role of PTL-1 in the oxidative stress response in C. elegans, and section 
two contains our data on the modulation of lifespan by PTL-1.  
 
4.1.2 ptl-1 mutant animals are defective in the response to oxidative stress 
Due to the link between oxidative stress and Tau-associated pathology, we investigated if ptl-1 
mutant animals displayed a normal stress response. We tested the survival of ptl-1 mutant 
animals after oxidative stress and heat stress. In general, we found that there was high variation 
in survival in all strains, including wild-type, after stress assays were conducted. However, we 
were able to resolve a difference in the oxidative stress response between ptl-1 mutant strains 
and wild-type controls.  
 
We first tested for the response to oxidative stress using hydrogen peroxide (H2O2) and paraquat 
treatment. After an acute exposure to H2O2 or paraquat, we monitored the survival of young 
Chapter 4: PTL-1 in the oxidative stress response and longevity regulation 
 
67 
 
adult ptl-1(ok621) null mutant and ptl-1(tm543) MBD-lacking mutant animals. With H2O2 
treatment, over many experimental replicates (7-8), we demonstrated that both ptl-1 mutant 
strains showed on average a decreased survival after exposure to 1 or 10 mM H2O2 compared 
with wild-type controls (Figure 4.1A). After exposure to 10 mM H2O2 for 2 hours, on average 
9% of ptl-1(ok621) and 15% of ptl-1(tm543) animals were alive compared with 45% of wild-
type animals (Figure 4.1A). However, we could not detect any differences in survival when 
animals were treated with the redox-active chemical paraquat (Figure 4.1B). Although a general 
trend of decreased survival was observed in ptl-1 mutant animals exposed to paraquat compared 
with wild-type controls, these differences were not statistically significant. This could be 
attributable to the high variation in survival in all strains in response to treatment (Figure 4.1B). 
 
We next investigated survival in response to acute heat stress (Figure 4.1C,D). Large 
fluctuations in temperature (~ 5 °C from the desired temperature) were detected when worms 
were heat shocked at 37.5 °C both in a standing incubator (air) (Figure 4.1C) or in a water bath 
(liquid) (Figure 4.1D). These fluctuations in temperature over the two hours of heat stress could 
contribute to the large variation observed for the survival of all three strains post-treatment. We 
also did not observe a significant difference between the survivals of both ptl-1 mutant strains 
compared to wild-type animals (Figure 4.1C,D).  
 
Although there were considerable difficulties in acquiring consistent data for these stress assays, 
our data using H2O2 treatment appeared to indicate a reduction in the capacity of ptl-1 mutant 
animals to survive oxidative stress. We next elected to investigate the pathways by which PTL-1 
regulates the oxidative stress response.  
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Figure 4.1: PTL-1 regulates the response to oxidative stress. A) ptl-1 mutants are hypersensitive to hydrogen 
peroxide stress. Animals were incubated at either 1 mM or 10 mM hydrogen peroxide for 1-2 hours in liquid at room 
temperature. Untreated animals were incubated for the same time period in M9 buffer. Animals were scored for 
survival 2-3 hours after treatment. 7-8 replicates were conducted per treatment condition, with at least 100 animals 
scored per treatment. B) Animals were incubated with paraquat (100 mM) or were untreated (M9 buffer) for 3 or 5 
hours in liquid at room temperature. Survival was scored 24 hours post-recovery. 2 replicates were conducted per 
treatment condition, with at least 100 animals scored per treatment. C) Acute heat shock assay using an incubator. 
Animals were heat shocked at 37.5 °C for 2 hours (heat shock) or kept at 25 °C for 2 hours (control) and survival 
scored 48 hours later. 2 duplicates were conducted, and at least 100 animals scored per treatment condition. D) 
Acute heat shock assay using a water bath. Animals were heat shocked at 37.5 °C for 2 hours (heat shock) or kept at 
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25 °C for 2 hours (control) and survival scored 24 hours later. 2 replicates were conducted, with at least 100 animals 
scored per treatment. For all stress experiments, first day adults synchronised by hypochlorite treatment were 
assayed. Statistical analysis: two-way ANOVA, p value is indicated by ns = not significant, *<0.05.  
 
4.1.3 ptl-1 mutant animals display a defective SKN-1 re-localisation response to oxidative stress 
but show no defect for DAF-16 
The role of the transcription factor SKN-1 in modulating the response to oxidative stress has 
been extensively studied in C. elegans (An and Blackwell, 2003, An et al., 2005, Glover-Cutter 
et al., 2013, Inoue et al., 2005, Kahn et al., 2008, Park et al., 2009, Staab et al., 2014). SKN-1b 
and SKN-1c are the two most studied isoforms, largely due to the generation of a SKN-
1b/c::GFP (ldIs7) reporter transgenic line (An and Blackwell, 2003), henceforth referred to as 
SKN-1::GFP. SKN-1c is present in the intestine and is normally diffuse in the cytoplasm, but in 
response to stress it rapidly localises to the nucleus (Figure 4.2Ai,ii) (An and Blackwell, 2003). 
SKN-1b is present in the ASI neurons, and appears to be constitutively nuclear (Figure 4.2Ai, 
indicated as white arrows in the head) (An and Blackwell, 2003). Initial investigations found that 
although the SKN-1::GFP reporter can be observed in intestinal nuclei after treatment with heat 
stress or paraquat, acute incubation with sodium azide (NaN3) was shown to be the most 
effective in inducing nuclear re-localisation of SKN-1::GFP (An and Blackwell, 2003). 
Furthermore, levels of SKN-1::GFP appeared to be the highest at larval stage two (L2) (An and 
Blackwell, 2003). Therefore, for all assays described here, SKN-1::GFP re-localisation was 
examined in L2 animals after treatment with sodium azide. 
 
We investigated whether localisation of SKN-1 was affected by defective PTL-1. We first 
examined intestinal SKN-1::GFP. In control wild-type and ptl-1 mutant animals treated with M9 
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buffer alone (untreated), there was no observable nuclear SKN-1::GFP in the intestine (Figure 
4.2B). For this reason, we do not display graphs for SKN-1::GFP localisation in untreated 
animals in subsequent presentations of data, although in all cases untreated controls were 
conducted alongside azide treatments. Wild-type animals showed a largely consistent response to 
sodium azide, in which SKN-1::GFP localised to some or all intestinal nuclei in ~60% of animals 
(Figure 4.2B). In contrast, a significantly lower proportion of ptl-1(ok621) animals (~20%) 
displayed nuclear SKN-1::GFP in response to azide stress (Figure 4.2B). We next determined if 
SKN-1::GFP expression in the ASI neurons changed when animals were exposed to sodium 
azide. In azide-treated animals, we did not detect a change in the constitutively nuclear SKN-
1::GFP localisation or fluorescence intensity in the ASI neurons in either wild-type or ptl-
1(ok621) animals compared with untreated controls (Figure 4.2Ai). This is consistent with data 
from previous research showing that SKN-1::GFP expression in the ASI neurons does not 
change after exposure to stress (An and Blackwell, 2003). 
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Figure 4.2: PTL-1 regulates the stress-mediated SKN-1 re-localisation to intestinal nuclei. A) The SKN-
1B/C::GFP (ldIs7) transgenic strain was used. (i) Untreated animals do not show clear nuclear SKN-1::GFP in the 
intestine. (ii) Intestinal SKN-1 re-localisation to the nucleus in response to sodium azide (50 mM) stress is indicated 
by white arrows pointing to intestinal nuclei. White arrowheads pointing in the head region indicate nuclear SKN-1 
in the ASI neurons, which is unaffected by stress. Scale, 10 µm. B) ptl-1(ok621) mutant animals are defective in 
SKN-1::GFP re-localisation to intestinal nuclei in response to azide stress. No nuclear SKN-1::GFP was observed in 
untreated animals. n=15 per replicate, data shown are averaged from three independent experiments. Statistical 
analysis: one-way ANOVA, p value is indicated by ns = not significant, *<0.05. C) SKN-1::GFP fluorescence in 
ASI nuclei does not change in intensity in response to azide stress in either wild-type or ptl-1(ok621) mutant 
animals. n=15. Quantification of fluorescence signal was measured in ImageJ. Statistical analysis: one-way 
ANOVA, p value is indicated by ns = not significant, *<0.05. n=15 per strain per treatment. 
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The insulin signalling pathway is known to be involved in the regulation of the stress and 
longevity response (Tullet et al., 2008, Honda and Honda, 1999, Li et al., 2014, Kenyon et al., 
1993, Wolkow et al., 2000). Important players in this pathway include the DAF-2 insulin-like 
receptor (Kenyon et al., 1993) and the downstream effector DAF-16, a FOXO transcription 
factor (Ogg et al., 1997). Briefly, in response to DAF-2 ligand binding, DAF-16 is 
phosphorylated by downstream kinases and excluded from the nucleus, preventing DAF-16-
mediated expression of longevity and stress responsive signals (Kaletsky and Murphy, 2010). 
We investigated if DAF-2 signalling via DAF-16 was also affected in ptl-1 mutant animals. Like 
SKN-1, DAF-16 in the intestine is normally diffuse in the cytoplasm, and localises to the nucleus 
in response to various stressors (Lee et al., 2001a) (Figure 4.3Ai). Using a DAF-16 translational 
reporter (zIs356), we assayed for intestinal DAF-16 localisation in response to azide treatment. 
This was performed using a DAF-16::GFP reporter expressed under the control of the daf-16 
promoter. Our data indicate that the localisation of DAF-16::GFP is unaffected by loss of PTL-1 
in treated animals (Figure 4.3Aii).  
 
We also investigated if PTL-1 was acting within the IIS pathway in its regulation of SKN-
1::GFP localisation. Here, we attempted to resolve subtle differences by binning our data into 
three categories: “high” where GFP was observed in all intestinal nuclei, “medium” where GFP 
was observed only in the most anterior/posterior nuclei, and “low” where no nuclear GFP was 
observed (Tullet et al., 2008). Contrary to data previously published by others (Tullet et al., 
2008), we were unable to resolve an effect of daf-2(e1370) reduction-of-function on SKN-
1::GFP re-localisation at either 15 °C or 20 °C (Figure 4.3Bi,ii). Tullet et al. observed 
constitutive nuclear SKN-1::GFP in the intestine, i.e. in the absence of stress exposure, in daf-
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2(e1370) mutant animals at both 15 °C and 20 °C (Tullet et al., 2008). This may be due to the 
difference in transgenic lines used in the current study compared with the previous investigation 
- we used a SKN-1::GFP integrated transgenic line that expresses at a much lower level 
compared with the extra-chromosomal line used in the earlier experiments (Tullet et al., 2008). 
Importantly, we observed that the addition of a daf-2(e1370) mutation did not affect the 
defective SKN-1::GFP response in ptl-1(ok621) mutant animals (Figure 4.3B). Therefore, the 
regulation of intestinal SKN-1 by PTL-1 does not involve the IIS pathway.  
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Figure 4.3: PTL-1 does not regulate DAF-16::GFP nuclear localisation, and SKN-1 nuclear re-localisation  is 
not affected by mutations in daf-2. A) (i) Pdaf-16::DAF-16::GFP (zls356) nuclear re-localisation in (top) an 
untreated animal (image taken from (Schafer et al., 2006)), and (bottom) in response to azide stress. (ii) ptl-1(ok621) 
mutant animals do not display a defect in DAF-16::GFP nuclear re-localisation in response to 50 mM sodium azide 
treatment. Untreated animals are incubated in M9 buffer only. Treatment was for 10 minutes at room temperature in 
liquid. Worms were scored as positive if DAF-16::GFP was localised to at least 1 intestinal nucleus. n=20 per 
replicate, data shown are averaged from three independent experiments. B) ptl-1 null mutation results in a defect in 
intestinal SKN-1::GFP nuclear re-localisation  in the presence of a daf-2(e1370) mutation at (i) 15 °C or (ii) 20 °C. 
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n=15 per biological replicate. Scoring is as follows: low – no observable intestinal nuclear GFP, medium – GFP in 
anterior/posterior intestinal nuclei only, high – GFP in all intestinal nuclei (Tullet et al., 2008). Statistical analysis: 
One-way ANOVA comparing the incidence of ‘low’ fluorescence. P-values indicated by ns = not significant, 
*<0.05. For all experiments, averaged data from three independent experiments are shown. 
 
4.1.4 Defective SKN-1 re-localisation in ptl-1 mutant animals in response to oxidative stress can 
be rescued by PTL-1 but not human Tau re-expression 
To confirm that the defect observed in intestinal SKN-1::GFP localisation in ptl-1 mutant worms 
is attributable to the loss of PTL-1 function, we generated a transgenic line expressing the ptl-1 
cDNA under the control of the ptl-1 promoter and the ptl-1 3ʹ UTR control element. As no 
commercial antibody against PTL-1 is available, we tagged PTL-1 at the C-terminus with the 
short peptide V5 in order to enable detection of PTL-1 expressed from the transgene with a V5-
specific antibody. Transgenic worms were generated by biolistic transformation, and an 
integrated line was obtained after selection using the dual antibiotic method (Semple et al., 
2012). We confirmed that our transgene was expressed by immunoblotting (Figure 4.4A) and 
immunofluorescence (Figure 4.4B). The migration of the band observed on the immunoblot is 
consistent with previous experiments that have shown that PTL-1 runs at approximately 75 kDa 
on an SDS-PAGE gel (Goedert et al., 1996) (Figure 4.4A). Furthermore, using a V5-specific 
antibody for immunofluorescence staining, we detected PTL-1::V5 localising to axons and cell 
bodies in neurons, including those comprising the nerve ring in the head, as well as in the tail 
(Figure 4.4B). We confirmed expression of the transgene in touch neurons by staining for PTL-
1::V5 in transgenic animals crossed with the Pmec-4::gfp reporter line and observing co-
localisation between signals from anti-V5 immunofluorescence and GFP (Figure 4.4Biii). We 
also generated integrated transgenic lines expressing V5::PTL-1 (N-terminal tag) under the 
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control of the same regulatory elements, however these were not used in our experiments 
(Appendix 2). We refer to the transgenic line described above as “PTL-1 Tg” followed by “ptl-
1(ok621)” if it is in the ptl-1 null mutant background. 
 
As noted, PTL-1 in C. elegans and Tau in humans have high sequence similarity in the C-
terminal domain that is important for microtubule binding, and also have a similar overall charge 
distribution (Gordon et al., 2008, McDermott et al., 1996, Goedert et al., 1996). To determine if 
there is functional conservation between these two proteins, we generated transgenic C. elegans 
strains expressing a cDNA of the longest isoform of human Tau (hTau40, referred to here as 
hTau). The hTau cDNA was expressed under the control of the ptl-1 promoter and PTL-1 3ʹ 
UTR as described above.  hTau transgenic animals were similarly generated by biolistic 
transformation and an integrated line was isolated. Immunoblotting analysis showed that hTau is 
expressed in the transgenic line but not in non-transgenic wild-type worms (Figure 4.4C). We 
refer to this transgenic line as “hTau Tg”. 
 
To extend our earlier findings (Figure 4.2), we determined if two ptl-1 mutant strains are 
defective in SKN-1::GFP re-localisation. ptl-1 null mutant animals (ok621), as shown previously, 
displayed a defect in SKN-1::GFP re-localisation to intestinal nuclei in response to stress 
(Figure 4.4D). In addition, truncated PTL-1 mutant (tm543) animals also displayed a similar 
phenotype (Figure 4.4D). This could be rescued by re-expression of PTL-1::V5 in a ptl-1(ok621) 
null mutant (Figure 4.4D). We chose to perform our rescue experiments in the ptl-1(ok621) 
background only as this is a null mutation and hence we should avoid any potentially detrimental 
effects of expressing transgenic PTL-1 together with truncated forms of the protein, as would be 
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the case with the ptl-1(tm543) mutant strain. Our findings indicate that the defect in stress 
responsive SKN-1 localisation is attributable to loss of PTL-1. In contrast, re-expression of hTau 
did not rescue this phenotype in a ptl-1 null mutant (Figure 4.4E). This demonstrates that with 
regards to the regulation of SKN-1 in C. elegans, hTau and PTL-1 do not display functional 
conservation.  
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Figure 4.4: Defective SKN-1::GFP re-localisation in response to stress can be rescued by re-expression of 
PTL-1 but not human Tau. ‘PTL-1 Tg’ refers to the PTL-1::V5 transgene, ‘hTau Tg’ refers to the human Tau 
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transgene. A) Immunoblot showing the presence of a band corresponding to PTL-1::V5 expression from the 
transgene, probed using an anti-V5 antibody. Non-Tg refers to non-transgenic wild-type animals. B) (i,ii,iii) 
Immunofluorescence micrographs showing the expression of the PTL-1::V5 transgene (anti-V5 antibody) in 
neurons. Grayscale images on the left show the red channel only, the nerve ring is indicated by arrows, axons by 
arrowheads, and cell bodies by asterisks. In (i), where the pharynx is shown, gfp expression can be observed from 
the Pmyo-2::gfp transformation reporter. Co-localisation with a reporter line for touch receptor neurons (Pmec-
4::gfp) is shown in (iii), demonstrating that the transgene is expressed in touch neurons, where PTL-1 was 
previously shown to be highly expressed (Goedert et al., 1996, Gordon et al., 2008). Dotted lines indicate the outline 
of the animal as determined by phase-contrast microscopy. Ventral is down. Scale, 50 µm. C) Immunoblot showing 
the presence of a band corresponding to the hTau40 transgene, probed using the Tau-13 antibody. Non-Tg refers to 
non-transgenic wild-type animals. D) Defective SKN-1 re-localisation to the intestinal nucleus in ptl-1(ok621) or 
ptl-1(tm543) mutant animals in response to azide stress can be rescued by re-expression of PTL-1 under the 
regulation of the ptl-1 promoter. SKN-1 re-localisation was scored as positive if GFP was localised to at least 1 
intestinal nucleus. E) Human Tau does not rescue the defect in SKN-1 re-localisation seen in ptl-1 mutant animals. 
For D and E, n=15 per biological replicate, showing data averaged from three independent experiments. Statistical 
analysis: One-way ANOVA. P-values indicated by ns = not significant, *<0.05. 
 
4.1.5 ptl-1 mutant animals are defective in the induction of a SKN-1::GFP responsive gene 
To complement the SKN-1::GFP experiments, we utilised another reporter transgene, Pgcs-
1::gfp (ldIs3) (Wang et al., 2010). GCS-1 (γ-glutamylcysteine synthetase) is a phase II 
detoxification enzyme that is induced at the transcriptional level by SKN-1 in response to 
oxidative stress (Liao and Yu, 2005). GFP expression from this transgene is low under normal 
conditions but it becomes highly expressed in the intestine and tail when the animal is exposed to 
stress conditions (Oliveira et al., 2009, An and Blackwell, 2003) (Figure 4.5A). Detection of 
SKN-1 responsiveness using the Pgcs-1::gfp reporter transgene has several advantages: firstly it 
can be undertaken in young adult animals, which are larger and easier to score compared with L2 
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animals, secondly the Pgcs-1::gfp signal in induced animals is brighter than the SKN-1::GFP and 
also facilitates more rapid scoring. These advantages allow for more animals (n=40) to be 
assayed in each Pgcs-1::gfp experiment compared with 15 animals in SKN-1::GFP assays. We 
scored Pgcs-1::gfp transgene induction as follows: (L) low – faint GFP in head, (M) medium – 
GFP in head and tail, and (H) high – GFP in head, tail and throughout intestine (Wang et al., 
2010) (Figure 4.5A). 
 
In untreated animals, a low baseline induction of the transgene was observed in wild-type 
animals, ptl-1 mutant strains, and PTL-1 transgene re-expressing animals (Figure 4.5B). This 
was consistent for all strains assayed in this study. For simplicity, we show only data from azide-
treated animals for the remainder of this section and Pgcs-1::gfp data from untreated animals in 
all subsequent assays can be found in Appendix 4. When we assayed animals treated with 
sodium azide, induction of Pgcs-1::gfp was found to be defective in both ptl-1(ok621) and ptl-
1(tm543) mutant strains and this defect could be rescued by re-expression of PTL-1 (Figure 
4.5B). In addition, we found that induction of another SKN-1 responsive gene, HSP-4 (Glover-
Cutter et al., 2013), is defective in ptl-1(ok621) mutant animals compared with wild-type 
(Appendix 5). This suggests that ptl-1 mutant animals are generally defective in the induction of 
genes regulated by SKN-1 in response to stress.  
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Figure 4.5: ptl-1 mutants show defective induction of the SKN-1-regulated gcs-1 promoter. A) 50 mM sodium 
azide treatment induces GFP expression in Pgcs-1::gfp (ldIs3) animals. Untreated animals were incubated in M9 
buffer only and showed no response (data not shown). Treatment was for 10 minutes at room temperature in liquid. 
n=15 per biological replicate. B) ptl-1 mutant strains show defective Pgcs-1::gfp induction in response to 50 mM 
sodium azide treatment, which can be rescued by re-expression of PTL-1 under the regulation of the ptl-1 promoter. 
Untreated animals show a baseline induction of Pgcs-1::gfp. Scoring was conducted as described in (Wang et al., 
2010) for Pgcs-1::gfp experiments. n=40 per biological replicate. Statistical analysis: One-way ANOVA comparing 
the incidence of ‘low’ fluorescence. P-values indicated by ns = not significant, *<0.05. For all experiments, 
averaged data from three independent experiments is shown. 
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Given the defects in SKN-1::GFP and Pgcs-1::gfp re-localisation and induction in response to 
azide stress observed in ptl-1 mutant animals at L2 and young adult stages, we aimed to 
investigate if these defects arise post-development (post-larval stage four/L4), or as a result of a 
developmental deficiency. To distinguish between these possibilities, we planned to knockdown 
ptl-1 by RNAi at L4 stage and determine if similar defects in Pgcs-1::gfp induction seen in ptl-1 
mutant strains could be observed after knockdown. However, a technical issue we faced was that 
PTL-1 is predominantly expressed in neurons (Chew et al., 2014a, Gordon et al., 2008), and 
wild-type neurons that do not express the dsRNA transporter SID-1 are refractory to RNAi 
(Feinberg and Hunter, 2003, Winston et al., 2002). To test if we could knockdown PTL-1 in 
neurons, we used a transgenic line where SID-1 was re-expressed in neurons alone (using an 
unc-119 promoter) in a sid-1(pk3321) null mutant background (referred to as the “pan-neuronal 
SID-1” line) (Calixto et al., 2010). In order to visualise if ptl-1 could be knocked down by RNAi, 
we generated a PTL-1::GFP fusion reporter that contains the coding sequence of PTL-1 fused to 
GFP at the C-terminus under the regulation of the ptl-1 promoter and an unc-54 3′ UTR. Using 
this transgenic line, we confirmed the expression pattern in the nervous system (Figure 4.6), and 
we additionally observed PTL-1 expression in non-neuronal tissues, as previously shown in 
examinations using a transcriptional reporter line expressing GFP from a ptl-1 promoter (Gordon 
et al., 2008). We further discuss the relevance of non-neuronal expression of PTL-1 in Chapter 
6 of this thesis.  
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Figure 4.6: PTL-1 is enriched in neurons but is also expressed in non-neuronal tissues. a) PTL-1 expression as 
shown by a translational GFP fusion is enriched in neurons and is also present in non-neuronal tissues in an adult 
animal. (i-iii) Micrographs from a single transgenic animal indicating particular anatomical features where PTL-
1::GFP is expressed including the nerve ring in the head, cells in the vulva and seam cells. (iv-vii) Micrographs from 
other transgenic animals indicating PTL-1::GFP expression in muscle, seam cells, vulval cells and neurons. The 
inset in (vii) is a magnified image of the nerve ring. Anatomical features are highlighted by white arrows.  
 
The PTL-1::GFP fusion protein was expressed in pan-neuronal SID-1 transgenic animals and an 
RNAi by feeding protocol (Timmons et al., 2001, Timmons and Fire, 1998) used to test if ptl-1 
could be efficiently knocked down at the L4 stage. Bacteria expressing ptl-1 RNAi feeding 
constructs or empty vector (EV) RNAi controls were fed to L4 animals and these animals 
imaged the following day to determine if any knockdown of ptl-1 was detectable. Interestingly, 
the fluorescence intensity of PTL-1::GFP decreased in both EV and ptl-1 RNAi-treated animals 
with age. However, we did not observe any significant change in PTL-1::GFP signal between 
ptl-1 RNAi and EV controls until day 3-4 of adulthood (Figure 4.7). Although these data were 
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collected from few (2-4) animals per treatment per time point, we concluded that we could not 
use this method to determine if PTL-1-mediated regulation of SKN-1 required PTL-1 during or 
post-development, as we could not confidently reduce PTL-1 levels at the early stages of 
adulthood.  
 
 
Figure 4.7: Pan-neuronal knockdown of ptl-1 by RNAi feeding at post-developmental stage. A) PTL-1::GFP 
animals were picked onto NGM plates seeded with RNAi feeding bacteria (empty vector, EV controls or ptl-1 
RNAi) at L4 stage. Animals were imaged at days 1-4 of adulthood using the same exposure time for imaging. Scale, 
200 µm. Images show representative animals from each treatment group. B) Quantification of fluorescence signal at 
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the nerve ring was measured using ImageJ software. n=1-4 animals per treatment per time point. Error bars indicate 
mean +/- SEM. Statistical analysis: unpaired t-test, p value is indicated by ns = not significant, *<0.05.  
 
4.1.6 PTL-1 re-expression in all neurons but not specifically in ASI neurons rescues SKN-1 re-
localisation defects 
PTL-1 is expressed in both neuronal and non-neuronal tissue (Chew et al., 2014a, Gordon et al., 
2008). Although it is generally accepted that PTL-1 is expressed predominantly in neurons 
(Goedert et al., 1996, McDermott et al., 1996, Gordon et al., 2008), we aimed to confirm that 
regulation of SKN-1 in the intestine involved a signal from neuronal PTL-1. To achieve this, we 
generated a transgenic line expressing PTL-1::V5 under the regulation of an aex-3 pan-neuronal 
promoter. We immunostained for V5 expressed from this transgene and observed PTL-1::V5 
expressed widely in neurons (Figure 4.8A). We found that pan-neuronal expression of PTL-1 
rescued the defect in SKN-1::GFP nuclear re-localisation (Figure 4.8B) and Pgcs-1::gfp 
induction (Figure 4.8C) in ptl-1 null mutant animals in response to stress. These data 
demonstrate that PTL-1 acts in the neurons to regulate intestinal SKN-1 and SKN-1-regulated 
targets.  
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Figure 4.8: PTL-1 in neurons regulates SKN-1 nuclear re-localisation in the intestine. A) 
Immunohistochemistry for PTL-1::V5 in pan-neuronal (aex-3 promoter) transgenic line. Left panels show the head, 
with the white arrow indicating neurons of the nerve ring and the pink outline indicating the approximate position of 
the pharynx. Right panels show the tail, with the white arrowheads indicating tail neurons. Pan-neuronal re-
expression of PTL-1 rescues the defect in B) intestinal SKN-1 nuclear re-localisation (n=15 per biological replicate) 
and C) Pgcs-1::gfp induction (n=40 per biological replicate) in response to 50 mM sodium azide. Untreated animals 
were incubated in M9 buffer only and showed no response for SKN-1::GFP re-localisation (data not shown). 
Treatment was for 10 minutes at room temperature in liquid. Scoring was conducted as described in (Tullet et al., 
2008) for SKN-1::GFP and as in (Wang et al., 2010) for Pgcs-1::gfp experiments. Statistical analysis: One-way 
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ANOVA comparing the incidence of ‘low’ fluorescence. P-values indicated by ns = not significant, *<0.05. For all 
experiments, averaged data from three independent experiments are shown. 
 
Given that SKN-1b is expressed in the ASI neurons and that it could co-localise with PTL-1, we 
aimed to determine if expressing PTL-1 in ASI neurons alone had an effect on intestinal SKN-1 
localisation in response to stress. We generated a transgene expressing PTL-1::V5 under the 
control of the gpa-4 ASI-specific promoter. Immunostaining for V5 indicated that transgene 
expression was restricted to few neurons in the head (Figure 4.9A), although due to technical 
difficulties we were unable to resolve unambiguously if these were the ASI neurons. We found 
that ASI-specific expression of PTL-1 did not rescue the defect in SKN-1::GFP nuclear re-
localisation (Figure 4.9Bi) and Pgcs-1::gfp induction (Figure 4.9Bii) in ptl-1 null mutant 
animals in response to stress. This indicates that expression of PTL-1 in the ASI neurons alone is 
not sufficient to modulate SKN-1::GFP re-localisation to the intestinal nuclei.  
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Figure 4.9: ASI-specific PTL-1 re-expression does not rescue SKN-1::GFP re-localisation and Pgcs-1::gfp 
induction in ptl-1(ok621) mutant animals when exposed to azide stress. A) Immunohistochemistry of transgenic 
animals carrying an extrachromosomal array of PTL-1::V5 expressed under the control of the gpa-4 promoter using 
an anti-V5 monoclonal antibody. Transgenic animals express the Pmyo-2::mCherry marker, which expresses in 
pharyngeal muscle. Arrows indicate the axon (upper panel) and cell body (lower panel) of head neurons, putatively 
ASI neurons, where PTL-1:V5 is localised. Rightmost panels are magnified insets indicating staining from DAPI, 
anti-V5 immunofluorescence and a composite merged image. Signal intensity has been increased in insets for 
clarity. B) (i) Intestinal SKN-1 nuclear re-localisation  in animals treated with sodium azide (50mM) for 10 minutes 
at room temperature in liquid. n=15 per biological replicate. (ii) Pgcs-1::gfp induction in response to 50 mM sodium 
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azide. n=40 per biological replicate.  Scoring was conducted as described in (Tullet et al., 2008) for SKN-1::GFP 
and as in (Wang et al., 2010) for Pgcs-1::gfp experiments. Statistical analysis: One-way ANOVA comparing the 
incidence of ‘low’ fluorescence. P-values indicated by ns = not significant, *<0.05. For all experiments, averaged 
data from three independent experiments is shown. 
 
4.1.7 Synaptic vesicle mutants show defective SKN-1 re-localisation that is dependent on PTL-1 
Our observation that neuronal expression of PTL-1 was sufficient to rescue SKN-1::GFP nuclear 
re-localisation in the intestine (Figure 4.8) suggests that part of the response to oxidative stress 
involves a cross-talk between the neurons and the intestine. One possibility is that loss of or 
mutations in PTL-1 result in a defect in vesicle transport or exocytosis from the nervous system, 
and that these vesicles contain the signal required for communication between these tissues. We 
assayed mutants that are defective in vesicle release to determine if this was the case. UNC-13 
regulates conformational changes in the membrane protein syntaxin to mediate exocytosis, and 
thus unc-13(e450) mutants are defective in synaptic vesicle (SV) exocytosis (Richmond et al., 
1999, Madison et al., 2005). We found that unc-13 mutant animals also display a defect in SKN-
1::GFP nuclear re-localisation and Pgcs-1::gfp induction in response to azide stress (Figure 
4.10A). To determine if PTL-1 is involved in the regulation of stress responsive SKN-1::GFP 
localisation by SV release mutants, we generated a unc-13(e450);ptl-1(ok621) double mutant 
strain expressing the SKN-1::GFP transgene and assayed for intestinal re-localisation of SKN-
1::GFP with azide treatment. We elected to test SKN-1::GFP localisation and not Pgcs-1::gfp 
induction for this purpose as we aimed to test for a direct link between SKN-1, PTL-1 and UNC-
13. We did not observe a significant difference in SKN-1::GFP localisation phenotypes between 
azide-treated unc-13(e450) and unc-13(e450);ptl-1(ok621) animals (Figure 4.10B), suggesting 
that PTL-1 and UNC-13 may act in similar pathways to regulate SKN-1.  
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Figure 4.10: SKN-1::GFP re-localisation and Pgcs-1::gfp induction are defective in unc-13 mutant animals. 
A) (i) Intestinal SKN-1 nuclear re-localisation in animals treated with sodium azide for 10 minutes at room 
temperature in liquid. n=15 per biological replicate,. (ii) Pgcs-1::gfp induction (n=40 per biological replicate) in 
response to sodium azide. B) Intestinal SKN-1 nuclear re-localisation for unc-13;ptl-1 double mutants treated with 
sodium azide. Scoring was conducted as described in (Tullet et al., 2008) for SKN-1::GFP and as in (Wang et al., 
2010) for Pgcs-1::gfp experiments. Untreated animals are incubated in M9 buffer only and showed no response. 
Statistical analysis: One-way ANOVA comparing the incidence of ‘low’ fluorescence. P-values indicated by ns = 
not significant, *<0.05. For all experiments, averaged data from three independent experiments is shown. 
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We next tested if another type of vesicle transport was involved in PTL-1-mediated regulation of 
SKN-1. UNC-31 is the C. elegans homolog of CAPS (calcium-dependent activator protein for 
secretion) and functions in calcium-regulated dense-core vesicle (DCV) fusion. unc-31(e928) 
mutants are defective in DCV exocytosis (Lin et al., 2010). We found that unc-31 mutant 
animals were intermediate between wild-type and ptl-1(ok621) mutant animals with regards to 
SKN-1::GFP nuclear re-localisation or Pgcs-1::gfp induction in response to azide stress (Figure 
4.11A). Next, unc-31(e928);ptl-1(ok621) double mutant animals were tested for intestinal re-
localisation of SKN-1::GFP with azide treatment. As above, we did not test Pgcs-1::gfp 
induction after azide treatment in the unc-31;ptl-1 double mutant strain. Intriguingly, we did not 
resolve a significant difference between unc-31(e928) single mutant and unc-31(e928);ptl-
1(ok621) double mutant animals (Figure 4.11B). Given that UNC-13 and UNC-31 appear to 
differentially regulate SKN-1, our data implies that through a different pathway from UNC-13, 
the unc-31(e928) mutation suppresses the effect of the ptl-1(ok621) mutation on SKN-1 
localisation.  
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Figure 4.11: SKN-1::GFP re-localisation and Pgcs-1::gfp induction are not defective in unc-31 mutants. A) (i) 
Intestinal SKN-1 nuclear re-localisation in animals treated with sodium azide for 10 minutes at room temperature in 
liquid. n=15 per biological replicate. (ii) Pgcs-1::gfp induction in response to sodium azide. n=40 per biological 
replicate. B) Intestinal SKN-1 nuclear re-localisation for unc-13;ptl-1 double mutants treated with sodium azide. 
Scoring was conducted as described in (Tullet et al., 2008) for SKN-1::GFP and as in (Wang et al., 2010) for Pgcs-
1::gfp experiments. Untreated animals are incubated in M9 buffer only and showed no response. Statistical analysis: 
One-way ANOVA comparing the incidence of ‘low’ fluorescence. P-values indicated by ns = not significant, 
*<0.05. For all experiments, averaged data from three independent experiments are shown.  
 
Given our observations in the synaptic vesicle release mutant unc-13(e450), we investigated if 
any differences could be observed in synaptic vesicle transport in ptl-1(ok621) mutant animals. 
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We visualised synaptic vesicles using a GFP::RAB-3 (jsIs682) marker in a strain expressing 
Pmec-4::mCherry (vdEx263) to highlight touch neurons, and counted the number of GFP::RAB-
3 punctae in a defined region of the axon in the ALM touch neuron. RAB-3 is a member of the 
Ras GTPase family that is involved in the regulation of SV release in neurons and is used as a 
marker for SVs (Mahoney et al., 2006, Margeta et al., 2009). Interestingly, we observed a small 
but significant difference between wild-type and ptl-1(ok621) animals when we monitored the 
number of GFP::RAB-3 punctae in this manner (Figure 4.12A). We observed that ptl-1(ok621) 
mutant animals had on average a lower number of GFP::RAB-3 punctae compared with wild-
type when punctae were counted along 70 µm of the ALM axon, starting from but not including 
the cell body. Specifically, ptl-1(ok621) animals had 11 punctae per 70 µm whereas wild-type 
animals showed 14 punctae per 70 µm (Figure 4.12B). This is in contrast with an earlier 
investigation that showed no significant difference in the number of SV punctae in ptl-1(ok621) 
mutant animals (Tien et al., 2011), albeit using a different SV reporter (SNB-1::mRFP) and a 
different scoring protocol. In our investigation, punctae were all counted manually and blind to 
the genotype of the strains. However, there were difficulties in developing a consistent scoring 
scheme for counting punctae, as some punctae are large and brighter whereas others are small 
and have a dimmer GFP signal. A more refined scoring scheme is required for future 
experimentation, possibly by quantifying fluorescence intensity along the axon using image 
analysis software and setting a strict definition for regions to be counted as puncta only if they 
exceed a particular signal threshold.  
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Figure 4.12: ptl-1(ok621) mutant animals have fewer synaptic vesicles in ALM neurons compared with wild-
type. A) Images indicating the GFP::RAB-3 (jsIs682) synaptic vesicle marker co-localising with ALM in wild-type 
and ptl-1(ok621) animals. The ALM neuron was visualised using a Pmec-4::mCherry (vdEx263) touch neuron 
reporter. Representative images are shown. Arrows indicate GFP::RAB-3 punctae quantified in this experiment. 
Scale, 10 µm. B) The average number of GFP::RAB-3 punctae counted 70 µm along the axon from (but not 
including) the cell body of ALM in wild-type and ptl-1(ok621) animals. The average of three replicates is shown, n 
=11-12 neurons per replicate. Statistical analysis: unpaired t-test, two-tailed p-value is represented by *<0.05.    
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4.1.8 Discussion  
Chronic oxidative stress has been postulated to contribute towards Tau pathology (Jo et al., 2014, 
Stack et al., 2014). We have demonstrated that the Tau-like protein PTL-1 is involved in (i) 
modulating the response to oxidative stress, and (ii) regulating the nuclear re-localisation of 
intestinal SKN-1 via the nervous system in a process that may require the synaptic vesicle fusion 
protein UNC-13.  
 
In ASI neurons, SKN-1b is constitutively nuclear-localised (An and Blackwell, 2003). In the 
intestine, SKN-1c is normally diffuse in the cytoplasm, but localises to the intestinal nucleus in 
response to stress (An and Blackwell, 2003). This re-localisation process requires p38 mitogen-
activated protein kinase (Inoue et al., 2005) and is also negatively regulated by glycogen 
synthase kinase 3 (GSK-3) (An et al., 2005). Another factor that has been shown to normally 
inhibit nuclear re-localisation of SKN-1 is the insulin receptor DAF-2, which does this in parallel 
to inhibition of another transcription factor that regulates stress and longevity, DAF-16 (Tullet et 
al., 2008). In our hands, we did not see any effect of a daf-2 reduction-of-function on SKN-1 re-
localisation, although we used a transgenic line with considerably lower expression compared 
with the transgenic line used in (Tullet et al., 2008). We now propose the microtubule-associated 
protein PTL-1 as an additional factor that is required for the efficient movement of intestinal 
SKN-1 from the cytoplasm to the nucleus. We also showed that loss of PTL-1 did not affect 
DAF-16 movement into the intestinal nuclei, which is also normally induced by stress, and DAF-
2 reduction-of-function did not alter the effect of ptl-1 mutation on intestinal SKN-1 re-
localisation. This suggests that regulation of SKN-1 by PTL-1 does not involve the insulin-like 
signalling pathway.  
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Using pan-neuronal transgenic lines that restrict PTL-1 expression to the nervous system, we 
have shown that PTL-1 in neurons promotes SKN-1 nuclear re-localisation in the intestine and 
hence the induction of SKN-1-responsive genes. We also found that expressing PTL-1 in ASI 
neurons alone, where SKN-1b remains constitutively nuclear, does not rescue the effect of ptl-1 
null mutation on intestinal SKN-1c localisation. This implies that any interaction between PTL-1 
and SKN-1b in the ASI neurons does not affect SKN-1c in the intestine.  
 
Regulatory processes that occur between proteins found in different tissues have been 
demonstrated previously in the insulin-like signalling pathway in C. elegans. DAF-16 in the 
intestine or neurons can signal to DAF-16 in other tissues to modulate lifespan, although the 
relative effect of intestine-derived signalling is higher than that of neuron-derived signalling 
(Libina et al., 2003). Reducing DAF-16 activity in all tissues also modulates expression levels of 
the insulin-like peptide INS-7 in the intestine but not in neurons (Murphy et al., 2007). In 
addition, the negative regulator WDR-23, which targets SKN-1 for proteasomal degradation, is 
expressed in several tissues including the neurons and intestine (Choe et al., 2009, Staab et al., 
2013). wdr-23 null mutant animals display severe aldicarb resistance, suggesting that WDR-23 
regulates acetylcholine signalling at neuromuscular junctions. However, intestine-specific 
expression of WDR-23, and hence intestine-specific SKN-1 degradation, is sufficient to rescue 
aldicarb resistance in wdr-23 mutant animals (Staab et al., 2013). This implies that SKN-1 
activation in the intestine is required to modulate proper functioning of neurons. These 
investigations reveal that there is substantial cross-talk between the nervous system and the 
intestine of C. elegans, particularly involving factors that regulate longevity or stress tolerance.  
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By monitoring synaptic vesicle distribution using a synaptobrevin-1 (SNB-1) reporter PTL-1 has 
previously been shown to regulate kinesin-based transport on microtubules (Tien et al., 2011). 
We postulated that one mechanism by which PTL-1 in the nervous system regulates SKN-1 in 
the intestine is via signalling molecules carried by synaptic vesicles released from the nervous 
system to communicate with other tissues. Using an unc-13 mutant strain that is defective in 
synaptic vesicle exocytosis (Richmond et al., 1999), we demonstrated that SKN-1 re-localisation 
into intestinal nuclei requires UNC-13. Furthermore, unc-13;ptl-1 double mutant animals were 
not significantly more defective in regulation the movement of intestinal SKN-1 into the nucleus, 
suggesting that PTL-1 and UNC-13 act within similar pathways to modulate SKN-1 localisation. 
However, we acknowledge that a shortcoming with the method used to investigate these 
interactions is that only on average 10-15% of ptl-1 mutant animals display nuclear SKN-
1::GFP, meaning that there is only a small window to resolve a worsening of this effect. Further 
experimentation is required to determine if UNC-13 is genuinely involved in the regulation of 
SKN-1 by PTL-1. Despite this caveat, our data present the first demonstration of the importance 
of SV exocytosis in the SKN-1 intestinal response. Interestingly, the promoter region of the unc-
13 gene contains SKN-1 binding sites and its expression is also regulated by WDR-23 in neurons 
(Staab et al., 2014). We also showed that the SV marker GFP::RAB-3 displayed fewer punctae in 
a designated region of the axon in ptl-1 mutant animals compared with wild-type controls, 
providing additional evidence of a defect in SV transport. Taken together, these findings suggest 
that a feedback loop exists between the nervous system and intestine to regulate neuronal 
function and the stress response. 
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4.2 Section 2: PTL-1 in longevity 
4.2.1 Introduction 
Investigations conducted in many systems suggests that there is a close relationship between the 
stress response and longevity (Buffenstein et al., 2008, Gemma et al., 2007, Sanz and Stefanatos, 
2008). In the previous section, we demonstrated that PTL-1 is involved in regulating the 
response to oxidative stress via the Nrf2 homolog in C. elegans, SKN-1. In mammals, Nrf2 has 
also been linked to lifespan modulation (Lewis et al., 2010, Bishop and Guarente, 2007, Leiser 
and Miller, 2010), as has SKN-1 in C. elegans (Bishop and Guarente, 2007, An et al., 2005). 
Here, we investigated if PTL-1 is involved in longevity, and whether it does so within a similar 
pathway to SKN-1.  
 
4.2.2 ptl-1 mutant animals are short-lived 
The data described above demonstrate that PTL-1 is involved in the stress response via the SKN-
1 transcription factor. For many genes in C. elegans, stress responsiveness is correlated with 
lifespan, such that some mutants that display decreased longevity also have lower tolerance to 
some stressors (reviewed in (Zhou et al., 2011)). We first investigated if PTL-1 plays a role in 
modulating longevity. We conducted lifespan experiments on ptl-1(ok621) and ptl-1(tm543) 
mutant strains and found that both strains were short-lived compared with wild-type controls 
(Figure 4.13A,B). Analysis of the two survival curves indicates that this difference is 
statistically significant; however, it appears that lifespan reduction is more severe in the ptl-
1(ok621) null mutant strain that has a 37% shorter median lifespan compared with wild-type 
(median lifespan 5 days versus 8 days), whereas the median lifespan in the ptl-1(tm543) mutant 
strain is 10% shorter than wild-type (median lifespan 9 days versus 10 days) (Figure 4.13). 
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Figure 4.13: ptl-1 mutant animals are short-lived compared with wild-type. Survival curves for A) ptl-1(ok621) 
and B) ptl-1(tm543) mutant strains compared with wild-type controls. n = 100 at day 0. Results of statistical analysis 
are indicated by p-values underneath each graph. 
 
4.2.3 Lifespan reduction in ptl-1 mutant strains can be rescued by re-expression of PTL-1 but not 
human Tau  
We checked if lifespan reduction observed in ptl-1 mutants could be rescued by re-expression of 
PTL-1 to determine if loss of PTL-1 was genuinely responsible for this phenotype. We found 
that re-expressing PTL-1 in a ptl-1 null mutant background resulted in a survival curve that was 
very similar to non-transgenic wild-type worms (median lifespan 8 days for both strains). 
Therefore, re-expressing PTL-1 in a ptl-1 null mutant is able to rescue the lifespan reduction 
observed in ptl-1(ok621) animals (median lifespan 7 days) (Figure 4.14A). Interestingly, 
expressing the PTL-1 transgene together with endogenous PTL-1 led to a reduction in lifespan 
(median lifespan 7 days). This reduction in lifespan for the “PTL-1 Tg; wild-type” strain is 
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statistically significant according to the Gehan-Breslow-Wilcoxon test for significance. 
Increasing the number of copies of ptl-1 thus appears to produce a detrimental effect.  
 
 
Figure 4.14: The reduction in lifespan observed in ptl-1 null mutant animals can be rescued by re-expression 
of PTL-1 but not human Tau. A) Survival curves for PTL-1 transgenic worms. B) Survival curves for human Tau 
transgenic worms. n=100 for each strain at the start of the assay. Results of statistical analysis are shown in the 
tables below the graphs. 
 
When we conducted the same experiment on transgenic lines expressing human Tau, we found 
that the “hTau Tg;wild-type” line showed a significant reduction in lifespan compared with the 
wild-type control (Figure 4.14B). Interestingly, we also observed that the transgenic line 
expressing hTau in a ptl-1 null mutant has a lifespan that is intermediate between that of non-
transgenic wild-type (median lifespan 8 days) and ptl-1(ok621) null mutant (median lifespan 7 
days) strains, and is not significantly different from these control strains (Figure 4.14B). 
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Furthermore, “hTau Tg;wild-type” animals have a significantly shorter lifespan (median lifespan 
6 days) compared with non-transgenic wild-type worms or with the “hTau Tg; ptl-1(ok621)” 
strain (median lifespan 8 days)  (Figure 4.14B). While these observations suggests that hTau 
may compensate in part for the absence of PTL-1 in the regulation of whole organism lifespan, 
overall our data indicate that hTau expression does not robustly rescue for the loss of PTL-1. 
 
4.2.4 PTL-1 and SKN-1 use similar pathways to regulate longevity 
The skn-1(zu67) mutation, which affects isoforms SKN-1a and SKN-1c, has been previously 
demonstrated to confer a short-lived phenotype (An et al., 2005, Bishop and Guarente, 2007). 
We recapitulated this result with a 13% reduction in median lifespan (median lifespan 7 days for 
skn-1 mutant animals versus 8 days in wild-type). We generated a ptl-1(ok621);skn-1(zu67) 
double mutant strain and conducted a lifespan experiment to investigate if SKN-1and PTL-1 act 
in the same pathway to regulate longevity. Our data indicate that ptl-1(ok621);skn-1(zu67) 
double mutant animals (median lifespan 7 days) were not significantly shorter or longer-lived 
compared to skn-1(zu67) or ptl-1(ok621) single mutant animals (median lifespans 7 days), in two 
independent lifespan experiments (Figure 4.15, Appendix 3). This suggests that SKN-1 and 
PTL-1 may regulate lifespan via similar pathways.  
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Figure 4.15: ptl-1(ok621);skn-1(zu67) double mutant animals are not significantly shorter or longer lived 
compared to ptl-1(ok621) or skn-1(zu67) single mutant animals. Survival curves for skn-1(zu67) and ptl-1(ok621) 
single mutants together with the skn-1(zu67);ptl-1(ok621) double mutant strain. n = 120 at day 0. Results of 
statistical analysis are indicated by p-values underneath each graph. Lifespan experiments were conducted twice 
independently and the results of one lifespan experiment are shown. Data from the second lifespan experiment are 
shown in Appendix 3.  
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4.2.5 Discussion 
In the previous section, we showed that PTL-1 is involved in stress tolerance. We expanded our 
investigation of PTL-1 into its role in the modulation of lifespan. We demonstrate that both null 
and truncated mutant alleles of PTL-1 are short-lived compared with wild-type. We also found 
that re-expressing PTL-1 in ptl-1 null mutant animals using a Pptl-1::PTL-1:V5 transgene was 
sufficient to fully rescue the lifespan defect. In addition, we observed that increasing the number 
of copies of ptl-1 by expressing the Pptl-1::PTL-1:V5 transgene in a wild-type background also 
results in a shortening of lifespan. This indicates that a tight regulation of PTL-1 levels is 
required to maintain wild-type lifespan.  
 
Interestingly, re-expressing human Tau did not rescue the lifespan phenotype observed in ptl-1 
null mutant animals. In fact, expression of human Tau transgene in a wild-type background 
resulted in a significantly shorter lifespan compared with wild-type controls, which is consistent 
with previous findings that human Tau expression in C. elegans is detrimental (Kraemer et al., 
2003). Technical challenges prevented a comparison of expression levels of hTau and PTL-1 in 
the transgenic lines generated in this study, and it is possible that differences in expression 
between these transgenes could explain the lack of rescue by hTau. Importantly, our finding that 
the detrimental effects of expressing human Tau are ameliorated in the absence of endogenous 
PTL-1 suggests some functional conservation between Tau and PTL-1. Although these proteins 
do not have high similarity over the entire sequence, the imperfect tandem repeats in the C-
terminal microtubule-binding domain that constitute the only region of homology between these 
proteins show high amino acid identity. Therefore, it is possible that the microtubule-binding 
functions of these proteins are responsible for their role in lifespan. 
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The skn-1(zu67) allele, which affects SKN-1a and SKN-1c, also results in a shortened lifespan 
(Bishop and Guarente, 2007). In this report, we have shown that ptl-1(ok621);skn-1(zu67) double 
mutant animals are neither shorter- nor longer-lived compared to single ptl-1 or skn-1 mutant 
animals, and these strains are all short-lived compared with wild-type. This suggests that the 
regulation of longevity by PTL-1 or SKN-1 may involve similar processes. Curiously, the skn-
1(zu135) allele that affects all three SKN-1 isoforms does not significantly affect lifespan 
(Bishop and Guarente, 2007), suggesting that interactions between SKN-1a/c and SKN-1b 
isoforms regulate longevity. We did not test if a ptl-1 null mutation would affect the lifespan of 
skn-1(zu135) animals. 
 
Factors that influence the stress response are often also involved in regulating longevity. This 
observation appears to lend support to the “free radical/oxidative stress” theory of ageing, which 
suggests that a chronic build-up of free radical metabolites results in tissue damage and 
senescence (reviewed in (Buffenstein et al., 2008, Gemma et al., 2007, Sanz and Stefanatos, 
2008)). Although this theory has since been widely challenged, there is a general agreement that 
the ability to tolerate oxidative stress is linked to longevity. SKN-1 in C. elegans, like its 
mammalian Nrf2 counterpart, regulates both stress tolerance and ageing, and has also been 
shown to be involved in mediating a physiological process that is impaired with ageing (Naidoo 
et al., 2008), the unfolded protein response (UPR) (Glover-Cutter et al., 2013). Given that Tau 
pathology in AD models has also been linked to oxidative stress, our findings provide an 
interesting avenue for further investigation into the role of a Tau-like protein in stress tolerance 
and longevity.   
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5.1 Introduction 
In the previous chapter, we demonstrated the involvement of PTL-1 in the stress response and 
longevity. Given the close relationship between stress tolerance, lifespan and tissue ageing, as 
well as the involvement of the mammalian homologue Tau in age-related neurodegeneration, we 
proceeded to investigate if PTL-1 was involved in ageing of the nervous system. We based our 
experimental approach on recent publications detailing the subtle parameters of cell body 
branching, axon blebbing or axon branching in touch receptor neurons or ventral nerve cord 
GABAergic neurons (Tank et al., 2011, Pan et al., 2011, Toth et al., 2012). In addition, we 
investigated if the phenotypes observed in ptl-1 mutant animals could be rescued by re-
expression of PTL-1 or human Tau.  
 
5.2The ptl-1(ok621) and ptl-1(tm543) mutant strains show a high frequency of abnormal 
neuronal structures in touch receptor neurons in early adulthood  
Previous investigations have demonstrated that C. elegans adult animals develop structural 
abnormalities with age in neurons such as the TRNs, which include branching along the cell 
body or axon, and blebbing along the axon (Tank et al., 2011, Pan et al., 2011, Toth et al., 2012), 
as detailed in Chapter 1. In the first instance, we grouped all these structural defects into a 
single category and scored animals that displayed any of these defects as positive. We studied the 
appearance of abnormal neuronal structures in wild-type and ptl-1(ok621) null mutant animals by 
imaging the ALM touch neuron in individual worms until the animals died (longitudinal 
experiment) (Figure 5.1). By assaying 15 worms of each genotype every day over their entire 
lifespan, we observed a progressive phenotype as previously reported, where wild-type neurons 
accumulated branching and blebbing structures with age (Figure 5.1A).  
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Figure 5.1: Imaging worms every day until death reveals that ptl-1(ok621) mutant animals display a higher frequency of abnormal neuronal structures 
in touch neurons compared with wild-type. Anterior touch receptor neuron imaging assay for individual animals, showing the neuron of a representative A) 
wild-type, and B) ptl-1(ok621) worm. Neurons were visualised using the Pmec-4::gfp (zdIs5) reporter. Worms were imaged every day until death. Arrowheads 
indicate the presence of structural defects such as cell body branching, axon blebbing and axon branching. Scale, 50 µm for all panels. 
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Interestingly, our data indicate that the accumulation of morphological changes is significantly 
accelerated in the touch receptor neurons in ptl-1(ok621) mutants (Figure 5.1B, Figure 5.2). 
Figure 5.2A highlights the differences between individual wild-type and ptl-1(ok621) animals at 
similar stages of adulthood. At day 7, the anterior touch neuron in a wild-type animal does not 
appear substantially different to the same neuron at day 1, however, in the ptl-1(ok621) mutant 
animal, the ALM neuron shows axon blebbing at day 5 that was not present at day 1 (indicated 
by arrowheads). We observed that the proportion of ptl-1(ok621) animals with neurons 
displaying abnormal structures reached 50% on day 4, compared with wild-type animals where 
this level was reached on day 8 (Figure 5.2B).  
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Figure 5.2: The ptl-1(ok621) mutant strain displays an accelerated onset of appearance of abnormal neuronal 
structures in ALM touch neurons. A) A representative animal is shown for each genotype (n =15 total). Neurons 
were visualised using the Pmec-4::gfp (zdIs5) reporter. Worms were imaged every day until death. Representative 
time points are shown in this figure (from Figure 5.1B), with arrowheads indicating blebbing and arrows indicating 
branching phenotypes. Insets on day 10 show a close-up of the cell body for the respective animal. (Top) ALM 
neuron of a wild-type worm. The worm died on day 15. (Bottom) ALM neuron of a ptl-1(ok621) mutant worm. The 
worm died on day 14. Scale, 50 µm for all panels. Percentage of branching/blebbing observed in ALM neurons of 
the complete data set of wild-type and ptl-1(ok621) animals (n =15, or 5 animals in 3 biological replicates) assayed 
in a longitudinal experiment. Error bars indicate mean ± SEM. A paired t-test was applied to the mean percentage 
branching/blebbing observed in each strain at each time point (for all replicates) and the average of the entire curve 
compared; p value is <0.001.  
 
To complement this experiment, we used a transverse approach, observing synchronised 
populations of wild-type and ptl-1 mutant animals on alternate days from day 1 to 15 of 
adulthood (Figure 5.3). We included ptl-1(tm543) mutant animals in these assays to test if we 
could detect a neuronal ageing phenotype in this strain. Based on our previous experiments, we 
refined our scoring model in two ways: firstly, we recorded data for the touch receptor neurons at 
the anterior and posterior halves of the animal separately, as it became apparent that the posterior 
touch neurons accumulate branches and blebs at a much faster rate compared with the anterior 
touch neurons, showing a high incidence of these abnormal structures even in early adulthood 
(Appendix 6, Figure 5.3A,B). Additionally, since PTL-1 has not been detected in one of the 
three posterior touch neurons (PVM) (Goedert et al., 1996, Gordon et al., 2008), we analysed the 
morphology of PLM and PVM neurons separately (Figure 5.3C). Our second refinement for 
scoring was that for all strains tested, we separately scored for cell body branching, axon 
blebbing, and axon branching (Figure 5.3A-C).  
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Figure 5.3: The ptl-1(ok621) and ptl-1(tm543) mutant strains display accelerated onset of appearance of 
abnormal neuronal structures in touch receptor neurons. Neurons were visualised using the Pmec-4::gfp (zdIs5) 
reporter. The neuron(s) scored in panels A, B and C are highlighted in red, the remaining touch neurons in green. A) 
Anterior touch neurons, B) PLM neurons, and C) PVM neurons in wild-type and ptl-1 mutants scored for cell body 
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branching, axon axon blebbing, and axon branching. Statistical analysis, χ2 test for independence, p value indicated 
by ns = no significance, * <0.05. Sample sizes are indicated below graphs. 
 
Consistent with earlier findings obtained by us and others (Pan et al., 2011, Tank et al., 2011, 
Toth et al., 2012), we found that wild-type animals accumulated structural abnormalities in 
neurons with age (Figure 5.3). In the anterior neurons of wild-type animals, these structural 
abnormalities occur in a particular order, with cell body branching occurring first, followed by 
axon blebbing and axon branching (Figure 5.3A). In contrast, in PLMs, a higher incidence of 
axon blebbing was observed in early adulthood, with cell body and axon branching occurring 
later in life. There was also a generally higher incidence of axon branching in PLMs compared 
with anterior neurons (Figure 5.3B). The PVMs of wild-type animals did not display a high 
incidence of any structural abnormalities in early to mid-adulthood (before day 9) (Figure 5.3C).  
 
When we scored for cell body branching, axon blebbing and axon branching in ptl-1 mutant 
animals in both anterior and posterior touch neurons, we observed a generally similar onset of 
abnormal structures with age as in wild-type animals (Figure 5.3). We also observed a higher 
incidence of abnormal structures in the ptl-1(ok621) null mutant compared with wild-type for 
anterior touch neurons and PLMs (Figure 5.3A,B). In addition, we found similar trends in the 
MBR-deficient ptl-1(tm543) strain. For anterior touch neurons, on day 5 of the assay we 
observed cell body branching in 81% of ptl-1(ok621) and 73% of ptl-1(tm543) animals assayed 
compared with 36% of wild-type controls. At the same time point, blebbing can be seen in 19% 
of ptl-1(ok621) and 22% of ptl-1(tm543) animals compared with 5% in wild-type controls, 
whereas axon branching is observed in 3% of both ptl-1 mutant strains assayed compared with 
0% of wild-type control animals (Figure 5.3A). We also observed similar trends in the PLMs, 
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where ptl-1 mutant animals displayed a higher incidence of all three phenotypes compared with 
wild-type (Figure 5.3B). In the PVMs, although we observed at some time points a high 
incidence of structural abnormalities in both ptl-1 mutant strains (for example, axon blebbing at 
days 13-15, where n<10), at time points before day 11 of adulthood there were generally no 
significant differences between ptl-1 mutant animals and wild-type controls (Figure 5.3C). Our 
results suggest that the ptl-1(tm543) mutation could be hypomorphic, such that the protein 
product in this mutant is able to sustain wild-type levels of touch sensitivity (Figure 3.3), but is 
not sufficient to protect the organism from susceptibility to age-dependent loss of structural 
integrity. 
 
Taken together, these observations demonstrate that PTL-1 is important in maintaining neuronal 
morphology in touch receptor neurons, as a complete loss of this protein or expression of a 
protein lacking the MBR domain results in a higher incidence of abnormal neuronal structures in 
younger animals. For subsequent assays on neuronal morphology, data are presented only for 
anterior touch receptor neurons as the percentage of animals showing abnormal structures in 
these neurons is low at early time points and is less variable compared with the same phenotype 
in posterior touch receptor neurons (Appendix 6, Figure 5.3B), making it easier to monitor 
changes in neuronal morphology with time.  
 
5.3 The ptl-1(ok621) and ptl-1(tm543) mutant strains show a high frequency of abnormal 
neuronal structures in GABAergic neurons in early adulthood  
We next investigated if these effects are specific for selected neuronal populations or whether 
they reflect a general consequence of perturbing PTL-1 function. To this end, we examined a 
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second neuronal cell type in which PTL-1 is also expressed (Gordon et al., 2008, McKay et al., 
2003). Using a Punc-47::gfp reporter line, we visualised the 25 GABAergic neurons, which are 
located mainly in the ventral nerve cord, as well as in the head and the tail (McIntire et al., 
1997). These neurons have commissures that project dorsally from the ventral side, and these 
commissures at times appear branched. Representative images of the branching phenotype in 
wild-type and ptl-1(ok621) animals are shown in Figure 5.4A. These branched commissures are 
observable in wild-type animals in early adulthood, and the incidence of these structures 
increases in late adulthood (day 13-15) (Figure 5.4B). We assayed this phenotype in ptl-1 
mutant animals and observed an accelerated accumulation of branching structures in both ptl-
1(ok621) and ptl-1(tm543) animals compared with wild-type, when each ptl-1 mutant strain was 
assayed separately (Figure 5.4B), or together (Figure 5.4C). In early to mid-adulthood, the 
GABAergic neurons do not appear to accumulate branching structures at substantially differing 
rates when comparing ptl-1(ok621) and ptl-1(tm543) mutant strains (Figure 5.4C). In particular 
at day 5, 68% of ptl-1(ok621) and 64% of ptl-1(tm543) animals displayed branching phenotypes 
compared with 41% in wild-type controls (Figure 5.4C).  
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Figure 5.4: The ptl-1(ok621) and ptl-1(tm543) mutant strains show defects in maintaining neuronal integrity 
with age in GABAergic neurons. Neurons were visualised using the Punc-47::gfp (oxIs12) reporter. A) A 
representative image of the phenotype scored in GABAergic neurons, showing healthy neurons and a branched 
commissure in wild-type, and representative images of branched commissures in ptl-1(ok621) worms. Arrows 
indicate branching. Scale, 50 µm. B) The incidence of branching in GABAergic neurons for ptl-1 mutant strains 
where each assay was conducted separately for each mutant. C) The incidence of branching in GABAergic neurons 
for ptl-1 mutant strains where both mutants were assayed in the same experiment. 
 
In conclusion, ptl-1 mutant strains also display defects in a neuronal subtype other than touch 
receptor neurons, suggesting that PTL-1 has a broader role in the maintenance of neuronal 
structural integrity. 
 
5.4 Functional consequences of mutations in ptl-1 
We next tested if loss of fully functional PTL-1 could affect the functionality of GABAergic 
motor neurons. The drug levamisole has been widely used to pharmacologically determine if C. 
elegans strains are defective in motor neuron activity, which requires cholinergic transmission. 
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Acetylcholine is an excitatory neurotransmitter at neuromuscular junctions (Richmond and 
Jorgensen, 1999). Once synthesised, acetylcholine is loaded onto synaptic vesicles and is 
transported into the synaptic cleft. It then binds to and activates acetylcholine receptors that are 
usually on post-synaptic sites, is enzymatically hydrolysed and the resulting choline then 
transported back into the pre-synaptic cell to be recycled (reviewed in (Rand, 2007)). A 
cholinergic agonist, levamisole results in hypercontracted paralysis in wild-type animals, 
followed by relaxation and death. Resistance to levamisole is therefore associated with defective 
cholinergic signalling (Lewis et al., 1980). We found that ptl-1 mutant strains show significantly 
lower sensitivity to levamisole compared with wild-type controls at early and mid-adulthood, 
with the ptl-1(tm543) strain appearing to have lower sensitivity compared with ptl-1(ok621) 
(Figure 5.5). This suggests that ptl-1 mutant animals are defective in cholinergic transmission. 
Additionally, if graphs from day 1 to day 7 were compared (not shown), we observed a 
substantial decrease in levamisole sensitivity for both ptl-1 mutant strains between day 1 and day 
7, which correlates with the higher incidence of branching commissures in GABAergic neurons 
at later time points (Figure 5.4C). 
 
 
Figure 5.5: The ptl-1(ok621) and ptl-1(tm543) mutant strains display allelic differences in levamisole 
sensitivity. Assay for paralysis after levamisole exposure. Worms were scored for paralysis over 90 minutes on drug 
plates on day 1, 5 and 7 of adulthood (n = 30 per strain, per time point). Statistical analysis, one-way ANOVA; ptl-
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1(ok621) and ptl-1(tm543) mutant strains, but not wild-type controls, show significant decreases in drug sensitivity 
between day 1 and day 7 (p value <0.05) when all graphs are combined.  
 
The six mechanosensory touch receptor neurons regulate the response of worms to gentle touch 
(Chalfie and Sulston, 1981). We showed in Chapter 3 that we could confirm the mild touch 
insensitive phenotype of ptl-1(ok621) animals as previously demonstrated (Gordon et al., 2008), 
and in addition that ptl-1(tm543) animals did not display a resolvable touch insensitive 
phenotype (Figure 3.3) at day one of adulthood. We observed a progressive accumulation of 
abnormal neuronal structures in the touch neurons with age in ptl-1 mutants (Figure 5.3); 
however, we could not reliably assay for touch sensitivity in late adulthood, as animals become 
considerably less motile with age (Huang et al., 2004), making it difficult to score positive 
responses defined as “movement away from touch” when body movement is poor in aged 
animals (Chalfie and Sulston, 1981). This prevented us from conducting an analogous 
experiment in the touch neurons to the levamisole assay described above to monitor GABAergic 
motor neuron functionality with age. Interestingly, others have described that touch sensitivity 
appears to decline in day 10 adult wild-type animals, which have relatively high levels of touch 
neuron branching (Tank et al., 2011).  
 
5.5 Re-expression of PTL-1 but not human Tau rescues defects observed in ptl-1 null mutant 
animals 
To confirm that the neuronal ageing phenotypes found in ptl-1 mutant worms are attributable to 
the loss of PTL-1 function, we tested if re-expressing PTL-1 in the ptl-1(ok621) mutant strain 
could rescue these phenotypes. We described the transgenic line where PTL-1::V5 is expressed 
under the regulation of a ptl-1 promoter and 3′ UTR in Chapter 4, and refer to this as “PTL-1 
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Tg” followed by “ptl-1(ok621)” if it is in the ptl-1 null mutant background. As in the earlier 
chapter, we chose to perform our rescue experiments in the ptl-1(ok621) background only. We 
also assayed the touch receptor neurons only and not the GABAergic neurons as abnormal 
structures in the touch neurons become apparent in early to mid-adulthood (Figure 5.3) whereas 
GABAergic neuron branching tends to increase in incidence only later in life (Figure 5.4), 
meaning that it is easier to resolve differences in touch neuron ageing.  
 
We crossed PTL-1 Tg worms with both the ptl-1(ok621) mutant strain and the Pmec-4::gfp 
reporter line, and assayed for age-related morphological changes in touch receptor neurons as 
previously described. For simplicity, we pooled all age-related defects (cell body branching, 
axon blebbing, and axon branching) into a single category and scored worms that displayed any 
of these phenotypes as positive. We found that re-expressing PTL-1 in ptl-1(ok621) animals 
appeared to delay the accumulation of abnormal neuronal structures to almost wild-type levels 
(Figure 5.6A), such that when these animals were assayed from day 5 onwards, the proportion of 
animals showing these phenotypes in anterior touch neurons was not significantly different from 
wild-type. For example, at day 5 of this assay 20% of “PTL-1 Tg; ptl-1(ok621)” worms 
displayed abnormal structures in anterior touch neurons compared with 32% in wild-type.  Thus 
we were able to rescue the accelerated accumulation of abnormal structures in touch neurons of 
ptl-1(ok621) mutants by re-expressing PTL-1 in these animals. Somewhat surprisingly, we also 
observed that animals expressing the PTL-1 transgene on a wild-type background accumulated 
branches and blebbing structures with increased frequency compared with non-transgenic wild-
type controls (Figure 5.6B), and that these levels were comparable with that observed in the 
strain carrying only the ptl-1(ok621) mutation (Figure 5.6C). For example, at day 5 of this assay, 
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55% of “PTL-1 Tg; wild-type” worms displayed abnormal neuronal structures, compared with 
32% in wild-type controls (Figure 5.6B). It therefore appears that modulation of PTL-1 levels by 
either a null mutation or increasing the gene copy number (by introducing copy(ies) of a PTL-1 
transgene in addition to the endogenous gene locus) negatively affects neuronal integrity. 
 
 
Figure 5.6: Re-expression of PTL-1 rescues age-related abnormal neuron morphology and touch sensitivity in 
the ptl-1(ok621) mutant. ‘PTL-1 Tg’ refers to the PTL-1::V5 transgene, and the terms ‘wild-type’ and ‘ptl-
1(ok621)’ following this refer to the genotype at the genomic ptl-1 locus, whether wild-type or ok621 mutant 
respectively. A) Neuron imaging time course of PTL-1 transgenic worms, showing data for anterior touch receptor 
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neurons visualised using the Pmec-4::gfp (zdIs5) reporter. A) shows control strains together with the PTL-1 Tg; ptl-
1(ok621) rescue strain. B) shows the effect of the PTL-1 Tg alone, compared with wild-type controls. C) compares 
the PTL-1 Tg transgenic line with the ptl-1(ok621) mutant strain. Sample sizes are indicated below the graphs. The 
χ2 test for independence was used to analyse differences between genotypes. p value is indicated by * < 0.05, ns = 
not significant. For statistical analysis in C), the expected value is that observed for “ptl-1(ok621)”. For all other 
graphs the expected value was that observed for wild-type.  
 
Using the human Tau transgenic line detailed in Chapter 4 (Figure 4.4), which expresses the 
longest isoform of human Tau (hTau40) under the regulation of the ptl-1 promoter and 3′ UTR, 
we next investigated whether human Tau would rescue the defects observed in the ptl-1 null 
mutant. We refer to this transgenic line as “hTau Tg” followed by “ptl-1(ok621)” if it is in the 
ptl-1 null mutant background. We found that the frequency of abnormal structures observed in 
anterior touch receptor neurons in “hTau Tg; ptl-1(ok621)” is not significantly different 
compared with the non-transgenic ptl-1 null mutant strain on days 3, 5, 7 and 9 of the assay 
(Figure 5.7A), indicating no robust rescue of the neuronal ageing phenotype. Interestingly, we 
observed that hTau expression in a wild-type background was detrimental to worms in terms of 
neuronal ageing, where these transgenic animals displayed a higher incidence of branching and 
blebbing phenotypes in anterior touch receptor neurons compared with non-transgenic wild-type 
worms at day 3, 5, 7 and 9 of the assay (Figure 5.7B). This observation reflects our earlier 
finding that “hTau Tg; wild-type” animals are short-lived compared with wild-type controls 
(Chapter 4). Our data are also consistent with previous reports indicating that wild-type hTau 
expression under the control of a pan-neuronal promoter results in defects in motility, cholinergic 
neuron transmission, and lifespan (Kraemer et al., 2003). It is notable that hTau transgenic lines 
reported in the study conducted by Kraemer et al. were generated by microinjection (Kraemer et 
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al., 2003), whereas the transgenic lines in our study were generated by biolistic transformation, 
which we would expect to introduce a lower transgene copy number than by microinjection, and 
hence a lower expected expression level (Praitis et al., 2001). Therefore it appears that wild-type 
hTau, even at a low expression level, is detrimental to C. elegans when expressed in addition to 
endogenous PTL-1.  
 
 
Figure 5.7: Expression of human Tau does not robustly rescue age-related abnormal neuron morphology in 
the ptl-1(ok621) mutant. Neuron imaging time course of hTau transgenic worms showing data for anterior touch 
receptor neurons visualised using the Pmec-4::gfp (zdIs5) reporter. A) shows control strains together with the hTau 
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Tg; ptl-1(ok621) rescue strain. B) shows the effect of the hTau Tg alone, compared with wild-type controls. C) 
compares the hTau Tg lines in wild-type or ptl-1(ok621) backgrounds. Sample sizes are indicated below the graph. 
Control strains (wild-type and ptl-1(ok621)) are the same as those shown for the PTL-1 transgenics (Figure 5.6). 
The χ2 test for independence was used to analyse differences between genotypes. p value is indicated by * < 0.05, ns 
= not significant. For statistical analysis in C), the expected value is that observed for “hTau Tg; wild-type”. For all 
other graphs the expected value was that observed for wild-type.  
 
Curiously, comparing human Tau transgenic lines that are either wild-type or null for 
endogenous PTL-1 indicates that the presence of the ptl-1(ok621) null mutation improved some 
of the detrimental effects of human Tau expression. For example, we found that “hTau Tg; wild-
type” animals showed a higher incidence of abnormal neuronal structures compared with the 
hTau Tg line in a ptl-1 null mutant background at days 1, 3, 5 and 9 of the assay (Figure 5.7C). 
In particular, on day 5, the percentage of “hTau Tg; wild-type” worms displaying branching or 
blebbing was 60% (n=40), compared with 40% in “hTau Tg; ptl-1(ok621)” worms (n=35) and 
32% in non-transgenic wild-type worms (n=40). These data suggest some degree of functional 
conservation between hTau and PTL-1. 
 
We next investigated whether PTL-1 or human Tau re-expression could rescue the functional 
defects in touch sensitivity observed in ptl-1(ok621) mutant animals. We observed that PTL-1 
transgenic animals are touch sensitive both in a wild-type and ptl-1(ok621) null mutant genetic 
background (Figure 5.8A). In contrast, the expression of human Tau in the wild-type 
background resulted in reduced touch sensitivity but rescued touch responsiveness in the null 
mutant (Figure 5.8B). This finding indicates that human Tau cannot compensate for loss of PTL-
1 in terms of protecting animals from premature neuronal ageing, but is able to rescue the 
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functional defect in touch neurons. Furthermore, expression of human Tau together with 
endogenous PTL-1 appears to be detrimental.  
 
 
Figure 5.8: Re-expression of PTL-1 but not human Tau rescues touch insensitivity in the ptl-1(ok621) mutant. 
A,B) Data for sensitivity to gentle touch, shown for A) PTL-1 Tg and B) hTau Tg animals (n > 45 total for two 
biological replicates). Control strains are the same for panel A and B. Assays were conducted on one day-old adults. 
Error bars indicate mean ± SEM. One-way ANOVA, Bonferroni post-test, p value is indicated by ns = no 
significance, * <0.05.   
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5.6 Discussion 
5.6.1. PTL-1 is important for the maintenance of neuronal integrity in C. elegans 
In this chapter, we have shown that PTL-1 in C. elegans is involved in the age-associated 
preservation of neuronal structural integrity. Moreover, we observed that the severity of 
phenotypes observed in human Tau transgenic worms is dependent on the presence or absence of 
endogenous PTL-1, suggesting some functional conservation between these proteins.  
 
We analysed two ptl-1 mutant strains in the context of neuronal ageing, the null mutant ptl-
1(ok621) (Gordon et al., 2008), and ptl-1(tm543), which putatively generates a protein product 
containing only the N-terminal region. Analysis of these mutant strains allowed us not only to 
investigate the role of PTL-1 in vivo, but also to dissociate functions of PTL-1 that are 
attributable solely to microtubule-binding from functions of the full-length protein. We found 
that both mutants of ptl-1 show a decreased capacity to maintain neuronal integrity with age, as 
evidenced by a higher frequency of abnormal morphological structures such as branching and 
blebbing in touch receptor and GABAergic motor neurons in early adulthood compared with 
wild-type. Interestingly, this effect was also observed when we increased the copy number of 
full-length PTL-1 by expression of a stable transgene in addition to the endogenous locus. 
Therefore, correct gene dosage of PTL-1 is critical for the maintenance of neuronal structures 
with age, as either increasing or decreasing this level is detrimental to the organism. This is 
consistent with previous investigations showing that transgenic lines generated by microinjection 
that over-express PTL-1 display a dumpy phenotype and show morphological abnormalities in 
neurons (Tien et al., 2011). In addition when we assayed touch sensitivity, a response that 
requires functional touch receptor neurons, we found that the ptl-1(ok621) null mutant is less 
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responsive to gentle touch compared with wild-type, but that there was no difference in touch 
sensitivity from wild-type in the ptl-1(tm543) mutant lacking the MBR domain, suggesting that 
this allele may be hypomorphic, or that the N-terminal region may have functions that are 
sufficient to maintain touch sensitivity (Figure 3.3). Interestingly, we observed the opposite 
effect when assaying for defects in cholinergic/GABAergic transmission, with ptl-1(tm543) 
animals displaying a more severe phenotype compared with ptl-1(ok621). Importantly, our data 
indicate that although the microtubule-binding functions of PTL-1 are not necessary for wild-
type touch sensitivity, the maintenance of touch neuron structural integrity with age requires full 
length PTL-1. Our findings also demonstrate that wild-type functioning of neurons may not be 
sufficient to preserve neuronal health with age. Another C. elegans MAP that is expressed in 
touch receptor neurons is the EMAP-like protein or ELP-1, which does not display high 
sequence similarity to PTL-1 but also regulates touch sensitivity (Hueston et al., 2008). In light 
of this, allelic differences in touch sensitivity observed between ptl-1 mutants could be due to a 
requirement for both ELP-1 and the N-terminus of PTL-1 for wild-type touch responsiveness. A 
role of ELP-1 in neuronal ageing, however, remains to be investigated.  
 
PTL-1 is largely enriched in neurons, particularly five of the six touch receptor neurons (the 
ALMs, AVM, and the PLMs) (Goedert et al., 1996, Gordon et al., 2008). We demonstrated that 
in these five neurons, loss or mutation in PTL-1 increased the incidence of structural defects in 
younger adults compared with wild-type, suggesting an accelerated rate of neuronal ageing. We 
also tested the rate of ageing in a neuron in which PTL-1 is thought not to be expressed. Within 
the limits of detection, PTL-1 has not been detected in PVM neurons (Gordon et al., 2008, 
Goedert et al., 1996). We observed a progressive accumulation of structural defects in PVM with 
Chapter 5: PTL-1 regulates ageing of the nervous system 
 
125 
 
age in all strains, although there was overall no significant difference between the incidence of 
branching and/or blebbing between ptl-1 mutant strains and wild-type, even at advanced age. 
This may be due to: 
1) PTL-1 not being expressed in PVM, therefore this neuron does not display 
accelerated structural defects with aging in ptl-1 mutants compared with wild-type 
controls. We acknowledge that at very late time points i.e. day 13 and 15, it appears 
that there is significantly more blebbing observed in PVM in  ptl-1 mutants compared 
with wild-type (Figure 5.3C), however, at this time point there are very few mutant 
animals still alive (n= ~4), making these results less statistically reliable. 
2) PVM being inherently less susceptible to the formation of abnormal structures. We 
and others (Toth et al., 2012) have found that in wild-type animals the incidence of 
abnormal structures in PVM is much lower than observed in the other touch neurons, 
meaning that it is more difficult to resolve differences (if any) between strains.  
 
Our data indicate that PTL-1 has biological functions in regulating both ageing in neurons and 
ageing in the whole organism (Chapter 4, Section 4.1). Does PTL-1 exert these effects from the 
nervous system alone, or from non-neuronal tissues? In adult worms, it appears that PTL-1 is 
enriched in neurons (Goedert et al., 1996, Gordon et al., 2008) (Figure 4.6). Previous studies 
have also established a role for PTL-1 specifically in touch neurons, in particular with respect to 
mechanosensation (Gordon et al., 2008) and microtubule-based transport (Tien et al., 2011). 
With regards to the role of PTL-1 in regulating organismal lifespan, previous studies have 
suggested that signalling events in neurons alone are sufficient to alter lifespan (Apfeld and 
Kenyon, 1999, Alcedo and Kenyon, 2004). If neuronal functions of PTL-1 regulate whole 
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organism lifespan, it remains to be determined whether this refers to a role in all neurons or in a 
particular subset of neurons. Ablation of sensory neurons such as thermosensory neurons (Lee 
and Kenyon, 2009) or gustatory and olfactory neurons (Alcedo and Kenyon, 2004) in C. elegans 
results in a shortening or extension of lifespan, respectively. In addition, C. elegans mutants 
defective in sensory cilia in some neurons have been shown to be long-lived (Apfeld and 
Kenyon, 1999). Studies performed using several mechanosensory defective (mec) mutants 
predominantly affecting touch receptor neurons, such as mec-1, mec-8 and mec-12, have also 
demonstrated differences in lifespan compared with wild-type (Apfeld and Kenyon, 1999, Pan et 
al., 2011). As PTL-1 is expressed in most, if not all, neurons in the worm, the reduced lifespan of 
ptl-1 mutants may be due to the loss of PTL-1 function in one or more of these neuronal subsets. 
 
5.6.2 Tau and PTL-1 display some functional conservation in the regulation of neuronal ageing 
and longevity 
We observed in terms of longevity and neuronal ageing, that (1) human Tau expression is 
detrimental to worms, (2) human Tau does not robustly rescue for loss of PTL-1, and (3) touch 
sensitivity, neuronal structural health and lifespan phenotypes of human Tau transgenic lines are 
dependent on PTL-1. The negative effect of expressing human Tau in C. elegans, as also 
observed in (Kraemer et al., 2003, Brandt et al., 2009, Miyasaka et al., 2005), may be due to 
over-expression of any MAP having a detrimental effect. Or, this could be due to a specific 
axonal role of Tau that evolved with the diversification of neuronal MAPs into mainly axon-
localised Tau and mainly dendrite-localised MAP2. In addition to some shared functions (Sontag 
et al., 2012), Tau and MAP2 play specific roles in their distinct subcellular compartments (Kosik 
and Finch, 1987, Hirokawa et al., 1996, Chen et al., 1992, Harada et al., 1994). In C. elegans, no 
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such diversification of neuronal MAPs exists, and as PTL-1 is a homolog of both MAP2 and 
Tau, it presumably has both axon- and dendrite-specific functions. Therefore, the axon-specific 
effects of human Tau could negatively affect the worm when Tau is present in addition to 
endogenous PTL-1, and could also be insufficient to rescue for the loss of PTL-1 in a null mutant 
with regards to neuronal and whole organismal ageing.  
 
Our observation that human Tau rescues touch insensitivity in a ptl-1 null mutant, together with 
the finding that the detrimental effects of expressing Tau are ameliorated in the absence of 
endogenous PTL-1, suggests some functional conservation between Tau and PTL-1. Although 
these proteins do not have high similarity over the entire sequence, the imperfect tandem repeats 
in the C-terminal microtubule-binding domain that constitute the only region of homology 
between these proteins show high amino acid identity. Therefore, these conserved functions may 
be those attributable to the microtubule-binding capacity of Tau and PTL-1.   
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6.1 Introduction 
In previous chapters, we demonstrated that PTL-1 is involved in the regulation of neuronal 
ageing and longevity. Here, we extended our investigation into the role of PTL-1 in maintaining 
the structural integrity of neurons with age by conducting neuron-specific re-expression and 
knockdown experiments. By investigating neuronal ageing in animals where PTL-1 is either 
present or knocked down in only one neuronal cell-type, we can test if the regulation of neuronal 
integrity by PTL-1 is cell autonomous. We chose the touch neurons as our model for this 
purpose, as (i) PTL-1 is most highly expressed in these neurons, implying that it has a particular 
physiological role in these cells, (ii) we have developed a robust and comprehensive scoring 
protocol for age-related structural abnormalities in the touch neurons, and (iii) we have shown 
that abnormal neuronal structures become apparent in early to mid-adulthood in ptl-1 mutant 
animals, making it easier to resolve differences between strains.  
 
6.2 PTL-1 is expressed in neuronal and non-neuronal tissues 
Previously, we demonstrated that re-expressing PTL-1 under the regulation of its endogenous 
promoter is sufficient to rescue both neuronal ageing and lifespan phenotypes observed in ptl-1 
null mutant animals (Chapter 4 and 5)(Chew et al., 2013). Immunohistochemistry experiments 
using a PTL-1-specific antibody detected expression only in touch neurons (Goedert et al., 
1996), however a transcriptional reporter expressing GFP under the control of a ptl-1 promoter 
showed expression in touch neurons as well as in many other neuronal subtypes including in the 
nerve ring and ventral cord, suggesting a more widespread expression of PTL-1 (Gordon et al., 
2008, McKay et al., 2003). Further analysis using this transcriptional reporter showed that PTL-1 
expression is indeed not restricted to neurons (Gordon et al., 2008, Goedert et al., 1996); it is also 
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expressed in non-neuronal tissues including vulval cells and stomatointestinal muscle (Gordon et 
al., 2008). As described in Chapter 4 (Figure 4.6), we generated a translational fusion reporter 
line that expresses PTL-1 fused to GFP at the C-terminus under the control of the ptl-1 promoter 
together with an unc-54 3′ UTR element for transcript stability. Although our fusion construct is 
transcribed using the same regulatory elements as the aforementioned transcriptional reporter 
(McKay et al., 2003), the PTL-1::GFP fusion would localise to particular subcellular sites where 
PTL-1 protein would be found, in contrast to the transcriptional reporter where GFP is 
distributed throughout the entire cells of those tissues where the ptl-1 promoter drives 
expression. By using this PTL-1::GFP translational fusion reporter, we confirmed the expression 
pattern detailed previously (Figure 4.6) and showed that in neurons, PTL-1 localisation is 
largely cytoplasmic and not nuclear (Figure 4.6v,vii). Given that PTL-1 appears to regulate both 
neuronal ageing and whole organismal ageing, we aimed to identify if these processes required 
PTL-1 in the nervous system and/or in non-neuronal tissues.  
 
6.3 Premature ageing of touch neurons in ptl-1 null mutant animals can be rescued by pan-
neuronal re-expression of PTL-1 
In Chapter 4, we described the generation of the pan-neuronal transgenic line (“Pan-neuronal 
Tg”), which contains a transgene expressing PTL-1::V5 under the regulation of an aex-3 
promoter together with a ptl-1 3′ UTR. We tested whether this transgene would be able to rescue 
neuronal ageing in a ptl-1 null mutant strain. As previously described (Chew et al., 2013, Tank et 
al., 2011, Pan et al., 2011, Toth et al., 2012), young touch neurons have straight axons and a 
round, unbranched cell body, whilst older neurons display cell body branching, axon blebbing 
and axon branching. We scored for these ageing phenotypes in anterior touch neurons at 20 °C 
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using the Pmec-4::gfp (zdIs5) reporter. In our previous experiments (Chapter 5), we had assayed 
animals until day 15. In general, we observed differences between wild-type and mutant strains 
only up to day 9, as after this time point a high proportion of wild-type animals also accumulated 
structural abnormalities in ageing neurons. Additionally, the short lifespan of ptl-1 mutant 
animals meant that at and after day 11, the sample size of these mutant strains was low (n<10 at 
day 15), making it more difficult to generate statistically meaningful data. For these reasons, for 
the remaining neuronal imaging experiments at 20 °C, we elected to assay animals on days 1, 5, 
7 and 9 of adulthood.  
 
Re-expression of PTL-1 in all neurons in the ptl-1 null mutant background (“Pan-neuronal Tg; 
ptl-1(ok621)”) was able to fully rescue the premature incidence of neuronal branching and 
blebbing seen in ptl-1(ok621) animals at 20 °C (Figure 6.1A). Specifically, 14% of wild-type 
worms on day 5 of adulthood displayed cell body branching in the anterior touch neurons 
compared with 29% of ptl-1(ok621) animals and 8% of “Pan-neuronal Tg; ptl-1(ok621)” animals 
(Figure 6.1Ai). In addition, we observed the same trends when the experiment was repeated at 
25 °C on days 1, 3, and 5 of adulthood (Figure 6.1B). We tested for neuronal ageing at the 
higher temperature because lifespan experiments shown in Chapter 4 (Section 4.2) were 
conducted at 25 °C, and given the substantial effect that temperature can have on ageing in C. 
elegans, a direct comparison between these phenotypes can only be made if the experiments 
were conducted at the same temperature. Our results using the pan-neuronal transgenic line 
indicate that PTL-1 acts within neurons to regulate neuronal ageing.  
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Figure 6.1: Pan-neuronal re-expression of PTL-1 rescues the neuronal ageing phenotype in touch neurons 
that is observed in the ptl-1(ok621) null mutant. The touch neurons were visualised using the Pmec-4::gfp (zdIs5) 
reporter construct. The presence of the ptl-1(ok621) null mutation in the genetic background of each transgenic line 
is indicated by the addition of “ptl-1(ok621)” in the strain name. Neuron imaging assay conducted at A) 20 °C or B) 
25 °C for pan-neuronal transgenic worms (“Pan-neuronal Tg”) showing (i) cell body branching, (ii) axon blebbing, 
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and (iii) axon branching. The sample size for each strain at each time point is given in the table underneath the 
graphs. The χ-squared statistical test was used to determine statistical significance. P-value is indicated by ns = not 
significant, *<0.05. Experiments were conducted twice independently, and the representative data shown are from 
one experiment. Data from the second independent experiment are shown in Appendix 7. 
 
6.4 Premature ageing of GABAergic neurons in ptl-1 null mutant animals can be rescued by 
pan-neuronal re-expression of PTL-1 
We tested if rescue of the neuronal ageing phenotype in the touch neurons with pan-neuronal re-
expression of PTL-1 could be observed in another neuronal subset, the GABAergic neurons. We 
visualised GABAergic neuron branching at 20 °C on days 1, 5, 7 and 9 of adulthood using the 
Punc-47::gfp (oxIs12) reporter. As noted previously (Toth et al., 2012, Pan et al., 2011, Tank et 
al., 2011, Chew et al., 2013), GABAergic neurons in young animals show only a low incidence 
of branching in the dorsally-projecting commissures, which are often branched in older adults. 
We found that re-expressing PTL-1 in all neurons in the ptl-1 null mutant background 
completely rescued premature neuronal ageing observed in ptl-1(ok621) mutant animals (Figure 
6.2A). For example, at day 5 of adulthood, 10% of wild-type animals displayed branching along 
the commissures of GABAergic neurons, compared with 36% of ptl-1(ok621) animals and 15% 
of “Pan-neuronal Tg; ptl-1(ok621)” animals (Figure 6.2A). We also observed the same rescue 
phenotypes when the experiment was repeated at 25 °C and animals were scored on days 1, 3 
and 5 of adulthood (Figure 6.2B). These results demonstrate that pan-neuronal re-expression of 
PTL-1 is able to rescue neuronal ageing in a ptl-1 null mutant in two subsets of neurons.  
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Figure 6.2: Pan-neuronal re-expression of PTL-1 rescues the neuronal ageing phenotype in GABAergic 
neurons that is observed in the ptl-1(ok621) null mutant. GABAergic neurons were visualised using the Punc-
47::gfp (oxIs12) reporter. The presence of the ptl-1(ok621) mutation in the genetic background of each transgenic 
line is indicated by the addition of “ptl-1(ok621)” in the strain name. Neuron imaging assay conducted at A) 20 °C 
or B) 25 °C for “Pan-neuronal Tg” worms. The χ-squared statistical test was used to determine statistical 
significance. P-value is indicated by ns = not significant, *<0.05. The sample size for each strain at each time point 
is given in the table underneath the graphs. Experiments were conducted twice independently, and the representative 
data shown are from one experiment. Data from the second independent experiment are shown in Appendix 8. 
 
6.5 The shortened lifespan observed in ptl-1 null mutant animals can be rescued by pan-
neuronal expression of PTL-1 
We performed lifespan assays to determine if expression of PTL-1 in all neurons would  rescue 
the shortened lifespan of ptl-1(ok621) null mutants (Chew et al., 2013). We found that pan-
neuronal expression of PTL-1 in a wild-type background (“Pan-neuronal Tg”) (median lifespan 
10 days) or re-expression in a ptl-1 null mutant background (“Pan-neuronal Tg; ptl-1(ok621)”) 
(median lifespan 11 days) restored the wild-type lifespan (median lifespan 10 days), and these 
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were all significantly higher than the lifespan of ptl-1(ok621) mutant animals (median lifespan 9 
days) (Figure 6.3). This indicates that PTL-1 regulates lifespan via the nervous system.  
 
 
Figure 6.3: The short-lived phenotype of ptl-1 null mutant animals can be rescued by pan-neuronal re-
expression of PTL-1. Lifespan assay for pan-neuronal transgenic worms. Survival curves for wild-type and ptl-
1(ok621) animals in both graphs were obtained in the same experiment. n = 120 at day 0. Results of statistical 
analysis are indicated by p-values underneath each graph. Lifespan experiments were conducted twice 
independently, and the representative data shown are from one experiment. Data from the second independent 
experiment are shown in Appendix 9. 
 
6.6 Premature ageing of touch neurons in ptl-1 null mutant animals can be rescued by touch 
neuron-specific re-expression of PTL-1 
Our results have shown that pan-neuronal re-expression of PTL-1 is sufficient to rescue neuronal 
ageing and lifespan phenotypes observed in a ptl-1 null mutant strain. We next tested if re-
expressing PTL-1 in touch neurons alone, the neuronal subset in which PTL-1 is most highly 
expressed, would also rescue these phenotypes. To this end, we additionally generated a 
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transgenic line expressing ptl-1::V5 cDNA under the regulation of the mec-7 touch neuron-
specific promoter. For clarity, we describe the touch neuron transgenic line as “TRN Tg”, 
followed by “ptl-1(ok621)” if it is in the ptl-1 null mutant background. We immunostained for 
the V5 epitope tag present at the C-terminus of PTL-1 in the TRN Tg line and confirmed that 
PTL-1 displayed expression in touch neurons only (Figure 6.4).  
 
 
Figure 6.4: Touch neuron-specific expression of PTL-1 can be achieved using a Pmec-7::ptl-1-v5 transgene. A) 
Staining for PTL-1::V5 in touch neuron-specific transgenic line. The left panel indicates the tail, with PLM neurons 
indicated by white arrowheads. The right panel indicates the mid-body of the worm, showing an ALM neuron. The 
white arrowhead here indicates the cell body. 
 
We then investigated if touch neuron-specific expression would affect neuronal ageing in these 
neurons by scoring for cell body branching, axon blebbing and axon branching in these 
transgenic lines at both 20 °C and 25 °C. When we assayed for the premature ageing phenotypes 
in the touch neurons of ptl-1 mutant animals, we found that these phenotypes were rescued when 
PTL-1 is re-expressed only in touch neurons (“TRN Tg;ptl-1(ok621)”) (Figure 6.5). For 
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example, at day 7 of adulthood, 8% of wild-type animals displayed axon blebbing, compared 
with 35% in ptl-1(ok621) mutants and 20% in “TRN Tg;ptl-1(ok621)” animals (Figure 6.5Aii). 
There was no observable detrimental effect of over-expressing PTL-1 in the touch neurons in this 
experiment; at the same time point, 11% of TRN Tg animals displayed axon blebbing, which is 
not significantly different from wild-type. We observed the same trends for all phenotypes at 25 
°C as at 20 °C (Figure 6.5B). 
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Figure 6.5: Touch neuron-specific re-expression of PTL-1 rescues the neuronal ageing phenotype in touch 
neurons that is observed in the ptl-1(ok621) null mutant. The touch neurons were visualised using the Pmec-
4::gfp (zdIs5) reporter. The presence of the ptl-1(ok621) null mutation in the genetic background of each transgenic 
line is indicated by the addition of “ptl-1(ok621)” in the strain name. Neuron imaging assay conducted at A) 20 °C 
or B) 25 °C for touch neuron-specific transgenic worms (“TRN Tg”). Data for wild-type and ptl-1(ok621) animals in 
both graphs were obtained in the same experiment as pan-neuronal transgenic lines at the same temperature (Figure 
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6.1). The chi-squared statistical test was used to determine statistical significance. P-value is indicated by ns = not 
significant, *<0.05. The sample size for each strain at each time point is given in the table underneath the graphs. 
Experiments were conducted twice independently, and the representative data shown are from one experiment. Data 
from the second independent experiment are shown in Appendix 10. 
 
6.7 Premature ageing of GABAergic neurons in ptl-1 null mutant animals is not rescued by 
touch neuron-specific re-expression of PTL-1 
We next investigated if PTL-1 expression specifically in one neuronal subset, the touch neurons, 
is able to regulate neuronal ageing in other neurons, such as the GABAergic neurons. To do this, 
we assayed for GABAergic neuron branching with age in animals expressing the TRN-specific 
transgene expressing PTL-1. We did not observe a substantial difference in the incidence of 
abnormal structures between “TRN Tg; ptl-1(ok621)” animals (53%) at day 7 of adulthood 
compared with ptl-1(ok621) mutants at the same time point (55%), which are both significantly 
higher than wild-type (24%) (Figure 6.6A). This demonstrates that expression of PTL-1 in one 
neuronal subset does not impact neuronal ageing in a second subset. Additionally, over-
expression of PTL-1 in touch neurons alone does not negatively impact on ageing in GABAergic 
neurons, as the incidence of branching in “TRN Tg” animals at this time point was 25%, and 
therefore not significantly different from wild-type. As for the neuronal ageing experiments in 
touch neurons, we observed the same trends at 25 °C as at 20 °C (Figure 6.6B). 
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Figure 6.6: Touch neuron-specific re-expression of PTL-1 does not rescue the neuronal ageing phenotype in 
GABAergic neurons that is observed in the ptl-1(ok621) null mutant. The GABAergic neurons were visualised 
using the Punc-47::gfp (oxIs12) reporter. The presence of the ptl-1(ok621) mutation in the genetic background of 
each transgenic line is indicated by the addition of “ptl-1(ok621)” in the strain name. Neuron imaging assay 
conducted at A) 20 °C or B) 25 °C for “TRN Tg” worms. Data for wild-type and ptl-1(ok621) animals were 
obtained in the same experiment as for pan-neuronal Tg animals at the same temperature (Figure 6.2). The chi-
squared statistical test was used to determine statistical significance. P-value is indicated by ns = not significant, 
*<0.05. The sample size for each strain at each time point is given in the table underneath the graphs. Experiments 
were conducted twice independently, and the representative data shown are from one experiment. Data from the 
second independent experiment are shown in Appendix 11. 
 
6.8 The shortened lifespan observed in ptl-1 null mutant animals is not rescued by touch 
neuron-specific re-expression of PTL-1 
We have shown that re-expressing PTL-1 in all neurons or under the regulation of the ptl-1 
promoter rescues the lifespan phenotype of ptl-1(ok621) null mutant animals. As we and others 
have observed that PTL-1 is highly expressed in the touch neurons (Chew et al., 2014b, Goedert 
et al., 1996, Gordon et al., 2008), we aimed to investigate if PTL-1 expression in these neurons 
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contributes to its effect on lifespan modulation. We found that expressing PTL-1 in touch 
neurons alone in the “TRN Tg; ptl-1(ok621)” (median lifespan 9 days) strain did not rescue the 
lifespan phenotype of the ptl-1(ok621) null mutant (median lifespan 9 days), as the survival 
curve of this transgenic line was not significantly different from that of the ptl-1(ok621) control 
(Figure 6.7). We also observed a small detrimental effect when PTL-1 was over-expressed in 
touch neurons: the “TRN Tg” line in a wild-type background displayed a significantly shorter 
lifespan (median lifespan 9 days) compared with wild-type controls (median lifespan 10 days) 
according to the log-rank statistical test (Figure 6.7). This difference was not significant using 
the Wilcoxon test, which places more weight on earlier deaths when comparing survival curves 
(GraphPad Prism 6).  
 
 
Figure 6.7: The short-lived phenotype of ptl-1 null mutant animals cannot be rescued by touch neuron-
specific re-expression of PTL-1. Lifespan assay for touch neuron-specific transgenic worms. Survival curves for 
control wild-type and ptl-1(ok621) animals in both graphs were obtained in the same experiment. n = 120 at day 0. 
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Results of statistical analysis are indicated by p-values underneath each graph. Lifespan experiments were conducted 
twice independently, and the representative data shown are from one experiment. Data from the second independent 
replicate are shown in Appendix 12.   
 
6.9 Knockdown of PTL-1 in touch neurons only has a cell autonomous effect on neuronal 
ageing 
We next complemented the assays involving tissue-specific re-expression of PTL-1 by 
conducting knockdown experiments in the touch neurons. We investigated the effect of PTL-1 
knockdown in the neuronal subset of touch neurons on the age-associated loss of structural 
integrity. To do this, we required a strain where the touch neurons are sensitised to RNAi by 
feeding, but other neurons are refractory. Our methods are summarised in Figure 6.8. SID-1 is a 
transmembrane protein that allows the passive uptake of dsRNA and is required for systemic 
RNAi knockdown. Wild-type neurons are refractory to RNAi as they do not express SID-
1(Feinberg and Hunter, 2003, Winston et al., 2002); however, Calixto et al. showed that neuronal 
re-expression of SID-1 in a sid-1 null mutant, such as in touch neurons, allowed RNAi 
knockdown to occur in these neurons (Calixto et al., 2010). The authors demonstrated that 
feeding mec-4 RNAi bacteria to these animals resulted in an expected loss of touch sensitivity, 
indicating that SID-1 expression in touch neurons efficiently sensitized these neurons to 
knockdown by RNAi treatment (Calixto et al., 2010). These animals that are henceforth referred 
to as the “TRN SID-1” strain carry a sid-1(qt2) mutation and a TRN-specific SID-1 rescue 
transgene (parent strain TU3403 (Calixto et al., 2010)). We used knockdown of unc-22 to test for 
the RNAi sensitivity of these strains. UNC-22 in muscle is required for motility, so feeding wild-
type animals (where muscle is sensitive to RNAi) unc-22 RNAi bacteria results in results in unc-
22 knockdown in muscle that can be observed as paralysis or twitching. However, the TRN SID-
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1 strain does not have SID-1 in muscle tissue, so feeding these animals unc-22 RNAi bacteria 
does not result in dsRNA being accessible to muscle and thus has no effect on motility (Figure 
6.8). We used unc-22 as a control for the RNAi experiment as well as to check strain integrity 
(see Methods section 2.2.13).  
 
 
Figure 6.8: Schematic of the protocol for RNAi knockdown experiments. Neurons in wild-type animals are 
refractory to knockdown by feeding RNAi as they lack the dsRNA transporter SID-1. SID-1 is expressed in other 
tissues such as the muscle, therefore if dsRNA fed to the animals enters via the intestine it can be passively 
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transported to non-neuronal tissues. unc-22 knockdown is able to occur in muscle in wild-type animals, which 
results in paralysis. When these animals are assayed for neuronal ageing, knockdown by RNAi should not affect 
transcript levels in neurons. If regulation of neuronal ageing is cell autonomous, there should be no expected effect 
on neuronal ageing. In contrast, TRN SID-1 animals are mutant for sid-1 and express a SID-1 transgene in touch 
neurons only. Therefore, unc-22 dsRNA fed to TRN SID-1 animals cannot access the muscle via the intestine and 
these animals are not paralysed. As the touch neurons in this strain are sensitised to RNAi knockdown, feeding 
RNAi is expected to affect transcript levels in these neurons, which may have an effect on touch neuron ageing if the 
regulation of neuronal ageing by PTL-1 is cell autonomous. 
 
We first tested whether PTL-1 in touch neurons could be effectively knocked down using this 
system. We fed either empty vector (EV) and ptl-1 RNAi bacteria to animals that express both 
SID-1 only in the touch neurons and a PTL-1::GFP fusion protein. These animals showed a loss 
of GFP signal in the touch neurons in the ptl-1 RNAi treated cohort different from those fed EV 
control RNAi bacteria (Figure 6.9), demonstrating the effectiveness of the ptl-1 RNAi treatment. 
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Figure 6.9: Knockdown of PTL-1 in touch neuron RNAi sensitised strains expressing PTL-1::GFP results in loss of fluorescence in touch neurons. 
Knockdown of ptl-1 in a TRN SID-1 transgenic animal results in loss of fluorescence in touch neurons only. The strain used for imaging expresses a PTL-1::GFP 
fusion protein and touch neuron-specific SID-1 in a sid-1 mutant background. Micrographs are shown for A) empty vector (EV) RNAi controls and for B) ptl-1 
RNAi treatment with PTL-1::GFP shown on the left and phase images shown on the right. For all micrographs showing fluorescence, boxed regions (solid lines) 
are shown as a magnified inset that is bordered by dashed lines. A(i) The ALM neuron in the EV control is clearly visible at a 200 ms exposure time, indicated by 
the white arrow. B(i). The approximate location of the ALM neuron in an animal exposed to ptl-1 RNAi treatment shows no fluorescence visible at 200 ms. 
A,B(ii). At a longer exposure time (5000 ms), the ALM neuron is clearly seen in the EV control, indicated by the white arrow (Aii) and as a faint signal in the 
ptl-1 RNAi-treated animal (Bii). (legend continued next page)
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Figure 6.9 (continued from previous page) A,B(iii)The PLM neuron cell body is clearly visible in the EV control 
(Aiii), indicated by the white arrow but not with ptl-1 RNAi treatment (Biii) at a 200 ms exposure time. Fourth 
larval stage/first day adult animals were imaged after being fed RNAi bacteria for two generations at 20 °C.  
 
We next crossed TRN SID-1 animals carrying neuronal GFP reporters with those that express 
SID-1 only in touch neurons. These animals were fed empty vector (EV) or ptl-1 RNAi feeding 
clones for two generations and were imaged on days 1, 3, 5 and 7 of adulthood to observe 
neuronal ageing. As an additional control, we carried out an experiment using animals containing 
only the neuronal GFP reporters that are wild-type at the sid-1 locus and do not have the TRN 
SID-1 transgene. Here, we would expect that no RNAi knockdown would occur within neurons 
in these animals as the neurons do not express SID-1. These animals did not show a substantial 
difference in the incidence of abnormal neuronal structures between RNAi treatments, further 
supporting our conclusion that PTL-1 acts within neurons to regulate neuronal ageing (Figure 
6.10).  
 
Figure 6.10: Non-neuronal knockdown of PTL-1 has no effect on neuronal ageing. Strains labelled as zdIs5 
indicate the allele name of the gfp reporter, are wild-type at the SID-1 locus and do not contain a SID-1 transgene. 
The RNAi treatment is either empty vector (EV) or ptl-1 and is indicated after the strain name. Touch neuron 
imaging assay for animals carrying the zdIs5 reporter only, indicating data for (i) cell body branching, (ii) axon 
branching and (iii) axon blebbing. n for each sample is indicated in the table. Statistical analysis: chi-squared test, p-
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value is indicated by ns = not significant, *<0.05. Experiments were conducted twice independently, and the 
representative data shown are from one experiment. Data from the second experiment are shown in Appendix 13. 
 
In contrast, when observing the anterior touch neurons in TRN SID-1 transgenic animals, we saw 
that worms fed with ptl-1 RNAi bacteria had a higher incidence of cell body branching and axon 
blebbing compared with those fed EV RNAi bacteria. Specifically, 70% of TRN SID-1 animals 
fed ptl-1 RNAi bacteria displayed cell body branching at day 7 compared with 47% in the EV 
RNAi control, and 53% of ptl-1 RNAi-fed animals displayed axon blebbing compared with 30% 
of the control population (Figure 6.11). In addition, we observed that TRN SID-1 animals 
displayed a relatively high frequency of axon branching, which is normally only present in late 
stage (day 10) adult animals (Chew et al., 2013, Toth et al., 2012) (Figure 5.3). TRN SID-1 
animals showed considerably higher levels of axon branching in the anterior touch neurons 
compared with controls that are wild-type at the sid-1 locus (Figure 6.10), although transgenic 
animals fed ptl-1 bacteria displayed a higher incidence of this phenotype compared with EV 
treatments (Figure 6.11ii). The high incidence of branching in TRN SID-1 animals could be due 
to the expression of multiple touch neuron-specific transgenes (both Pmec-18::sid-1 and Pmec-
4::gfp) that may alter the development or ageing process of the neuron.  
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Figure 6.11: Knockdown of PTL-1 in touch neurons results in a loss of structural integrity. SID-1 transgenic 
worms are labelled as “sid-1(qt2);TRN SID-1” to indicate the presence of the sid-1 mutation and Pmec-18::sid-1 
transgene. The RNAi treatment is either empty vector (EV) or ptl-1 and is indicated after the strain name. Touch 
neuron imaging assay for animals carrying the Pmec-4::gfp (zdIs5) reporter and the “TRN SID-1” Tg in a sid-1(qt2) 
background, indicating data for (i) cell body branching, (ii) axon branching and (iii) axon blebbing. n for each 
sample is indicated in the table. Statistical analysis: chi-squared test, p-value is indicated by ns = not significant, 
*<0.05. Experiments were conducted twice independently, and the representative data shown are from one 
experiment. Data from the second experiment are shown in Appendix 13. 
 
We then further tested the effect of the loss of PTL-1 in touch neurons by examining neuronal 
ageing in a different set of neurons. For this, we generated a strain expressing a GABAergic 
neuron GFP reporter in a TRN SID-1 background. As SID-1 is only expressed in touch neurons, 
we would not expect PTL-1 levels in the GABAergic neurons to be affected by feeding RNAi 
bacteria in this strain. Therefore, although PTL-1 levels in the touch neurons of TRN SID-1 
animals should decrease with ptl-1 feeding RNAi, PTL-1 expression in the GABAergic neurons 
of these animals should remain at endogenous levels. As above, we also performed a control 
RNAi experiment using animals containing only the GABAergic neuron GFP reporter and not 
the TRN SID-1 transgene, and no differences were observed between RNAi treatments (Figure 
6.12A). When GABAergic neuron ageing in TRN SID-1 transgenic worms was monitored, we 
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observed no difference between ptl-1 RNAi treatment and EV treatment (Figure 6.12B). This 
demonstrates that loss of PTL-1 in the touch neurons appears not to affect neuronal ageing in the 
GABAergic neurons. 
 
 
Figure 6.12: Knockdown of PTL-1 in touch neurons does not affect GABAergic neuron integrity during 
ageing. Strains labelled as oxIs12 indicate the allele name of the gfp reporter, are wild-type at the SID-1 locus and 
do not contain a SID-1 transgene. SID-1 transgenic worms are labelled as “sid-1(qt2);TRN SID-1” to indicate the 
presence of the sid-1 mutation and Pmec-18::sid-1 transgene. The RNAi treatment is either empty vector (EV) or 
ptl-1 and is indicated after the strain name. GABAergic imaging assay A) for animals carrying the oxIs12 reporter 
only, and B) for animals carrying the Punc-47::gfp (oxIs12) reporter together with the “TRN SID-1” Tg in a sid-
1(qt2) mutant background. n for each sample is indicated in the table. Statistical analysis: chi-squared test, p-value is 
indicated by ns = not significant, *<0.05. Experiments were conducted twice independently, and the representative 
data shown are from one experiment. Data from the second experiment are shown in Appendix 13. 
 
Taken together, these data from tissue-specific re-expression and RNAi knockdown experiments 
indicate that the effect of ptl-1 on neuronal ageing is cell autonomous.  
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6.10 Discussion 
The key findings in this chapter are: (i) PTL-1 functions through neurons to regulate organismal 
ageing, (ii) PTL-1 regulates neuronal ageing in a cell-autonomous manner, and (iii) the processes 
that regulate organismal ageing and tissue-specific ageing can be separable. 
 
6.10.1 The regulation of neuronal ageing by PTL-1 is cell autonomous 
Using a combination of tissue-specific transgene expression and RNAi knockdown, we showed 
that PTL-1 regulates neuronal structural integrity in a cell autonomous manner. Re-expression or 
knockdown of PTL-1 in touch neurons alone contributed to the structural stability in those 
neurons but failed to affect ageing in another neuronal subset, the GABAergic neurons. There is 
evidence in other pathways that age-associated structural abnormalities in neurons are due to 
cell-autonomous effects (Toth et al., 2012, Tank et al., 2011). For example, the FOXO 
transcription factor DAF-16 is required for the longevity effects of the DAF-2 insulin receptor 
(Kenyon et al., 1993). Expression of DAF-16 only in neurons of a daf-2;daf-16 mutant delays the 
formation of abnormal neuron structures compared with a non-transgenic daf-2;daf-16 control 
(Tank et al., 2011). In addition, reduced activity of the heat shock factor-1 transcription factor 
(hsf-1) in the whole organism resulted in early onset branching and blebbing in touch receptor 
neurons, and re-expressing hsf-1 only in this subset of neurons was able to rescue this effect 
(Toth et al., 2012). 
 
PTL-1 binds to and stabilizes microtubules (Goedert et al., 1996, McDermott et al., 1996, Tien et 
al., 2011), and this function may contribute to cell autonomous regulation of structural integrity. 
Consistent with this, we have shown in the previous chapter that a microtubule-binding domain-
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deficient mutant of PTL-1 (tm543 allele) also displays the same neuronal ageing phenotype as 
ptl-1 null mutants (Figure 5.3) (Chew et al., 2013).  
 
6.10.2 PTL-1 does not regulate longevity via the touch neurons 
Previous research has highlighted the importance of neurons, and sensory neurons in particular, 
in the modulation of lifespan. Examples include the role of olfactory neurons and ciliated 
sensory neurons in inhibiting longevity (Alcedo and Kenyon, 2004, Apfeld and Kenyon, 1999), 
and that of thermosensory neurons in regulating lifespan at high temperatures (Lee and Kenyon, 
2009). Our data using a pan-neuronal transgenic line indicate that although PTL-1 is also 
expressed in non-neuronal tissues (Gordon et al., 2008)(Figure 4.6), its neuronal effects are 
sufficient to regulate whole organismal lifespan. In addition, we also demonstrate that expression 
of PTL-1 in mechanosensory touch neurons alone, the neuronal subset in which PTL-1 is most 
highly expressed (Goedert et al., 1996, Gordon et al., 2008), does not rescue the shortened 
lifespan of ptl-1 null mutants. Interestingly, mec genes that are expressed predominantly in touch 
neurons have also been implicated in lifespan modulation. Mutations in the mechanosensory 
channel components MEC-2, MEC-4, MEC-6, MEC-10 and extracellular matrix (ECM) proteins 
MEC-5 and MEC-9 also result in a shortened lifespan, whereas mutations in the ECM protein 
MEC-1 and α-tubulin MEC-12 do not (Pan et al., 2011). It is likely that PTL-1 regulates 
organismal ageing through a combination of neuronal subsets, possibly including the touch 
neurons. 
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6.10.3 Regulation of neuronal ageing and lifespan by PTL-1 can be separable 
Work detailed in Chapters 4 and 5 has demonstrated that ptl-1(ok621) null mutants display both 
accelerated organismal ageing and premature neuronal ageing (Chew et al., 2013). We have now 
shown that animals that express PTL-1 in touch neurons alone have a shortened lifespan 
compared with wild-type as have ptl-1(ok621) null mutants (Figure 6.7B), but that their touch 
neurons age at the same rate as wild-type animals (Figure 6.5B). This demonstrates that PTL-1-
mediated processes that influence lifespan or neuronal ageing can be decoupled from each other. 
We also acknowledge the possibility that there may simply be a threshold number of neurons 
required, such that restoration of ptl-1 function in only 6 touch neurons out of 302 total neurons 
may be insufficient to restore normal lifespan. However, our observation that over-expression of 
PTL-1 in touch neurons on a wild-type background has a small negative impact on lifespan 
highlights a role for touch neurons compared with other neuronal populations.  
 
A similar segregation of organismal and neuronal ageing has been observed for components of 
the insulin-like/IGF-1 signalling pathway. Long-lived daf-2/insulin receptor mutants show less 
neuronal branching in early adulthood compared with wild-type, and this effect is ameliorated in 
daf-2;daf-16/FOXO transcription factor double mutants, which have a wild-type lifespan (Tank 
et al., 2011, Kenyon et al., 1993). However, RNAi-mediated knockdown of daf-16 in non-
neuronal tissues in a daf-2 mutant results in an animal with wild-type lifespan, but has no effect 
on the daf-2-mediated delay of neuronal ageing (Tank et al., 2011). Therefore, although neuronal 
cell body branching and axon blebbing increase with age, tissue-specific ageing and whole 
organism ageing appear to be separable. This suggests that the mechanisms that define these 
ageing processes contain both distinct and overlapping processes. It is of considerable interest in 
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the fields of ageing and neurodegeneration to identify the genetic players involved in these 
processes. 
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7.1 Summary 
Mammalian Tau has been extensively studied with regards to its role in neurodegenerative 
diseases, termed Tauopathies, such as Alzheimer’s disease (Buee et al., 2000, Iqbal et al., 2010, 
Ittner et al., 2011, Ittner and Gotz, 2011). Tauopathies are thought to be caused, at least in part, 
due to a toxic gain-of-function of aggregated and hyperphosphorylated Tau, the loss of an 
important physiological role played by normally functioning Tau, or a combination of these 
factors.  Despite the large number of advances that have been made using mammalian models to 
investigate Tau (Gotz et al., 2010), attempts to test the physiological functions of Tau have been 
made more challenging by the presence of multiple neuronal MAPs that are thought to be 
functionally redundant in vivo (Dehmelt and Halpain, 2005, Kosik and Finch, 1987, Chen et al., 
1992). PTL-1 is the sole homolog of Tau/MAP2/MAP4 in C. elegans, and contains highly 
similar C-terminal MBRs to those of the mammalian MAPs (Goedert et al., 1996, McDermott et 
al., 1996). We have used C. elegans as a model to study the physiological roles of a Tau-like 
protein without the complication of functional redundancy (Chew et al., 2013, Chew et al., 
2014a). The overall aim of this work was to investigate the involvement of PTL-1 in the 
regulation of ageing and stress tolerance, two closely-related processes that are also associated 
with neurodegenerative disease incidence in humans (Guglielmotto et al., 2009, Zhao and Zhao, 
2013, WHO, 2012, Blennow et al., 2006, Bishop et al., 2010).  The convenience of the nematode 
model, particularly its short lifespan of two to three weeks and its ease of maintenance, 
facilitated our investigation into the role of PTL-1 in both neuronal ageing and whole organism 
lifespan. In addition, we explored the related functions of PTL-1 in modulating the response to 
oxidative stress via the Nrf2 transcription factor homolog, SKN-1.  
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7.2 PTL-1 in the nervous system regulates the oxidative stress response in a pathway that may 
involve SKN-1 
Increased oxidative stress characterizes many pathological conditions and has also been observed 
in the brains of AD patients and animal models of AD (Butterfield et al., 2007, Filipcik et al., 
2006, Guglielmotto et al., 2009, Zhao and Zhao, 2013). The Nrf2 transcription factor is an 
important mediator of the oxidative stress response in mammals (Leiser and Miller, 2010). 
Increased Nrf2 activity has been linked to reductions in Tau-mediated neurotoxicity in Tau 
transgenic mice treated with the aggregation blocker methylene blue (Stack et al., 2014) and in 
primary neuron culture from a mouse model of AD (Jo et al., 2014). We have shown that PTL-1 
regulates the function of the Nrf2 homolog SKN-1 in C. elegans possibly by regulating its re-
localisation from the cytoplasm into the nucleus of intestinal tissue. We also demonstrated that 
expression of PTL-1 in the nervous system alone is sufficient to rescue the defects in SKN-1 
nuclear accumulation observed in ptl-1 mutant strains. This process could involve the SV fusion 
protein UNC-13, which is required to prime SVs for exocytosis (Madison et al., 2005).  
 
The movement of SKN-1 from the intestinal cytoplasm into the nucleus requires p38 MAPK 
(Inoue et al., 2005), which becomes activated in response to various stressors in both vertebrate 
and C. elegans models (Kyriakis and Avruch, 2001, Johnson and Lapadat, 2002, Lim et al., 
2012). PTL-1 in neurons has previously been shown to be involved in microtubule-based 
motility via kinesin-3 (UNC-104/KIF1A) (Tien et al., 2011). Therefore, the role of PTL-1 in 
mediating communication between tissues may involve signalling molecules such as 
neurotransmitters that are transported along microtubules in SVs and are eventually exocytosed. 
This mode of communication may be required to promote signalling processes such as the p38 
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MAPK pathway that induces SKN-1 re-localisation. In fact, neurotransmitter release from 
dopaminergic neurons was previously shown to “condition” the C. elegans innate immune 
response to pathogenic E. coli, a process that involves MAPK signalling (Anyanful et al., 2009). 
This suggests that neurotransmitters that are carried by SVs in neurons are able to activate the 
p38 MAPK pathway in non-neuronal tissue. However, it is also conceivable that PTL-1 mediates 
a developmental process within the nervous system that is required for neurons to signal to 
intestinal SKN-1 and thus trigger nuclear re-localisation during stress. As we could not observe 
detectable knockdown of ptl-1 in young adulthood when animals were fed RNAi bacteria at the 
fourth larval stage, we were unable to determine if the SKN-1 defect in ptl-1 mutant animals 
arose post-developmentally or as a result of a developmental defect. However, our observations 
of the nervous system in young adult ptl-1 mutant animals indicate that the overall neuronal 
architecture appears overtly normal (Chapters 5 and 6), suggesting that any developmental 
effects of loss of PTL-1 are subtle or do not affect the gross anatomy of the nervous system. 
Alternatively, it is possible that the lack of PTL-1 compromises the health of animals to the 
extent that they are unable to properly respond to environmental insults. However, as ptl-1 
mutant animals are still at least partially able to response to stress (~20% SKN-1 nuclear 
accumulation in ptl-1(ok621) azide-stressed animals), this indicates that lack of functional PTL-1 
does not result in an overall inability to detect stress.  
 
Another possibility is that PTL-1 and SKN-1 interact with each other in the nervous system, and 
that this cross-talk “activates” neuronal SKN-1 to promote its re-localisation in the intestine. 
Such a mechanism has been postulated for the FOXO transcription factor DAF-16, in that 
intestinal DAF-16 activation leads to increased DAF-16 activity in other tissues. This “FOXO-
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to-FOXO” communication requires the insulin-like gene ins-7 that is positively regulated by 
DAF-16 (Murphy et al., 2007). Although the expression pattern of SKN-1 appears restricted to 
the ASI neurons in the head and the intestine for SKN-1b and SKN-1c, respectively (An and 
Blackwell, 2003, Bishop and Guarente, 2007), the localisation of SKN-1a remains largely 
uncharacterised. A transgenic line expressing GFP-tagged SKN-1a under the regulation of a 7.3 
kb upstream region, including the coding sequence of a widely-expressed upstream gene bec-1, 
shows GFP localised to many tissues including the ventral nerve cord (Staab et al., 2014). PTL-1 
is broadly expressed in the nervous system, including in the ventral cord and in many of the head 
neurons likely including the ASI neurons (Gordon et al., 2008, Chew et al., 2014a). We showed 
that, unlike re-expression in all neurons, PTL-1 expression in the ASI neurons where SKN-1b is 
constitutively localised to the nucleus (An and Blackwell, 2003), is not sufficient to rescue the 
defect in SKN-1 re-localisation observed in ptl-1 mutant animals. However, although the gpa-4 
promoter that we used to generate the ASI Tg line had been previously used to express 
transgenes specifically in the ASI neurons (Bishop and Guarente, 2007), technical difficulties 
prevented us from confirming that the head neurons in which we observed transgene expression 
were definitively the ASI neurons. It is possible that a direct interaction between PTL-1 and 
SKN-1 in other neurons, such as the ventral cord neurons, could modulate SKN-1 in the intestine 
in response to stress.  
 
7.3 PTL-1 modulates longevity from the nervous system 
We showed that ptl-1 null mutant or MBR-deficient strains are short-lived and that this can be 
rescued by either re-expression of PTL-1 in the null mutant strain under the regulation of the 
endogenous promoter or by a pan-neuronal-specific promoter. We also showed that PTL-1 
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expressed solely in the touch neurons was not sufficient to rescue the premature lifespan 
observed in ptl-1 mutant animals. Additionally, over-expression of PTL-1 in touch neurons alone 
was detrimental to the animal. We noted that the negative effect of touch neuron over-expression 
(TRN Tg) appears to be subtly less than that of over-expressing PTL-1 under the regulation of its 
endogenous promoter (PTL-1 Tg), which would express PTL-1 in neuronal and non-neuronal 
tissues. Although these strains were never assayed in the same experiment, the TRN Tg over-
expression strain is not significantly short-lived compared with wild-type using the Wilcoxon 
statistical test, whereas the PTL-1 Tg over-expression strain (regulated by the ptl-1 endogenous 
promoter) is short-lived using the same statistical analysis. Unlike the log-rank test, the 
Wilcoxon test places more weight on earlier deaths (Machin et al., 2006), suggesting that in 
terms of survival, the TRN Tg strain, but not the PTL-1 Tg strain, behaves like wild-type in 
young adulthood. Interestingly, there was no observable adverse effect of over-expressing PTL-1 
only in the nervous system (Pan-neuronal Tg). It should be noted that transcript levels of the 
transgene in each of these transgenic lines are likely to vary to a considerable degree, which 
according to our data using PTL-1 Tg lines that express PTL-1 under the control of the ptl-1 
promoter, may have an effect on whole organismal ageing. Nonetheless, our observations 
suggest that the touch neurons play a particular role in lifespan modulation by PTL-1, and that 
the levels of PTL-1 in non-neuronal tissues may also contribute to this function. It is likely that 
functional PTL-1 in a combination of neuronal subsets, possibly including the touch neurons, is 
required to maintain wild-type lifespan.  
 
In addition, we found that human Tau does not rescue the shortened lifespan observed in ptl-1 
mutant strains. This could be because the detrimental effect of expressing the human Tau 
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transgene in C. elegans, which was also observed in other transgenic lines (Brandt et al., 2009, 
Kraemer et al., 2003, Miyasaka et al., 2005), masks any positive effects that could potentially 
rescue the longevity phenotype. Or, it could be that unlike PTL-1, human Tau lacks the ability to 
interact with other C. elegans proteins that may be required to maintain wild-type lifespan. The 
N-termini of PTL-1 and human Tau display limited sequence homology and this region could 
contain the sequences that are required for protein–protein interactions that mediate longevity in 
C. elegans. For mammalian Tau, the N-terminus is required for several important interactions, 
such as those required to mediate axonal transport (Kanaan et al., 2012) and post-synaptic 
targeting of signalling molecules (Ittner et al., 2010).  
 
When we performed lifespan assays with short-lived ptl-1(ok621) and skn-1(zu67) mutant 
strains, we found that double mutant ptl-1;skn-1 animals were not significantly more or less 
short-lived than the single mutant animals. This suggests that PTL-1 and SKN-1 may regulate 
lifespan via similar pathways. It is unclear how SKN-1 affects lifespan, although several lines of 
evidence suggest that this involves components of the insulin-like signalling pathway, which is 
the most well-characterised lifespan regulator in C. elegans (Paek et al., 2012, Tullet et al., 2008, 
Inoue et al., 2005). The p38 MAPK pathway, which is required for SKN-1 re-localisation to the 
intestinal nucleus in response to stress, appears to regulate lifespan via SKN-1 and the IIS 
pathway (Inoue et al., 2005). Mammalian Tau is phosphorylated by p38 MAPKs and glycogen 
synthase kinase-3β (GSK-3β) (Goedert et al., 1997, Anderton et al., 2001). GSK-3β is modulated 
by several pathways including insulin signalling (Wada, 2009), and in C. elegans it inhibits 
intestinal SKN-1 from localising to the nucleus in the absence of stress (An et al., 2005). 
Excessive phosphorylation of Tau by these and other factors is understood to be a major 
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contributor to neurodegenerative pathology (Goedert et al., 1997, Anderton et al., 2001, 
Mandelkow et al., 1993, Zheng-Fischhofer et al., 1998, Lovestone et al., 1994). Given the 
relationship between mammalian Tau and p38 MAPK and GSK-3 β signalling, it is possible that 
PTL-1 requires these kinases for its roles in neuronal ageing and lifespan in C. elegans. We have 
not tested whether PTL-1 interacts with members of the IIS, p38 MAPK or GSK-3β pathway in 
its modulation of lifespan.  
 
On a related note, expression of SKN-1b in the ASI neurons has been shown to be critical in the 
regulation of dietary-restriction-mediated lifespan extension (Bishop and Guarente, 2007). A role 
for PTL-1 in dietary-restriction-dependent longevity has not been described, although it would 
be interesting to test if such a phenotype exists and if so, whether it is able to be rescued by ASI-
specific PTL-1 re-expression. We also did not test if PTL-1 re-expression in the ASI neurons is 
sufficient to rescue the shortened lifespan of ptl-1 null mutant animals observed under ad libitum 
feeding conditions. Curiously, the skn-1(zu67) allele, which confers a short-lived phenotype, 
affects SKN-1a and SKN-1c isoforms only, suggesting that SKN-1b in the ASI neurons does not 
affect lifespan under non-restricted feeding conditions (Bishop and Guarente, 2007). SKN-1a is 
potentially expressed in several parts of the nervous system (Staab et al., 2014), whereas SKN-1c 
appears restricted to the intestine (An and Blackwell, 2003). It is likely that there is some overlap 
between the expression of PTL-1 and SKN-1 in these tissues, and as noted above, it is possible 
that PTL-1 and SKN-1 interact within the nervous system. Therefore, to regulate lifespan, PTL-1 
and SKN-1 may act within the same tissues, or across tissues.  
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7.4 PTL-1 maintains age-related structural integrity in neurons potentially by stabilising 
microtubules 
We have shown that PTL-1 is not only involved in mediating whole organism lifespan, but that it 
also regulates neuronal ageing in two subsets of neurons, the touch neurons and the GABAergic 
neurons of the ventral cord. We tested only these neuronal subsets because they are the most 
well-defined in terms of the subtle parameters that characterise neuronal ageing in C. elegans 
(Pan et al., 2011, Tank et al., 2011, Toth et al., 2012). However, our results suggest that PTL-1 is 
likely to also regulate tissue ageing throughout the nervous system. Using a combination of 
tissue-specific transgenic re-expression and RNAi knockdown, we have shown that PTL-1 
regulates neuronal ageing in a cell autonomous manner. This is perhaps unsurprising, as PTL-1 is 
a microtubule-binding protein and is likely to maintain structural integrity in neurons by its 
ability to stabilise the components of the cytoskeleton formed form from microtubules (Goedert 
et al., 1996, McDermott et al., 1996). Consistent with this theory, we showed that both loss of 
PTL-1 or expression of a truncated form lacking the MBRs in the ptl-1(tm543) mutant strain, 
results in an age-related loss of neuronal structural integrity. Furthermore, the neurons in which 
PTL-1 is most highly expressed are the touch receptor neurons, which have specialised 15-
protofilament microtubule structures (as opposed to the ‘normal’ 11-protofilament structures) 
that are believed to play an essential role in mechanosensation (Chalfie and Sulston, 1981, 
Savage et al., 1994). This and our observations suggest that PTL-1 plays an important role in 
stabilising microtubule structures in C. elegans. It would be interesting to investigate if these 15-
protofilament microtubule structures, which are disrupted in mutations in genes such as the β-
tubulin gene mec-7, can still be formed in a ptl-1 mutant strain.  
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An established function of mammalian Tau/MAP2/MAP4 is the ability to interact with tubulin 
monomers and to promote microtubule assembly and stability (Witman et al., 1976, Weingarten 
et al., 1975). The ability to bind microtubules is predominantly conferred by the MBRs, so Tau 
isoforms that have more MBRs (4 repeat/R Tau versus 3R Tau) bind more strongly (Lee and 
Rook, 1992), in a similar manner as PTL-1 (Goedert et al., 1996). Interestingly, some mutations 
in the familial Tauopathy FTDP-17 alter the normal ~50:50 ratio of 4R:3R Tau isoform ratio to 
one that results in an excess of 4R Tau (Ingram and Spillantini, 2002, Hong et al., 1998). 
Furthermore, hyperphosphorylation of Tau reduces its ability to bind to microtubules (Iqbal et 
al., 2010, Alonso et al., 2008). These observations suggest that modulations in the ability of 
MAPs to bind microtubules can contribute to increased neurodegeneration. In this work, we 
generated transgenic lines solely using one PTL-1 isoform. Although the functional differences 
between PTL-1 isoforms have not been extensively studied, given the importance of isoform 
ratios for mammalian Tau, it is possible that re-expressing different isoforms of PTL-1 could 
produce varying phenotypes. It is also not known if different ptl-1 transcripts are expressed in 
different tissues or subcellular localisations. Future work could expand on our investigations by 
testing for potential functional differences in PTL-1 isoforms.  
 
7.5 Conclusions  
We have shown that levels of PTL-1 need to be tightly controlled in the regulation of neuronal 
ageing, longevity, and stress tolerance (summarised in Figure 7.1). Loss of PTL-1, the 
expression of a truncated form lacking the MBRs, or expression levels that are too high, all lead 
to detrimental effects. This has implications for the development of therapeutics for AD and 
other Tauopathies that rely on the reduction of Tau levels. As aggregated Tau is an important 
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pathological hallmark for several neurodegenerative diseases, some therapeutic strategies focus 
on reducing Tau levels. Our data indicate that it may not be ideal to reduce Tau to too low levels 
in AD patients, as the loss of PTL-1 in C. elegans has several negative effects on the organism. 
Although differences between C. elegans and higher organisms may be due to the lack of other 
Tau/MAP2/MAP4 homologs in the worm that can compensate for loss of PTL-1, our findings 
nonetheless demonstrate the importance of Tau-like proteins in regulating not only neuronal 
physiology, but also important biological processes within the whole organism. Further 
investigations are needed to understand the mechanisms involved in these processes, which 
would be interesting not solely to the fields of ageing and neurodegeneration, but also to our 
understanding of how various tissues regulate whole animal physiology.  
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Figure 7.1: Summary of the functions of PTL-1 determined in this investigation. PTL-1 appears to modulate 
longevity, neuronal ageing, and stress tolerance. Although these phenotypes have been linked to one another, for 
example increased stress tolerance is correlated with lifespan extension, and ptl-1 mutant animals that are short-lived 
have accelerated neuronal ageing (whereas daf-2 mutant animals are long-lived and show delayed neuronal ageing) 
(Tank et al., 2011), it is unclear if PTL-1 drives these processes separately or if it is involved in a general pathway 
that is upstream of these phenotypes. 
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Appendix 1 
 
Appendix 1: Three distinct daf-2(e1370)ptl-1(ok621) recombinant lines are not substantially different from 
daf-2(e1370) single mutant animals in regulating the re-localisation of SKN-1::GFP to the intestinal nucleus 
in response to stress. Recombinant lines were generating by crossing ptl-1(ok621) III males with daf-2(e1370) 
hermaphrodites and genotyping >100 animals to isolate rare recombinants. No nuclear SKN-1::GFP was observed in 
untreated animals. n=15 per genotype.  
 
Appendix 2 
 
Appendix 2: The V5::PTL-1 transgene expressed from the ptl-1 promoter is widely expressed in neurons. 
Immunofluorescence micrographs showing the expression of the V5::PTL-1 transgene (anti-V5 antibody). The 
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Pmyo-2::mCherry co-transformation marker is also shown. All images show clear anti-V5 immunostaining in the 
nerve ring in the head and in axons. Scale, dotted line 50 µm, solid line 20 µm. 
 
Appendix 3 
 
Appendix 3: ptl-1(ok621);skn-1(zu67) double mutant animals are not significantly shorter or longer lived 
compared to ptl-1(ok621) or skn-1(zu67) single mutant animals. Survival curves for skn-1(zu67) and ptl-1(ok621) 
single mutants together with the skn-1(zu67);ptl-1(ok621) double mutant strain. n = 120 at day 0. Results of 
statistical analysis are indicated by p-values underneath each graph. Lifespan experiments were conducted twice 
independently and the results of one lifespan experiment are shown. Data from the first experiment are shown in 
Figure 4.15. Median lifespans are 7 days (wild-type), 7 days (ptl-1(ok621)), 6 days (skn-1(zu67)), and 6 days (skn-
1(zu67);ptl-1(ok621)). 
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Appendix 4 
 
Appendix 4: Non-stressed animals display a low basal induction of Pgcs-1::gfp. Day one adult animals were 
assayed at the same time as the relevant strains incubated with sodium azide (Chapter 4, section 4.1). If the 
transgenic line has been crossed into the ptl-1(ok621) m      b   g         s  s           b   ptl-1(ok621)” stated 
following the transgene name. Pgcs-1::gfp fluorescence is shown in non-stressed animals for A) transgenic lines 
expressing PTL-1 under the regulation of the ptl-1 p  m     ( P L-1  g ), B) transgenic lines expressing PTL-1 in 
neurons using the aex-3 p  m     ( p  -          g ), C) transgenic lines expressing PTL-1 in ASI neurons using 
the gpa-4 promoter, and D) unc-13(e450) and unc-31(e928) mutant animals. The graphs show averaged data from 3 
independent experiments. Scoring was conducted as in (Wang et al., 2010). p-value: ns=not significant.  
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Appendix 5 
 
Appendix 5: ptl-1(ok621) mutant animals display a lower induction of Phsp-4::gfp (zcIs4) compared with 
wild-type in response to azide stress. 20 young adult animals of each genotype were assayed per replicate. GFP 
signal from the posterior end of the worm to the anterior-most portion of the intestine was quantified using ImageJ 
software. The graphs show averaged data from 2 independent experiments. Error bars indicate mean ±SEM. 
Statistical analysis: one-way ANOVA (GraphPad Prism). p-value: ns=not significant, *<0.05.   
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Appendix 6 
 
Appendix 6: Percentage of branching/blebbing observed in the posterior touch receptor neurons of wild-type 
and ptl-1(ok621) animals (n =5) assayed in a longitudinal experiment. Compared with anterior touch neurons 
assayed at the same stages of adulthood (Figure 4.2), the incidence of branching/blebbing structures appears to be 
higher in the posterior neurons.  
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Appendix 7 
 
Appendix 7: Pan-neuronal re-expression of PTL-1 rescues the neuronal ageing phenotype in TRNs that is 
observed in the ptl-1(ok621) null mutant. The TRNs were visualised using the Pmec-4::gfp (zdIs5) reporter. The 
presence of the ptl-1(ok621) mutation in the genetic background of each transgenic line is indicated by the addition 
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of “ptl-1(ok621)” in the strain name. Neuron imaging assay conducted at A) 20 °C or B) 25 °C for pan-neuronal 
transgenic worms (“Pan-neuronal Tg”) showing (i) cell body branching, (ii) axon blebbing, and (iii) axon branching. 
The chi-squared statistical test was used to determine statistical significance. P-value is indicated by ns = not 
significant, *<0.05. The sample size for each strain at each time point is given in the table underneath the graphs. 
Experiments were conducted twice independently, and the representative data shown are from one experiment. Data 
from the first experiment are shown in Figure 6.1.  
 
Appendix 8 
 
Appendix 8: Pan-neuronal re-expression of PTL-1 rescues the neuronal ageing phenotype in GABAergic 
neurons that is observed in the ptl-1(ok621) null mutant. The GABAergic neurons were visualised using the 
Punc-47::gfp (oxIs12) reporter. The presence of the ptl-1(ok621) mutation in the genetic background of each 
transgenic line is indicated by the addition of “ptl-1(ok621)” in the strain name. Neuron imaging assay conducted at 
A) 20 °C or B) 25 °C for “Pan-neuronal Tg” worms. The chi-squared statistical test was used to determine statistical 
significance. P-value is indicated by ns = not significant, *<0.05. The sample size for each strain at each time point 
is given in the table underneath the graphs. Experiments were conducted twice independently, and the representative 
data shown are from one experiment. Data from the first experiment are shown in Figure 6.2. 
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Appendix 9 
 
Appendix 9: The short-lived phenotype of ptl-1 null mutants can be rescued by pan-neuronal re-expression of 
PTL-1. Lifespan assay for pan-neuronal transgenic worms. n = 120 at day 0. Results of statistical analysis are 
indicated by p-values underneath each graph. Lifespan experiments were conducted twice independently, and the 
representative data shown are from one experiment. Data from the first experiment are shown in Figure 6.3. Median 
lifespans are 8 days (wild-type), 7 days (ptl-1(ok621), 8 days (Pan-neuronal Tg; wild-type), and 8 days (Pan-
neuronal Tg; ptl-1(ok621)). 
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Appendix 10 
 
Appendix 10: TRN-specific re-expression of PTL-1 rescues the neuronal ageing phenotype in TRNs that is 
observed in the ptl-1(ok621) null mutant. The TRNs were visualised using the Pmec-4::gfp (zdIs5) reporter. The 
presence of the ptl-1(ok621) mutation in the genetic background of each transgenic line is indicated by the addition 
of “ptl-1(ok621)” in the strain name. Neuron imaging assay conducted at A) 20 °C or B) 25 °C for TRN-specific 
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transgenic worms (“TRN Tg”). Data for wild-type and ptl-1(ok621) animals in both graphs were obtained in the 
same experiment as pan-neuronal transgenic lines at the same temperature (Appendix 7). The chi-squared statistical 
test was used to determine statistical significance. P-value is indicated by ns = not significant, *<0.05. The sample 
size for each strain at each time point is given in the table underneath the graphs. Experiments were conducted twice 
independently, and the representative data shown are from one experiment. Data from the first experiment are 
shown in Figure 6.5. 
 
Appendix 11 
 
Appendix 11: TRN-specific re-expression of PTL-1 does not rescue the neuronal ageing phenotype in 
GABAergic neurons that is observed in the ptl-1(ok621) null mutant. The GABAergic neurons were visualised 
using the Punc-47::gfp (oxIs12) reporter. The presence of the ptl-1(ok621) mutation in the genetic background of 
each transgenic line is indicated by the addition of “ptl-1(ok621)” in the strain name. Neuron imaging assay 
conducted at A) 20 °C or B) 25 °C for “TRN Tg” worms. Data for wild-type and ptl-1(ok621) animals were 
obtained in the same experiment as for pan-neuronal Tg animals at the same temperature (Appendix 8). The chi-
squared statistical test was used to determine statistical significance. P-value is indicated by ns = not significant, 
*<0.05. The sample size for each strain at each time point is given in the table underneath the graphs. Experiments 
were conducted twice independently, and the representative data shown are from one experiment. Data from the first 
experiment are shown in Figure 6.6. 
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Appendix 12 
 
Appendix 12: The short-lived phenotype of ptl-1 null mutants cannot be rescued by TRN-specific re-
expression of PTL-1. Lifespan assay for TRN-specific transgenic worms. Survival curves for control wild-type and 
ptl-1(ok621) animals were obtained in the same experiment as shown in Appendix 9. n = 120 at day 0. Results of 
statistical analysis are indicated by p-values underneath each graph. Lifespan experiments were conducted twice 
independently, and the representative data shown are from one experiment. Data from the first experiment are 
shown in Figure 6.7. Median lifespans are 8 days (wild-type), 7 days (ptl-1(ok621), 8 days (TRN Tg; wild-type), 
and 7 days (TRN Tg; ptl-1(ok621)). 
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Appendix 13 
 
Appendix 13: Knockdown of PTL-1 in touch neurons has a cell autonomous effect on neuronal ageing. Strains 
labelled as zdIs5 or oxIs12 indicate the allele name of the gfp reporter, are wild-type at the SID-1 locus and do not 
contain a SID-1 transgene. SID-1 transgenic worms are labelled as “sid-1(qt2);TRN SID-1” to indicate the presence 
of the sid-1 mutation and Pmec-18::sid-1 transgene. The RNAi treatment is either empty vector (EV) or ptl-1 and is 
indicated after the strain name. A) TRN imaging assay for animals carrying the zdIs5 reporter only, indicating data 
for (i) cell body branching, (ii) axon branching and (iii) axon blebbing. B) TRN imaging assay for animals carrying 
the zdIs5 reporter together with the “TRN SID-1” Tg in a sid-1(qt2) mutant background, indicating data for (i) cell 
Appendices 
 
193 
 
body branching, (ii) axon blebbing and (iii) axon branching. C) GABAergic imaging assay for animals carrying the 
oxIs12 reporter, (i) strains assayed carry the oxIs12 reporter alone, (ii) strains assayed also carry the “sid-1(qt2); 
TRN SID-1” transgene. Statistical analysis: chi-squared test, p-value is indicated by ns = not significant, *<0.05. 
The sample size for each strain at each time point is given in the table underneath the graphs. Experiments were 
conducted twice independently, and the representative data shown are from one experiment. Data from the first 
experiment are shown in Figures 6.10, 6.11 and 6.12. 
 
 
